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WRAP53	   is	   a	   gene	   of	   multiple	   functions;	   it	   encodes	   for	   a	   natural	   antisense	  transcript	  that	  regulates	  the	  actions	  of	  the	  tumour	  suppressor	  p53,	  and	  it	  gives	  rise	   to	   a	   protein	   with	   oncogenic	   properties	   that	   is	   important	   for	   Cajal	   body	  formation	   and	   maintenance.	   Natural	   antisense	   transcripts	   are	   a	   group	   of	  regulatory	   RNAs	   implicated	   in	   many	   aspects	   of	   eukaryotic	   gene	   expression	  including	   transcription,	   RNA	   localization,	   translation	   and	   RNA	   stability.	   Even	  though	  up	  to	  70%	  of	  all	  human	  genes	  may	  overlap	  in	  an	  antisense	  fashion,	  little	  is	   known	  about	   their	  biological	   significance.	   In	   this	  work,	  we	  have	   identified	  a	  natural	   antisense	   transcript	   of	   p53	   that	   regulates	   the	   steady-­‐state	   levels	   of	  endogenous	  p53	  mRNA	  and	   the	   induction	  of	   p53	   in	   response	   to	  DNA	  damage.	  p53	  is	  a	  transcription	  factor	  that	  upon	  DNA	  damage	  and	  other	  types	  of	  cellular	  stress	   induces	   either	   growth	   arrest	   or	   apoptosis.	   The	   significance	   of	   p53	   in	  cancer	   is	   clearly	   demonstrated	   by	   the	   fact	   that	   approximately	   50%	   of	   human	  cancers	   carry	  alterations	  within	   the	  p53	  gene	  and	   that	   the	   remaining	   tumours	  frequently	   show	   other	   defects	   within	   the	   p53	   pathway.	   Our	   discovery	   that	  WRAP53	  stabilizes	  the	  p53	  mRNA	  by	  targeting	  its	  5’	  untranslated	  region,	  reveals	  a	   novel	   pathway	   for	   p53	   regulation	   and	   also	   suggests	   a	   novel	   therapeutic	  strategy	  for	  cancer	  treatment.	  	  The	  WRAP53	   gene	  also	   codes	   for	   a	  protein	   that	  has	  a	  major	   role	   in	  Cajal	  body	  integrity	  and	  function.	  Cajal	  bodies	  are	  nuclear	  structures	  implicated	  in	  diverse	  functions	  such	  as	  maturation	  of	  the	  splicing	  machinery	  and	  telomere	  biogenesis.	  The	  WRAP53	  protein	  has	  been	  shown	  to	  direct	  small	  Cajal	  body-­‐specific	  RNAs,	  including	   the	  TERT,	   the	  RNA	  part	   of	   the	   telomerase	   complex,	   to	   these	   nuclear	  structures.	   We	   reveal	   that	   WRAP53	   in	   addition	   directs	   the	   survival	   of	   motor	  neuron	   (SMN)	   complex	   to	   Cajal	   bodies	   and	   that	  WRAP53	   is	   essential	   for	   Cajal	  body	  integrity.	  Our	  findings	  further	  highlight	  the	  role	  of	  WRAP53	  as	  a	  Cajal	  body	  recruitment	   factor	   and	   contribute	   to	   our	   understanding	   of	   the	   molecular	  mechanisms	  behind	  Cajal	  body	  formation.	  	  Interestingly,	   we	   also	   find	   that	   WRAP53	   has	   oncogenic	   properties	   and	   is	  overexpressed	   in	   human	   cancers	   in	   comparison	   to	   primary	   cells.	   Moreover,	  knockdown	   of	   WRAP53	   leads	   to	   massive	   apoptosis	   through	   the	   intrinsic	  mitochondrial	   pathway.	   Human	   cancer	   cells	   are	   more	   sensitive	   to	   WRAP53	  depletion	   as	   compared	   to	   normal	   human	   fibroblasts,	   identifying	  WRAP53	   as	   a	  novel	  therapeutic	  target	  in	  cancer.	  Altogether,	  our	  findings	  suggest	  an	  important	  role	  of	  the	  WRAP53	  RNA	  and	  protein	  in	  tumourigenesis	  with	  great	  implications	  in	  cancer	  therapy.	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2. INTRODUCTION 
2.1 FOREWORD 
This	   thesis	   touches	  upon	  many	  aspects	  of	  cell	  biology,	   including	  regulatory	  RNAs,	  
tumour	   suppressors	   and	   oncogenes,	   cancer,	   cell	   death,	   splicing	   and	   nuclear	  
structure	   formation	   and	   function.	   The	   reason	   is	   that	  WRAP53	   is	   a	   multifaceted	  
gene;	   it	   gives	   rise	   to	   a	   regulatory	   RNA	   that	   is	   important	   for	   the	   action	   of	   the	  
tumour	   suppressor	   gene	   p53,	   and	   it	   also	   encodes	   for	   a	   protein	   with	   cancer	  
promoting	   properties	   that	   is	   essential	   for	   the	   formation	   and	   maintenance	   of	  
specific	  nuclear	   structures	   called	  Cajal	  bodies.	  Although	  at	   first	   it	  may	  be	  a	   little	  
difficult	  to	  imagine	  how	  all	  these	  parts	  relate	  to	  each	  other,	  I	  hope	  that	  as	  the	  thesis	  
progresses	  you	  might	  appreciate	  how	  nature	  has	  elegantly	  constructed	  this	  gene	  to	  
fit	  its	  needs.	  This	  work	  is	  just	  the	  beginning,	  and	  future	  studies	  will	  certainly	  shed	  
more	  light	  on	  the	  apparently	  complex	  genomic	  arrangement	  of	  the	  WRAP53	  gene	  
and	  its	  biological	  significance.	  But	  that	  I	  will	  leave	  to	  my	  fellow	  colleagues.	  
With	  that	  said	  let’s	  take	  a	  closer	  look	  at	  the	  biology	  of	  cancer.	  	  
	  
2.2 IT IS ALL ABOUT BALANCE  A	  healthy	  life	  is	  all	  about	  balance.	  You	  need	  to	  find	  a	  balance	  between	  work	  and	  personal	  life,	  and	  between	  eating	  and	  exercising	  to	  remain	  in	  good	  psychological	  and	  physical	  shape.	  The	  same	  rule	  applies	  to	  your	  organs	  and	  tissues;	  they	  need	  to	  coordinate	   the	  balance	  between	  cells	   that	  are	  growing	  and	  the	  cells	   that	  are	  dying	   for	   the	   well-­‐being	   of	   the	   tissues.	   Imbalance	   in	   either	   or	   both	   of	   these	  processes	  may	  have	  dire	  consequences	  causing	  hyperproliferative	  diseases	  such	  as	  cancer.	  Considering	  the	  importance	  of	  sustaining	  tissue	  homeostasis,	  the	  cell	  has	  developed	  an	  arsenal	  of	  regulatory	  circuits	   to	  be	  able	   to	  make	  the	  decision	  on	   whether	   it	   should	   keep	   on	   growing	   and	   dividing,	   or	   arrest	   and	   die.	   This	  decision	  is	  based	  on	  its	  environment	  as	  well	  as	  the	  inner	  condition	  of	  the	  cell	  that	  continuously	   signals	   to	   a	   group	   of	   regulators	   of	   life	   or	   death	   that	   will	   in	   turn	  interpret	   these	   signals	   to	   execute	   appropriate	   responses.	   This	   important	  repertoire	  of	  cellular	  moderators	  can	  be	  divided	  into	  two	  groups;	  oncogenes	  and	  tumour	   suppressor	   genes.	   While	   oncogenes	   are	   the	   green	   lights	   of	   the	   cell,	  promoting	   growth	   and	   preventing	   cell	   death,	   tumour	   suppressors	   are	   the	   red	  lights	   of	   the	   cell,	   preventing	   proliferation	   and	   inducing	   arrest	   and	   cell	   death.	  Malfunction	  in	  one	  or	  several	  of	  these	  essential	  regulatory	  proteins	  is	  enough	  to	  initiate	  a	  process	  that	  eventually	  can	  lead	  to	  the	  growth	  of	  a	  tumour.	  Considering	  the	   large	   number	   of	   existing	   oncogenes	   and	   tumour	   suppressors,	   a	   variety	   of	  different	  combinations	  can	  induce	  tumour	  development.	  Thus	  cancer	  is	  not	  one	  disease	  but	  represents	  a	  spectrum	  of	  different	  diseases,	  each	  with	  their	  own	  set	  of	  genetic	  defects.	  Nevertheless,	  all	  cancers	  have	  some	  characteristic	  phenotypes	  in	   common.	   They	   all	   have	   rendered	   themselves	   insensitive	   to	   growth	  suppressive	   and	   apoptotic	   factors	   by	   inactivating	   tumour	   suppressor	   genes.	   In	  addition,	   they	   have	   activated	   proto-­‐oncogenes	   to	   be	   able	   to	   keep	   on	  proliferating,	   producing	   new	   blood	   vessels	   to	   maintain	   the	   constant	   flow	   of	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nutrients	  and	  oxygen,	  and	  have	  acquired	  invasive	  properties	  to	  be	  able	  to	  move	  out	  from	  their	  own	  niche[1].	  All	  these	  changes	  disrupt	  the	  sacred	  equilibrium	  in	  tissue	  homeostasis	  in	  one	  way	  or	  another.	  Thus,	  cancer	  can	  simply	  be	  described	  as	  a	  disease	  where	  the	  cell	  has	  gone	  out	  of	  balance.	  
What	   is	   then	   an	   antisense	   transcript	   and	   how	   is	   that	   related	   to	   p53	   regulation?	  
Well,	  to	  understand	  that	  we	  need	  to	  take	  one	  step	  back	  and	  see	  what	  has	  happened	  
in	  the	  biological	  research	  community	  the	  past	  decade.	  
	  
2.3 REVISING OUR THOUGHTS No	  area	  of	  molecular	  biology	  has	  experienced	  a	  more	  dramatic	  change	  in	  concept	  and	  perspective	  the	  past	  decade	  than	  the	  ribonucleic	  acid	  (RNA)	  field.	  With	  that,	  also	  the	  traditional	  view	  of	  a	  gene	  has	  been	  revised.	  A	  gene	  was	  considered	  to	  be	  a	   segment	   of	   DNA	   giving	   rise	   to	   the	   functional	   end	   product:	   a	   protein.	   The	  principal	  role	  of	  the	  RNA	  was	  to	  transfer	  the	  genetic	  information	  from	  the	  DNA	  to	  the	  protein,	  either	  as	  a	  messenger	  RNA	  (mRNA)	  or	  as	  part	  of	  the	  translational	  machinery	   in	   the	   form	  of	  ribosomal	  (r)RNA	  and	  transfer	  (t)RNA.	  This	  view	  has	  rapidly	  changed	   in	  recent	  years,	   in	  part	  by	  data	   from	  large-­‐scale	  transcriptome	  projects	   and	   in	  part	  by	   the	   constant	   identification	  of	  new	  classes	  of	   regulatory	  RNAs.	  The	   fact	   that	  80%	  of	   the	  human	  genome	   is	  being	   transcribed	  while	  only	  2%	  of	  the	  genome	  encodes	  for	  proteins	  suggests	  that	  these	  transcripts	  are	  more	  than	   transcriptional	   noise[2,3,4,5].	   Indeed,	   the	   past	   decade	   has	   shown	   us	   that	  RNAs	  per	   se	   can	  have	  similar	   functional	   capabilities	  as	   cellular	  proteins.	  Today	  we	   know	   that	   a	   great	   number	   of	   RNAs	   play	   essential	   roles	   in	  many	   biological	  processes,	   such	   as	   in	   regulation	   of	   gene	   expression	   (microRNAs,	   small	  interfering	   (si)RNAs,	   promoter-­‐associated	   RNAs,	   natural	   antisense	  transcripts(NATs)),	  RNA	  processing	   and	  modification	   (small	   nuclear	   (sn)RNAs,	  small	   nucleolar	   (sno)RNAs,	   small	   Cajal	   body	   (sca)RNAs),	   editing	   (guide	  (g)RNAs),	   protein	   export	   (7S	   RNA	   in	   signal	   recognition	   particle),	   genomic	  stability	   	   (telomerase	  RNA,	  TERC),	   catalytic	   processes	   (ribozymes),	   epigenetics	  (long	  intergenic	  non-­‐coding	  (linc)RNAs),	  and	  the	  list	  goes	  on.	  As	  the	  technology	  improves	   and	   becomes	   more	   cost-­‐effective	   –	   researchers	   are	   discovering	   that	  there	  is	  an	  RNA	  world	  out	  there.	  Thus,	  we	  are	  revising	  what	  we	  used	  to	  consider	  junk	  DNA	  and	  functional	  genes.	  
For	   the	   purpose	   of	   this	   thesis	   I	   will	   focus	   on	   only	   two	   types	   of	   regulatory	   RNAs,	  
namely	  the	  NATs	  and	  the	  RNAs	  involved	  in	  RNA	  processing	  and	  modification.	  Lets	  
start	  by	  taking	  a	  closer	  look	  at	  the	  NAT	  field.	  
	  	  
2.4 NATURAL ANTISENSE TRANSCRIPTS A	   transcriptional	   jungle	   is	   emerging	   in	   which	   both	   DNA	   strands	   are	  simultaneously	   transcribed,	   genes	   overlap	   each	   other	   in	   both	   orientations	   and	  many	   transcripts	   with	   essential	   biological	   functions	   do	   not	   code	   for	   proteins.	  NATs	   are	   a	   group	   of	   regulatory	   RNAs	   that	   are	   defined	   by	   their	   complete	   or	  partial	   complementarity	   to	   target	   (sense)	   RNAs.	   They	   are	   divided	   into	   two	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groups	   depending	   on	   whether	   they	   act	   in	   trans	   or	   cis.	   While	   trans-­‐NATs	   are	  transcribed	   from	  different	   locations	   than	   their	   targets	   such	   as	  microRNAs,	   cis-­‐NATs	  are	  transcribed	  from	  the	  same	  genomic	  locus	  as	  their	  target	  but	  from	  the	  opposite	  DNA	  strand.	  	  Large-­‐scale	   transcriptome	   projects	   indicate	   that	   overlapping	   genes	   are	   a	  common	   phenomenon	   in	   the	   human	   genome.	   Up	   to	   50-­‐70%	   of	   all	   genes	   have	  been	  suggested	  to	  have	  antisense	  partners[6,7,8,9].	  They	  can	  overlap	  in	  a	  head-­‐to-­‐head	   (5’	   to	  5’)	  or	   tail-­‐to-­‐tail	   (3’	   to	  3’)	  direction	  or	  one	  gene	  may	  completely	  overlap	   the	  other	  gene	   (Figure	  1).	  Many	  antisense	   transcripts	  have	  maintained	  their	   genomic	   organization	   during	   evolution	   suggesting	   that	   they	   have	   a	  functional	  significance[10].	   	  Although	  the	  majority	  of	  these	  transcripts	  are	  non-­‐coding	   RNAs[8],	   there	   are	   many	   examples	   of	   protein-­‐coding	   genes	   with	  overlaps[11,12].	   Expression	   profiling	   as	   well	   as	   experimental	   studies	   have	  revealed	   that	   the	   sense/antisense	   pairs	   may	   be	   expressed	   in	   a	   concordant	   or	  discordant	   fashion.	   While	   a	   concordant	   expression	   describes	   a	   positive	  correlation	  between	  the	  sense/antisense	  pair	  –	  knockdown	  of	  antisense	  lead	  to	  decreased	   levels	   of	   sense	   transcript,	   the	   discordant	   regulation	   refers	   to	   an	  inverse	   correlation	   –	   knockdown	   of	   antisense	   leads	   to	   increased	   levels	   of	   the	  sense	   transcript[8,13].	   Although	   only	   a	   handful	   of	   sense/antisense	   pairs	   have	  been	   carefully	   characterized[11,14,15],	   it	   has	   been	   suggested	   that	   antisense	  regulation	  is	  a	  common	  type	  of	  gene	  control	  in	  the	  human	  genome.	  
	  
Figure	  1:	  Illustration	  of	  the	  different	  types	  of	  overlap	  between	  sense/antisense	  genes	  
	  
2.4.1 Mechanisms of Action NATs	   are	   a	   heterogeneous	   group	   of	   RNAs,	   apparent	   from	   the	   fact	   that	   they	  display	  both	  concordant	  and	  discordant	  types	  of	  regulation.	  Several	  models	  have	  been	   proposed	   to	   explain	   the	   molecular	   mechanisms	   of	   cis-­‐acting	   NATs,	  including	   transcriptional	   interference,	   RNA	  masking,	   epigenetic	   alteration	   and	  double-­‐stranded	   RNA	   (dsRNA)	   mechanisms[16,17].	   Next	   will	   follow	   a	   short	  description	  of	  each	  model	  and,	  when	  possible,	  an	  example	  with	   implications	   in	  cancer.	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to	  either	  pass	  or	  displace	  one	  another,	   instead	   they	  stop	  at	   the	  crash	  site.	  This	  leads	   to	   transcriptional	   interference	   and	   the	   degradation	   of	   the	   incomplete	  transcripts.	  In	  this	  type	  of	  regulation,	  it	  is	  not	  the	  antisense	  transcript	  per	  se	  that	  is	  important	  for	  the	  regulation	  but	  rather	  the	  act	  of	  transcription.	  In	  silico	  studies	  suggest	   that	   transcriptional	   collision	   might	   also	   be	   prevalent	   in	   mammals,	  especially	   for	   sense/antisense	   genes	   with	   an	   overlap	   of	   more	   than	   2	   kb[22].	  However,	   it	   is	   not	   believed	   to	   be	   the	  predominant	  mechanisms	  of	   action	   since	  transcription	   can	   occur	   at	   different	   times	   at	   the	   same	   chromosomal	   locus	   or	  sense/antisense	   genes	   may	   be	   transcribed	   at	   the	   same	   time	   from	   different	  chromosomes[16].	  	  
2.4.1.2 RNA Masking RNA	  masking	  refers	  to	  the	  function	  of	  an	  antisense	  transcript	  to	  block	  splice	  sites	  or	  block	  binding	  of	  enhancers/repressors	  of	   splicing.	   In	   this	  way	   the	  antisense	  transcript	  will	  change	  the	  balance	  between	  splice	  variants,	  favouring	  one	  splice	  variant	  over	  the	  other.	  An	  example	  of	  this,	  which	  also	  has	  implications	  in	  cancer,	  is	  the	  antisense	  gene	  of	  ZEB2/SIP1	  called	  ZEB2	  AS[23].	  ZEB2	  is	  a	  transcriptional	  repressor	   of	   E-­‐cadherin,	   a	   cell-­‐cell	   adhesion	   protein	   whose	   downregulation	   is	  associated	   with	   increased	   proliferation,	   invasion	   and/or	   metastasis[24].	   The	  ZEB2	  AS	  inhibits	  the	  splicing	  of	  the	  first	  intron	  of	  ZEB2,	  favouring	  a	  splice	  variant	  with	  enhanced	  translational	  capacity.	  This	  leads	  to	  increased	  levels	  of	  ZEB2	  and	  consequently	   decreased	   levels	   of	   E-­‐cadherin[23].	   ZEB2	   AS	   is	   often	  overexpressed	  in	  tumours	  with	  low	  E-­‐cadherin	  expression[23].	  
2.4.1.3 Epigenetic Modulators NATs	   have	   also	   been	   linked	   to	   epigenetic	   regulation	   via	   DNA	   methylation	   or	  chromatin	  remodelling	  [25,26,27,28].	  Antisense	  transcripts	  have	  been	  suggested	  to	   recruit	   either	   DNA	   or	   histone-­‐modifying	   enzymes,	   leading	   to	   epigenetic	  changes[16,29].	  Depending	  on	  the	  type	  of	  complex	  that	  the	  NAT	  recruits,	   it	  can	  hypothetically	   lead	  to	   increased	  or	  decreased	  transcription	  of	   the	  sense	  mRNA.	  The	   antisense	   transcripts	   of	   both	   the	   tumour	   suppressor	   genes	   p15	   and	   p21	  have	   been	   shown	   to	   recruit	   chromatin	   remodelling	   complexes	   that	   induce	  inhibitory	  histone	  modifications	  to	  shut	  down	  their	  transcription[26,28].	  	  	  
2.4.1.4 dsRNA Mechanisms dsRNA	  duplex	  formation,	  which	  refers	  to	  the	  interaction	  between	  the	  sense	  and	  antisense	  transcript,	  may	  have	  several	  outcomes	  leading	  to	  both	  concordant	  and	  discordant	  regulation.	  Sense/antisense	  duplex	  formation	  has	  been	  suggested	  to	  lead	   to	   RNA	   editing,	   activation	   of	   the	   RNAi	   pathway,	   and	   changes	   in	   RNA	  turnover,	  export	  and	  translation	  rates[16].	  RNA	  editing	  refers	  to	  numerous	  cellular	  processes	  that	  change	  the	  RNA	  sequence	  from	   that	   designated	   by	   their	   DNA	   templates[30].	   One	   such	   process	   is	   the	  deamination	  of	  adenosine	  to	  inosine	  in	  dsRNA	  that	  can	  lead	  to	  nuclear	  retention	  or	   cytoplasmic	   degradation	   of	   the	   RNA	   transcripts[31].	   Although,	   RNA	   editing	  has	   been	   shown	   to	   be	   prevalent	   in	   introns	   of	   primary	   transcripts,	   they	   are	  uncommon	  in	  sense/antisense	  overlapping	  regions[32],	  suggesting	  that	  it	  is	  not	  a	  common	  pathway	  of	  action.	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Sense/antisense	   hybrids	   can	   also	   be	   targeted	   by	   the	   RNAi	   pathway	   to	   be	  processed	   into	   so-­‐called	   endogenous	   small	   interfering	   RNAs	   (endo-­‐siRNA),	  which	  would	   lead	   to	   the	   sequence-­‐specific	   silencing	   of	   targeted	   genes.	   In	   fact,	  several	   endogenous	   siRNAs	   mapped	   to	   overlapping	   transcripts	   have	   been	  identified	   in	   Arabidopsis	   and	  Drosophila[33,34].	   Their	   existence	   has	   also	   been	  confirmed	  in	  both	  mouse	  and	  human	  in	  recent	  years	  [35,36],	  suggesting	  a	  role	  of	  this	  pathway	  in	  NAT-­‐mediated	  gene	  regulation.	  	  Antisense	   transcripts	   can	   also	   directly	   or	   indirectly	   induce	   changes	   in	   the	  stability	  of	  their	  sense	  mRNAs[11,14,15,37].	  They	  have	  been	  proposed	  to	  act	  by	  nuclear	   import/export	   mechanisms,	   by	   inducing	   alterations	   in	   the	   secondary	  structure	   of	   the	   sense	   transcript	   to	   either	   expose	   or	   mask	   binding	   sites	   for	  stabilizing/destabilizing	   factors,	   by	   masking	   microRNA-­‐binding	   sites	   or	   by	  recruiting	  stabilizing	  factors[16].	  WRAP53	  belongs	  to	  this	  group	  of	  NATs,	  since	  it	  stabilizes	   p53	   mRNA	   seemingly	   via	   direct	   RNA-­‐RNA	   interaction[11].	   WRAP53	  will	  be	  discussed	  in	  detail	  in	  Paper	  I.	  
Clearly,	  cis-­‐NATs	  can	  have	  impact	  on	  many	  levels	  of	  gene	  expression.	  As	  additional	  
NATs	  are	  being	   identified	  and	   characterized	  also	   their	   roles	   in	   further	  biological	  
settings	  are	  being	  uncovered.	  Future	  studies	  will	   certainly	  yield	  new	   insights	   into	  
both	  their	  prevalence	  and	  significance	  in	  the	  human	  genome.	  Now	  it	  is	  time	  to	  turn	  
our	  focus	  to	  another	  aspect	  of	  my	  thesis,	  namely	  the	  tumour	  suppressor	  gene	  p53,	  
and	  to	  why	  p53	  is	  one	  of	  the	  most	  studied	  genes	  in	  history,	  all	  categories.	  
	  
2.5 THE GUARDIAN OF THE GENOME One	  of	  the	  biggest	  obstacles	  for	  most	  cancers	  is	  to	  escape	  the	  tumour	  suppressor	  gene	  p53,	  also	  known	  as	  the	  guardian	  of	  the	  genome.	  This	  is	  demonstrated	  by	  the	  fact	   that	   the	  p53	  gene	   is	  mutated	   in	  more	   than	  50%	  of	   all	   human	   cancers	   and	  that	   the	   rest	   have	   in	   one	   way	   or	   another	   inactivated	   the	   p53	   pathway[38](	  www.iarc.fr/p53;	  p53.free.fr).	  p53	  is	  a	  transcription	  factor	  that	  is	  induced	  upon	  cellular	   stress,	   such	  as	  DNA	  damage,	  oncogene	  activation,	  nutrient	  deprivation,	  hypoxia,	  and	  ribosomal	  stress.	  Depending	  on	  the	  type,	  strength	  and	  persistence	  of	  the	  stress,	  p53	  will	  alter	  the	  expression	  of	  a	  subset	  of	  target	  genes	  to	  induce	  cell	  cycle	  arrest,	  apoptosis,	  senescence,	  differentiation,	  DNA	  repair,	  inhibition	  of	  angiogenesis	   and	   even	   survival	   [39,40,41,42,43].	  However,	   the	   function	   of	   p53	  goes	  beyond	   its	   function	   in	  stress	  response,	  p53	  has	  been	   implicated	   in	  a	  wide	  range	   of	   processes	   such	   as	   embryonic	   development,	   neurodegenerative	   and	  metabolic	  diseases	  and	  aging[44,45,46].	  p53	  acts	  at	  several	  levels	  to	  direct	  the	  cell	  towards	  the	  desired	  response.	  Its	  role	  as	  a	  transcriptional	  activator	  is	  probably	  the	  best	  characterized	  function	  of	  p53.	  The	  p53	  protein	  forms	  a	  tetramer	  that	  binds	  DNA	  with	  a	  certain	  consensus	  site,	  which	  is	  made	  up	  of	  two	  tandem	  copies	  of	  the	  motif	  “RRRCWWGYYY”	  separated	  by	  a	  spacer	  of	  0	  to	  13	  base	  pairs	  (“R”	  represents	  purines,	  “W”	  represents	  adenine	  or	  thymine,	  and	  “Y”	  represents	  pyrimidines).	  By	  binding	  to	  the	  DNA,	  p53	  recruits	  the	   general	   transcription	   machinery	   to	   the	   promoter-­‐enhancer	   region	   of	   its	  target	   genes,	   inducing	   their	   transcription[47,48].	   However,	   p53	   can	   also	   block	  transcription	   by	   binding	   to	   DNA[49].	   In	   addition,	   p53	   can	   re-­‐localize	   to	   the	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mitochondria	  and	  directly	  promote	  apoptosis[50]	  as	  well	  as	  affect	  RNA-­‐binding	  and	  microRNA	  processing[51].	  	  The	   list	  of	  p53	  target	  genes	   is	   long	  and	   it	  keeps	  growing,	  adding	  new	  potential	  outcomes	   of	   p53	   induction.	   But	   how	   exactly	   does	   p53	   decide	   which	   genes	   to	  activate?	  Well,	   there	   is	  no	  simple	  answer	  to	   this	  question	  but	   there	  are	  several	  hypothetical	   explanations.	   One	   explanation	   refers	   to	   the	   affinity	   of	   the	   p53	  protein	   to	   its	   target	  genes.	  While	  some	  genes	  have	  perfect	  p53	  consensus	  sites	  (high	   affinity),	   other	   genes	   have	   less	   perfect	   but	   still	   functional	   sites	   (low-­‐affinity).	   Since	   cell	   cycle	   genes	   tend	   to	   have	   high	   affinity	   response	   elements,	  whereas	  pro-­‐apoptotic	  genes	  have	  low-­‐affinity	  response	  elements,	  the	  initial	  p53	  response	   is	   cell	   cycle	   arrest	   followed	   by	   apoptosis.	   The	   abundance	   of	   the	   p53	  protein	  also	  plays	  an	  important	  role	  in	  p53’s	  choice	  of	  targets,	  where	  high	  levels	  of	   p53	   promote	   a	   pro-­‐apoptotic	   response.	   In	   addition,	   post-­‐transcriptional	  modifications	   as	   well	   as	   cofactors	   bound	   to	   the	   p53	   protein	   affect	   p53’s	  selectivity	  [40,52,53,54].	  Thus,	  the	  abundance	  of	  the	  p53	  protein,	  the	  persistence	  of	  its	  activation,	  post-­‐translational	  modifications	  and	  p53	  binding	  partners	  help	  p53	  in	  the	  activation	  of	  the	  appropriate	  response.	  Moreover,	  basal	  levels	  of	  p53	  are	  enough	  to	  execute	  certain	  of	  its	  functions	  such	  as	  those	  involved	  in	  fertility,	  development,	  metabolism,	  and	  stem	  cell	  maintenance[53,55].	  	  
2.5.1 p53 in DNA Damage Response DNA	   damage	   has	   many	   origins;	   it	   can	   be	   induced	   by	   exposure	   to	   different	  environmental	  stress	  factors	  such	  as	  radiation	  or	  DNA	  damaging	  agents	  or	  it	  can	  occur	   during	   natural	   processes	   such	   as	  mitosis	   or	   DNA	   replication.	   Since	  DNA	  damage	  is	  practically	   inevitable,	  eukaryotes	  have	  developed	  a	  highly	  conserved	  genome	  surveillance	  system	  called	  the	  DNA	  damage	  response	  (DDR).	  Depending	  on	  the	  type	  of	  DNA	  damage,	  DDR	  will	  activate	  different	  signalling	  cascades	  that	  will	  initially	  induce	  cell	  cycle	  arrest,	  allowing	  the	  cell	  to	  repair	  the	  damage,	  and	  if	  the	  damage	  persists	  to	  trigger	  apoptosis.	  p53	  is	  a	  central	  player	  in	  this	  process.	  From	   being	   barely	   detectable	   in	   healthy	   non-­‐stressed	   cells,	   p53	   levels	   are	  dramatically	  increased	  upon	  DNA	  damage.	  This	  induction	  is	  mainly	  achieved	  by	  the	   stabilization	   of	   the	   p53	   protein	   that	   allows	   p53	   to	   exert	   its	   function	   as	   a	  transcription	  factor	  [54,56].	  Interestingly,	  p53	  has	  been	  shown	  to	  be	  activated	  in	  a	  cyclically	  periodic	  manner	  upon	  DNA	  damage[57].	  This	  would	  provide	  the	  cell	  time	   to	   repair	   the	   DNA	   damage	   during	   the	   first	   activation	   and	   if	   the	   damage	  persists	  to	  induce	  cell	  death	  upon	  the	  second	  round	  of	  induction[56].	  	  An	   important	   target	   gene	   in	   the	   induction	  of	   cell	   cycle	   arrests	   is	   p21.	   p21	   is	   a	  cyclin-­‐dependent	   kinase	   (CDK)	   inhibitor	   that	   upon	   induction	   binds	   and	   blocks	  cyclin-­‐CDK	  complexes.	  Cyclin-­‐CDK	  complexes	  are	  essential	  in	  the	  progression	  of	  the	  cell-­‐cycle	  and	  once	  blocked	  the	  cell-­‐cycle	  will	  halt	  to	  allow	  for	  DNA	  repair.	  In	  addition	  to	  inhibiting	  cyclin-­‐CDK	  complexes,	  p21	  associates	  with	  PCNA,	  a	  protein	  involved	  in	  DNA	  synthesis,	  to	  block	  DNA	  replication[58].	  	  	  	  If	   the	   damage	   is	   too	   severe	   for	   the	   cell	   to	   handle,	   the	   p53	   response	   shifts	   to	  apoptosis.	   P53	   can	   induce	   both	   mitochondrial-­‐independent	   cell	   death	   via	  induction	   of	   the	   death	   receptor	   Fas,	   as	   well	   as	   mitochondrial-­‐dependent	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apoptosis	  via	  the	  BH3-­‐family	  proteins	  Bax,	  NOXA	  and	  PUMA[59].	  I	  will	  cover	  the	  different	  cell	  death	  pathways	  later	  on	  so	  bear	  with	  me	  for	  now.	  	  
2.5.2 p53 Regulation Considering	  that	  p53,	  literally,	  decides	  over	  life	  and	  death,	  the	  cell	  needs	  to	  keep	  a	   close	   eye	  on	  p53	   levels.	  You	  do	  not	  want	   to	  die	   if	   you	  do	  not	  need	   to,	   right?	  Thus	  different	  regulatory	  mechanisms	  have	  been	  established	  to	  ensure	  that	  p53	  gets	   activated	   only	  when	   necessary,	   and	   to	   control	   that	   p53	   induces	   the	   right	  response	  to	  a	  given	  signal[60,61].	  	  Thirty	   years	   of	   intense	   p53	   research	   have	   revealed	   an	   impressive	   arsenal	   of	  regulatory	   circuits	   that	   can	   induce	  p53	   response.	  However,	   the	   focus	  has	  been	  mainly,	  if	  not	  solely,	  on	  the	  post-­‐translational	  regulation	  of	  p53.	  Relatively	  little	  is	  known	  about	  the	  transcriptional	  and	  post-­‐transcriptional	  regulation	  of	  p53.	  It	  is	   only	   until	   quite	   recently	   that	   just	   a	   handful	   of	   papers	   have	   been	   published	  regarding	   this	   aspect	   of	   p53	   regulation,	   in	   comparison	   to	   thousands	   that	   deal	  with	  its	  post-­‐translational	  regulation.	  
2.5.2.1 Post-translational Regulation To	  continuously	  synthesize	  and	  degrade	  a	  protein	  is	  an	  efficient	  way	  for	  a	  cell	  to	  maintain	  an	  important	  regulator	  of	  life	  and	  death	  at	  low	  levels	  while	  allowing	  it	  to	  have	  a	  rapid	  response	  to	  a	  stimulus.	  Thus,	  the	  p53	  protein	  is	  degraded	  almost	  as	   soon	  as	   it	   has	  been	   synthesized	   in	  normal,	   healthy	   cells.	  There	   are	  multiple	  mechanisms	  that	  keep	  p53	  at	  low	  levels	  but	  the	  main	  regulator	  is	  Mdm2.	  Mdm2	  is	  an	  E3	  ligase	  that	  targets	  p53	  for	  degradation	  by	  adding	  ubiquitin	  proteins	  to	  it,	  in	   a	   process	   called	   poly-­‐ubiquitination.	   The	   addition	   of	   these	   small	   molecules	  marks	   p53	   as	   a	   substrate	   for	   the	   cell’s	   protein	   degradation	   machinery,	   the	  proteasome.	   Mdm2	   also	   binds	   to	   p53	   to	   mask	   its	   transactivation	   domain,	  preventing	  p53	   from	  activating	   target	   genes.	  To	   ensure	   that	   the	  p53	   induction	  upon	   stress	   is	   not	   stronger	   or	   persists	   longer	   than	   necessary,	  Mdm2	   is	   also	   a	  target	  gene	  of	  p53.	  Thus,	   there	   is	  a	  negative	   feed-­‐back	   loop	  where	   induction	  of	  p53	  leads	  to	  its	  own	  destruction	  by	  increasing	  the	  levels	  of	  its	  E3	  ligase,	  Mdm2.	  In	  addition	  to	  Mdm2,	  there	  are	  many	  other	  proteins	  shown	  to	  bind	  and	  regulate	  p53,	   and	   p53	   activity	   and	   action	   can	   also	   be	   regulated	   by	   a	   number	   of	   post-­‐translational	   modifications	   such	   as	   phosphorylation,	   acetylation	   and	  methylation[62,63].	  	  
2.5.2.2 Transcriptional Regulation Little	   is	   known	   about	   the	   transcriptional	   regulation	   of	   p53.	   The	   few	   studies	  conducted	   suggest	   that	   p53	   in	   fact	   can	   transactivatate	   itself[64]	   and	   also	   that	  PKCδ	   and	   HOXA5	   are	   positive	   and	   Bcl6	   negative	   regulators	   of	   p53	  transcription[65,66,67].	  	  
As	  I	  mentioned	  earlier,	  the	  constant	  synthesis	  and	  degradation	  of	  a	  protein	  might	  
allow	  for	  a	  rapid	  response	  to	  external	  stimuli	  but	  it	  is	  also	  very	  energy	  consuming.	  
A	  slightly	  slower	  but	  more	  energy-­‐conserving	  way	  of	  regulating	  gene	  expression	  is	  
via	  post-­‐transcriptional	  pathways,	  which	  include	  modification	  of	  mRNA	  stability	  or	  
translational	  rates.	  Before	  I	  get	  into	  the	  post-­‐transcriptional	  regulation	  of	  p53,	  lets	  
take	  a	  moment	  to	  discuss	  the	  mRNA	  per	  se.	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2.5.2.3 The Conventional mRNA A	   conventional	   eukaryotic	  mRNA	   encodes	   for	   a	   protein	   and	   is	   synthesized	   by	  RNA	  polymerase	  II.	  Immediately	  after	  transcription,	  the	  mRNA	  is	  capped	  with	  a	  5’7-­‐methylguanosine	   structure	   and	   a	   3’poly(A)	   tail	   is	   added.	   These	   two	  structures	  are	  essential	  for	  the	  processing	  of	  the	  mRNA	  and	  provide	  binding	  sites	  for	   different	   types	   of	   factors	   affecting	   export,	   translation	   and	   stability	   of	   the	  mRNA	   transcript[68].	   Before	   the	   transcript	   is	   shipped	   to	   the	   cytoplasm	   for	  translation	  of	   the	  protein,	   the	  non-­‐coding	   intervening	   sequences	   called	   introns	  must	  be	   removed	  so	   that	   the	  mRNA	  can	  be	   translated	   into	   the	  correct	  protein.	  The	  removal	  of	   introns	  and	  rejoining	  of	   the	  exons	   is	  called	  splicing	  and	  will	  be	  discussed	  later	  in	  the	  thesis.	  The	  mRNA	  per	  se	  is	  divided	  into	  three	  regions;	  a	  5’	  untranslated	  region	  (UTR),	  an	  open	   reading	   frame	   (ORF)	   and	   a	   3’UTR.	  While	   the	   ORF	   codes	   for	   the	   protein,	  there	  are	  sequences	  within	  the	  two	  UTRs	  that	  control	  different	  aspects	  of	  mRNA	  regulation	  such	  as	  stability/turnover,	  export,	  silencing	  and	  translation.	  Examples	  of	  regulatory	  sequences	  are	  internal	  ribosomal	  entry	  sites	  (IRES),	  which	  provide	  alternative	  translation	  initiations	  sites,	  AU-­‐rich	  elements	  (AREs),	  which	  provide	  docking	   sites	   usually	   for	   degradation	   and	   translational	   inhibition	   factors,	  microRNA	   sites	   for	   Drosha-­‐mediated	   regulation	   as	   well	   as	   protein-­‐binding	  sequences[69,70,71].	  	  
2.5.2.4 The Importance of mRNA Stability mRNA	   turnover	   is	   important	   for	   the	   abundance	   of	   cellular	   transcripts	   and	   the	  proteins	  they	  encode[72].	  While	  some	  mRNAs	  are	  degraded	  within	  a	  few	  hours	  other	   transcripts	   have	   half-­‐lives	   extending	   over	   several	   cell	   cycles[73].	   The	  decay	  rates	  of	  most	  transcripts,	  such	  as	  those	  encoding	  housekeeping	  genes,	  do	  not	   change	  upon	  environmental	   signals[68].	  However,	   transcripts	   encoding	   for	  proteins	  that	  need	  to	  be	  under	  tight	  control	  because	  of	  their	  important	  roles	  in,	  for	  example,	  cell	  growth	  or	  cell	  death,	  such	  as	  cyclins,	  p21	  and	  p53,	  do	  change	  in	  response	   to	  external	   factors[68,74,75].	  By	  providing	  stability	  and	  consequently	  changing	   decay	   rates	   of	   unstable	   mRNAs,	   the	   cell	   can	   in	   a	   rapid	   and	   energy-­‐preserving	   way	   implement	   dramatic	   changes	   in	   the	   expression	   of	   specific	  genes[68].	  	  There	   are	   several	  mRNA	  decay	   pathways	   initiated	   either	   from	   the	   5’	   or	   the	   3’	  ends.	   In	  general,	   the	  removal	  of	   the	  5’cap	  or	  the	  poly(A)	  tail	   is	  rate	   limiting	  for	  degradation.	   These	   protective	   structures	   need	   to	   be	   removed	   for	   the	  exonucleases	  to	  access	  the	  mRNA	  ends.	  In	  mammals	  the	  main	  pathway	  of	  mRNA	  decay	   is	  via	  deadenylation.	  This	  happens	  either	  by	   the	  removal	  of	   the	  5’cap	  by	  the	   exonuclease	  Xrn1	  or	   the	   loss	   of	   the	  poly(A)-­‐tail	   by	   the	   exosome.	  Although,	  most	  of	  the	  mRNA	  degradation	  occurs	  in	  the	  cytoplasm,	  there	  is	  evidence	  of	  the	  existence	  of	  the	  exosome	  in	  the	  nucleus[76].	  	  
2.5.3.5 Post-transcriptional Regulation A	   series	   of	   papers	   published	   within	   the	   past	   few	   years	   have	   highlighted	   the	  importance	   of	   post-­‐transcriptional	   regulation	   in	   p53	   expression	   and	   function	  (Figure	  2)[77].	  	  All	  three	  regions	  of	  the	  p53	  mRNA,	  including	  the	  5’UTR,	  ORF	  and	  3’UTR,	  have	  been	   implicated	   in	   the	  post-­‐translational	   regulation.	  The	  existence	  of	   destabilizing	   elements	   in	   the	   5’UTR	   of	   p53	  was	   already	   suggested	   a	   decade	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ago,	  when	  studies	  in	  chicken	  and	  mice	  showed	  that	  5’UTR	  deletion	  constructs	  of	  p53	  were	  significantly	  more	  stable	  compared	   to	   full-­‐length	  p53	  constructs[78].	  In	   recent	   years,	   it	   has	   been	   shown	   that	   the	   p53	   5’UTR	   can	   form	   a	   stem-­‐loop	  which	  hinders	  ribosome	  access	  during	  cap-­‐dependent	  translation	  initiation.	  The	  ribosomal	   protein	   RPL26	   can	   help	   to	   overcome	   this	   inhibitory	   effect	   by	  promoting	  the	  usage	  of	  an	  IRES	  that	  exists	  within	  the	  5’UTR[79].	  In	  addition,	  the	  p53	  3’UTR	  can	  fold	  back	  on	  itself	  and	  form	  a	  loop	  by	  base-­‐pairing	  with	  a	  region	  in	   the	   5’UTR,	   which	   further	   enhances	   the	   translational	   promoting	   effects	   of	  RPL26[80].	   Nucleolin,	   another	   regulatory	   protein	   that	   was	   shown	   to	   bind	   the	  5’UTR	  of	  p53,	  instead	  inhibits	  translation	  rates	  presumably	  by	  stabilizing	  the	  5’	  stem-­‐loop[79].	  Furthermore,	  WRAP53,	  a	  cis-­‐antisense	  gene	  of	  p53,	  stabilizes	  p53	  mRNA	  via	  the	  5’UTR	  of	  the	  mRNA	  [11].	  The	  WRAP53	  gene	  and	  its	  function	  in	  p53	  action	  are	  described	  in	  Paper	  I.	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As	   mentioned	   earlier,	   the	   3’UTR	   are	   in	   general	   important	   regulatory	   regions	  containing	  both	  stabilizing	  and	  destabilizing	  sequences.	  The	  3’UTR	  of	  p53	  is	  no	  exception;	   it	   contains	   AREs	   and	   other	   protein-­‐binding	   sequences	   as	   well	   as	  microRNA-­‐target	   sites.	   AREs	   exist	   in	   transcripts	   that	   generally	   require	   very	  precise	  control	  of	   their	  expression,	   such	  as	   in	   the	  proto-­‐oncogene	  myc	  and	   the	  cyclins[75].	  These	   sequences	   are	  protein-­‐binding	   sites	   that	   are	  often	  bound	  by	  factors	   that	   exert	   a	   negative	   effect	   on	   the	   mRNA,	   by	   either	   promoting	  degradation	  or	  inhibiting	  translation.	  However,	  in	  the	  case	  p53,	  the	  ARE	  is	  bound	  by	  two	  positive	  regulators,	  namely	  HuR	  and	  Wig-­‐1,	  which	  confer	  both	  increased	  p53	  mRNA	  stability	  and	  increased	  translation[83,84,85,86].	  Interestingly,	  Wig-­‐1	  is	   also	  a	   target	  gene	  of	  p53	   that	   is	   induced	  upon	  stress,	   constituting	  a	  positive	  feedback	  loop	  to	  stabilize	  p53	  mRNA	  levels	  upon	  DNA	  damage.	  This	  stresses	  the	  importance	  of	  increased	  p53	  mRNA	  stability	  in	  DNA	  damage	  response.	  Also,	  two	  negative	   regulators	   of	   p53	   translation	   have	   been	   reported	   to	   bind	   within	   the	  3’UTR	  of	  p53,	  namely	  a	  still	  unidentified	  protein	  referred	  to	  as	  protein	  X	  and	  Gld-­‐1[84,87].	   Several	   microRNAs	   have	   also	   recently	   been	   found	   to	   regulate	   p53	  expression	  by	  targeting	  the	  3’UTR[88,89,90,91,92].	  	  
Another	  aspect	  of	  my	  thesis	   that	   is	  partly	   touched	  upon	   in	  Paper	   I,	  as	  part	  of	   the	  
p53	  DNA	  damage	  response,	  but	  that	  is	  the	  main	  focus	  of	  Paper	  III	  is	  what	  awaits	  all	  
of	  us	  sooner	  or	  later:	  the	  eternal	  death!	  	  
	  
2.6 DEATH AS PART OF LIFE 	  Every	  day	  50-­‐70	  billion	  cells	  die	  in	  an	  adult	  human	  body.	  The	  maintenance	  of	  cell	  numbers	   and	   cellular	   positioning	  within	   the	   different	   tissues	   are	   prerequisites	  for	   the	  well-­‐being	   of	   a	  multicellular	   organism.	  Defects	   in	   the	   regulation	   of	   cell	  death	   results	   in	   pathological	   conditions	   such	   as	   developmental	   defects,	  autoimmune	  and	  neurodegenerative	  diseases,	  and	  cancer[93,94,95].	  	  There	  are	  two	  major	  types	  of	  cell	  death;	  programmed	  cell	  death,	  also	  known	  as	  apoptosis,	   and	   necrosis.	   Apoptosis	   is	   a	   programmed,	   multistep,	   energy-­‐dependent	   cell	   death	   characterized	   by	   membrane	   blebbing,	   cell	   shrinkage,	  chromatin	  condensation	  and	  ultimately	  nuclear	  and	  cellular	   fragmentation	   into	  apoptotic	   bodies.	   Since	   neighbouring	   phagocytic	   cells	   engulf	   these	   nuclear	  bodies,	   their	   inner	   content	   is	   not	   released	   to	   the	   outer	   tissue	   and	   no	   immune	  response	   is	   triggered.	   Necrosis,	   on	   the	   other	   hand,	   occurs	  when	   cells	   rupture,	  often	  due	  to	  external	  factors	  such	  as	  heat	  or	  cold,	  mechanical	  tearing	  of	  cells	  and	  low	   blood	   supply.	   Necrotic	   cell	   death	   leads	   to	   the	   release	   of	   cellular	  compartments	   into	  the	  surrounding	  tissue,	   triggering	  an	   inflammatory	  reaction	  by	  the	  immune	  system[96,97,98].	  	  
2.6.1 Apoptosis Programmed	   cell	   death	   is	   a	   highly	   conserved	   mechanism	   responsible	   for	   the	  removal	  of	  unwanted	  and	  damaged	  cells,	  which	  is	  critical	  for	  tissue	  homeostasis	  and	   development[99,100].	   Two	   signalling	   pathways	   trigger	   apoptosis;	   the	  extrinsic	   or	   receptor-­‐mediated	   pathway,	   and	   the	   intrinsic	   or	   mitochondrial-­‐mediated	  pathway	  (Figure	  3).	  While	  the	  extrinsic	  pathway	  has	  its	  origin	  outside	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the	  cell	  through	  the	  activation	  of	  specific	  death	  receptors	  on	  the	  cell	  surface,	  the	  intrinsic	  pathway	  is	  initiated	  from	  within	  the	  cell[93,101].	  	  	  
 
Figure	  3:	  A	  simplified	  overview	  of	  the	  intrinsic	  and	  the	  extrinsic	  apoptotic	  pathways.	  tBid	  stands	  for	  
truncated	  Bid	  
 
2.6.2 Caspases Caspase	   (cysteine-­‐dependent	   aspartate	   specific	   protease)	   activation	   plays	   a	  central	  role	  in	  both	  intrinsic	  and	  extrinsic	  pathways.	  In	  normal	  cells,	  all	  caspases	  exist	   in	   an	   inactive	   form	   (pro-­‐caspase);	   however,	   upon	   death	   stimuli,	   these	  caspases	  are	  proteolytically	  cleaved,	  rendering	  them	  active.	  In	  general,	  they	  are	  divided	   into	   initiator	   and	   executioner	   caspases.	   Initiator	   caspases,	   such	   as	  caspase	  8	  and	  9,	  are	  activated	  upon	  death	  stimuli	  by	  autocleavage	  and	  they	  will	  in	  turn	  cleave	  the	  executioner	  caspase,	  such	  as	  caspase	  3,	  6	  and	  7,	  to	  shift	  them	  into	   their	   active	   forms.	   The	   executioner	   caspases	   will	   then	   breakdown	   the	  cytoskeletal	  and	  nuclear	  structures	  as	  well	  as	  activate	  DNases	  that	  subsequently	  will	  fragment	  the	  DNA	  into	  small	  pieces[93,102,103].	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membrane	  leads	  to	  the	  release	  of	  multiple	  proteins	  including	  cytochrome	  c	  (cyt	  c)	  from	  the	  inner	  membrane	  out	  to	  the	  cytosol[104,105].	  The	  release	  of	  cyt	  c	  will	  promote	   the	   activation	   of	   the	   caspase	   9,	   an	   initiator	   caspase	   that	   in	   turn	   will	  activate	  the	  executioner	  caspase	  3[106].	  Other	  pro-­‐apoptotic	  factors	  that	  are	  also	  released	  from	  the	  disrupted	  mitochondria,	  includes	  SMAC/Diablo	  and	  AIF,	  which	  further	  promote	  cell	  death[107].	  The	   permeability	   of	   the	   mitochondrial	   membrane	   is	   highly	   dependent	   on	   the	  balance	  between	  pro-­‐	  and	  anti-­‐apoptotic	  members	  of	  the	  Bcl-­‐2	  family[108,109].	  The	   pro-­‐apoptotic	   proteins	   Bax	   and/or	   Bak	   have	   been	   shown	   to	   form	  heterotetrameric	   channels	   that	   induce	   permeabilization	   of	   mitochondrial	  proteins	   such	   as	   cyt	   c[110].	   The	   anti-­‐apoptotic	  members,	   Bcl-­‐2	   and	  Bcl-­‐XL,	   on	  the	   other	   hand,	   maintain	   the	   integrity	   of	   the	   membrane	   by	   inhibiting	  oligomerization	  of	  Bax	  and/or	  Bak[111].	  The	  actions	  of	  Bcl-­‐2/Bcl-­‐XL	  can	  in	  turn	  be	   counteracted	   by	   other	   pro-­‐apoptotic	  members	   such	   as	   PUMA,	   which	   binds	  Bcl-­‐2/Bcl-­‐XL	  and	  blocks	  their	  anti-­‐apoptotic	  functions[112].	  	  
2.6.4 Death Receptors The	   extrinsic	   pathway	   is	   triggered	   by	   the	   activation	   of	   the	   death	   receptors	   by	  their	   respective	   ligands,	   such	   as	   FasL	   binding	   to	   its	   receptor	   Fas.	   It	   can	   be	  induced	   by	   either	   the	   release	   of	   the	   death	   ligands	   or	   the	   upregulation	   of	   the	  death	   receptors	   to	   sensitize	   the	   cells	   to	   the	  existing	   ligands.	  Upon	  activation,	   a	  complex	   cascade	   of	   events	   is	   initiated	   that	   includes	   the	   recruitment	   of	   the	  adaptor	   protein	   Fas-­‐associated	   death	   domain	   (FADD)	   and	   the	   formation	   of	   a	  death-­‐inducing	  signalling	  complex	  (DISC)	  via	  caspase-­‐8	  or	  -­‐10.	  The	  activation	  of	  DISC	   will	   in	   turn	   activate	   the	   effector	   caspases	   3,	   6,	   and	   7,	   leading	   to	  fragmentation	  of	  the	  cell[93,113].	  
2.6.5 p53-Dependent and Independent Apoptosis Both	  extrinsic	  and	  intrinsic	  pro-­‐apoptotic	  genes	  are	  found	  among	  the	  extensive	  list	   of	   p53	   target	   genes.	   p53-­‐mediated	   apoptosis	   acts	   primarily	   through	   the	  intrinsic	   pathway	   by	   the	   transactivation	   of	   factors	   that	   act	   upstream	   of	   the	  mitochondria,	  such	  as	  Bax	  and	  PUMA,	  as	  well	  as	  genes	  that	  act	  downstream,	  such	  as	   APAF1.	   APAF1	   acts	   as	   a	   coactivator	   of	   caspase	   9	   and	   helps	   to	   initiate	   the	  caspase	   cascade.	   However,	   p53	   can	   also	   activate	   the	   extrinsic	   pathway	   by	  inducting	   the	   expression	   of	   Fas	   and	   DR5	   death	   receptors	   as	   well	   as	   the	   gene	  coding	   for	   the	   Fas	   ligand,	   TNFS6.	   Furthermore,	   p53	   can	   upregulate	   the	  expression	   of	   caspase	   6	   to	   potentiate	   the	   already	   initiated	   cell	  death[59,114,115].	  	  Although	  p53	  has	   a	  major	   role	   in	   the	   induction	  of	   the	  mitochondrial	   apoptotic	  pathway,	  the	  intrinsic	  pathway	  can	  also	  be	  induced	  by	  p53-­‐independent	  means.	  	  In	  fact	  many	  of	  the	  genes	  that	  are	  strongly	  linked	  to	  p53-­‐mediated	  apoptosis	  can	  also	  be	  triggered	  in	  the	  absence	  of	  p53[116,117,118].	  An	  example	  is	  PUMA	  that	  is	  induced	  in	  response	  to	  a	  variety	  of	  signals	  such	  as	  ER	  stress	  and	  growth	  factor	  withdrawal[118].	  
It	   is	   time	   to	   completely	   shift	   gears	   and	   turn	   our	   attention	   to	   a	   specific	   nuclear	  
structure	  called	  the	  Cajal	  body,	  which	  is	  the	  main	  focus	  of	  Paper	  II.	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2.7 THE CAJAL BODY – A CENTURY LATER The	   cell	   nucleus	   is	   highly	   organized	   and	   contains	   an	   array	   of	   nonmembrane-­‐bound	  structures	   that	  allow	  for	  essential	  processes,	  such	  as	  RNA	  synthesis	  and	  processing,	   to	   occur	   in	   the	   most	   efficient	   way.	   The	   Cajal	   body	   is	   one	   of	   the	  organelles	  that	  was	  discovered	   in	  vertebrate	  neurons	  more	  than	  100	  years	  ago	  by	  the	  neurologist	  Santiago	  Ramon	  y	  Cajal[119].	  It	  is	  an	  evolutionary	  conserved	  structure	  found	  in	  very	  divergent	  organisms	  including	  plants,	  insects,	  fish,	  mice	  and	  humans	  [120,121].	  Cajal	  bodies	  are	  dynamic	  structures	  that	  move,	  split	  and	  fuse	  in	  the	  nucleoplasm	  and	  within	  the	  nucleolus[122]	  and	  their	  size	  and	  number	  varies	  depending	  on	  cell	   type	  and	  cell	   cycle	  stage[123].	  Cajal	  bodies	  have	  been	  implicated	   in	   many	   biological	   processes	   such	   as	   in	   the	   spliceosomal	   snRNP	  biogenesis[124,125]	   and	   in	   the	   assembly	   of	   spliceosomal	   sub-­‐complexes[126,127].	   They	   have	   also	   been	   reported	   to	   be	   involved	   in	   the	  biogenesis	  and	  delivery	  of	  telomerase	  to	  telomeres[128,129,130,131].	  Moreover,	  Cajal	   bodies	   contain	   basal	   transcription	   factors	   and	   can	   associate	  with	   snRNA	  genes,	   histone	   gene	   cluster	   and	   PML	   (promyelocytic	   leukemia)	  bodies[132,133,134].	   Studies	   in	   Arabidopsis	   further	   suggest	   a	   role	   of	   Cajal	  bodies	  in	  certain	  steps	  of	  microRNA	  and	  siRNA	  biogenesis[135,136].	  	  	  Although	  Cajal	  bodies	  have	  been	   linked	  to	  many	  essential	  processes	   in	   the	  cell,	  their	  biological	  significance	  remains	  unclear.	  Arabidopsis	  or	  Drosophila	  mutants	  lacking	  coilin	  (a	  signature	  protein	  of	  Cajal	  bodies	  described	  in	  detail	  below),	  and	  thus	   lacking	   Cajal	   bodies,	   are	   viable	   and	   show	  no	   obvious	   growth	   suppressive	  phenotype[137,138].	   Similarly,	   human	   cells	   lacking	   Cajal	   bodies	   are	   viable	   but	  exhibit	   decreased	   proliferation	   and	   splicing	   rates[139,140].	   However,	   coilin	  knockout	   mice	   display	   a	   semi-­‐lethal	   phenotype.	   Half	   of	   these	   mice	   die	   at	   late	  gestation,	  and	  the	  remaining	  mice	  exhibit	  reduced	  fertility	  and	  fecundity[141].	  In	  addition,	  knockdown	  of	  coilin	  in	  zebrafish	  is	  embryonically	  lethal[142].	  Although	  these	   results	   may	   seem	   inconsistent,	   they	   have	   been	   suggested	   to	   reflect	   the	  differences	  in	  development	  rates	  between	  the	  organisms	  and	  their	  requirement	  for	   splicing	  efficiency[142].	  Many	  of	   the	  processes	   that	  occur	   in	   the	  Cajal	  body	  can	  also	  take	  place	   in	  the	  nucleoplasm	  in	  the	  absence	  of	  Cajal	  bodies[143].	  The	  formation	  of	  Cajal	  bodies	  is	  therefore	  believed	  to	  be	  a	  way	  for	  the	  cell	  to	  increase	  the	   efficiency	   of	   these	   processes	   by	   concentrating	   all	   the	   factors	   in	   one	   place.	  Thus,	  having	  Cajal	  bodies	  ensures	  robust	  and	  efficient	  processing	  during	  periods	  of	   rapid	   growth[144,145].	   In	   contrast	   to	   this	   notion,	   they	   have	   also	   been	  suggested	   to	   regulate	   the	   rate	   of	   RNA	   processing	   in	   the	   cell	   by	   sequestering	  splicing	   components[146].	   In	   either	   case,	   the	   fact	   that	   Cajal	   bodies	   are	   highly	  conserved	   in	   evolution	   provides	   evidence	   that	   they	   confer	   advantage	   to	   the	  organism.	  	  
2.7.1 Cajal Bodies and Cancer Several	   lines	   of	   data	   suggest	   that	   Cajal	   bodies	   might	   be	   involved	   in	  carcinogenesis.	   Cajal	   body	   number	   and	   size	   are	   increased	   in	   transformed	  cells[147].	   Although	   this	   may	   just	   be	   a	   reflection	   of	   the	   increased	  transcriptional/metabolic	  state	  of	  the	  cells,	   it	  also	  implies	  an	  increased	  need	  or	  even	   a	   dependency	   of	   Cajal	   body	   functions.	   Also,	   TERT	   has	   been	   shown	   to	  accumulate	   in	  Cajal	  bodies	   in	  cancer	  cells[148].	  Furthermore,	   the	  region	  where	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the	  coilin	  gene	  resides	  has	  been	  reported	  to	  be	  amplified	   in	  anaplastic,	  but	  not	  benign	  or	  atypical	  meningiomas[149].	  Moreover,	  coilin	  -­‐/-­‐	  mice	  are	  less	  prone	  to	  develop	   spontaneous	   tumours[132].	   Future	   studies	   will	   tell	   if	   these	   data	   are	  circumstantial	   or	   if	   Cajal	   bodies	   in	   fact	   have	   a	   role	   in	   tumour	   development.	  However,	   it	   is	   important	   to	   keep	   in	  mind	   that	   coilin	   has	   functions	   outside	   the	  Cajal	   bodies[150]	   (see	   below),	   suggesting	   that	   coilin	  per	   se	  may	   play	   a	   role	   in	  cancer	  progression.	  	  
Cajal	   bodies	   are	   enriched	   in	   a	   diversity	   of	   factors,	   such	   as	   coilin,	   snRNPs,	   SMN,	  
snoRNPs,	   scaRNAs	  and	  TERT,	   reflecting	   the	   ongoing	  processes	   that	   take	   place	   in	  
these	  structures.	  Lets	  go	  through	  the	  different	  components	  that	  may	  be	  of	  interest	  
for	  us.	  	  
2.7.2 Coilin Coilin	   is	   the	   marker	   protein	   for	   Cajal	   bodies	   and	   is	   essential	   for	   Cajal	   body	  integrity	  and	   function[151].	  Although	   the	  exact	   function	  of	  coilin	   is	  not	  known,	  coilin	   is	   believed	   to	   act	   as	   the	   platform	   of	   the	   Cajal	   bodies	   and	   to	   bring	   all	  components	   of	   the	   Cajal	   body	   together	   to	   facilitate	   their	   various	   activities.	  Additionally,	   coilin	   has	   a	   role	   in	   the	   association	   of	   Cajal	   bodies	   with	   PML	  bodies[134],	   which	   are	   nuclear	   structures	   that	   are	   associated	   with	  transcriptional	  regulation,	  apoptosis	  and	  genome	  stability[152],	  and	  with	  gemini	  of	   coiled	   bodies	   (gems)[151]	   (described	   below).	   Coilin	   has	   an	   oligomerization	  domain	  in	  the	  N-­‐terminus	  necessary	  for	  its	  localization	  to	  Cajal	  bodies[153],	  and	  Sm-­‐protein	  and	  SMN-­‐protein	  binding	  sites	   in	   its	  C-­‐terminus	  [151,154].	  Because	  coilin	  has	   separate	  binding	  domains	   for	  SMN	  and	  Sm,	   it	  has	  been	   suggested	   to	  interact	   with	   both	   free	   Sm-­‐proteins	   and	   intact	   snRNPs[154],	   consequently	  having	  roles	  in	  snRNP	  biogenesis	  and	  recycling	  (these	  processes	  are	  described	  in	  more	  detail	  below).	  	  Experimental	   removal	   of	   coilin	   leads	   to	   the	   disruption	   of	   typical	   Cajal	   bodies,	  whereas	  so	  called	  “residual	  Cajal	  bodies”	  remain.	  There	  are	  two	  types	  of	  residual	  Cajal	   bodies;	   one	   that	   contains	   scaRNAs	   [125]	   and	   one	   that	   contains	   proteins	  such	  as	  fibrillarin	  and	  Nopp140	  [155].	  However,	  neither	  of	  the	  structures	  is	  able	  to	   recruit	   SMN,	   highlighting	   the	   role	   of	   coilin	   in	   the	   association	   of	   the	   SMN	  complex	  with	   Cajal	   bodies.	   In	   line	  with	   these	   data,	   it	   has	   been	   suggested	   that	  Cajal	  bodies	  have	  separate	  compartments	  for	  different	  activities[140].	  Inhibition	  of	   snRNP	   biogenesis	   by	   depletion	   of	   protein	   such	   as	   SMN,	   TGS1	   and	   PHAX	   in	  HeLa	   cells,	   leads	   to	   the	   disruption	   of	   typical	   Cajal	   bodies,	   but	   at	   least	   two	  different	   coilin-­‐containing	   nuclear	   bodies	   remain	   containing	   snoRNP/scaRNP	  components[140].	   Therefore,	   it	   is	   conceivable	   that	   Cajal	   bodies	   indeed	   have	  different	   compartments	   and	   that	   depletion	   of	   factors	   in	   certain	   compartments	  only	   disrupts	   that	   compartment,	   while	   other	   compartments	   remain	   and	   form	  residual	  Cajal	  bodies.	  	  	  The	   fact	   that	   only	   30%	   of	   the	   total	   amount	   of	   coilin	   is	   found	   in	   the	   Cajal	  bodies[156],	   suggests	   that	   coilin	   has	   other	   functions	   in	   addition	   to	   its	   role	   in	  Cajal	   body	   formation	   and	   maintenance.	   Indeed,	   coilin	   has	   been	   recently	  implicated	  in	  DNA	  repair	  and	  centromere	  damage	  response[150,157].	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snRNPs	  are	   the	   rate-­‐limiting	   factors	   for	  de	  novo	   formation	  of	  Cajal	  bodies	   [140].	  
Let’s	  have	  a	  brief	  overview	  of	  their	  function	  in	  splicing.	  	  
2.7.3 Splicing RNA	   splicing	   refers	   to	   the	   process	   by	   which	   non-­‐coding	   introns	   are	   removed	  from	  newly	   synthesised	  mRNA	  and	   the	  exons	  are	   rejoined.	  This	   is	   an	  essential	  process	   that	   occurs	   before	   a	   typical	   eukaryotic	   mRNA	   is	   exported	   to	   the	  cytoplasm	   for	   translation.	   The	   splicing	   reaction	   is	   performed	   in	   a	   series	   of	  reactions	   that	   are	   catalysed	   by	   the	   spliceosome,	   a	   large	   RNA/protein	  macromolecular	   machine.	   Spliceosomes	   consist	   of	   several	   ribonucleoprotein	  (RNP)	   units	   called	   snRNPs	   and	   numerous	   non-­‐snRNP	   factors.	   A	   snRNP	   unit	  contains	  seven	  core	  proteins	  assembled	  on	  a	  uridine-­‐rich	  RNA	  molecule	  called	  a	  U	  snRNA	  (described	  in	  more	  detail	  below)[158,159,160].	  There	  are	  two	  types	  of	  spliceosomes	   consisting	   of	   slightly	   different	   snRNPs:	   the	  major	   and	   the	  minor	  spliceosomes.	   The	   major	   spliceosome	   is	   composed	   of	   U1,	   U2,	   U4,	   U5	   and	   U6	  snRNPs	   and	   is	   responsible	   for	   splicing	   of	   the	   vast	   majority	   of	   pre-­‐mRNA	  introns[161].	  The	  minor	  spliceosome	  consists	  of	  U11,	  U12,	  U4ATAC,	  U5	  (same	  as	  in	   the	  major	   form)	   and	   U6ATAC	   snRNPs	   and	   splices	   out	   rare	   classes	   of	   introns	  [162].	  	  	  	  
	  
 
Figure	  4:	  The	   life-­‐cycle	  of	  U1,	  U2,	  U4	  and	  U5	  snRNPs.	  The	  drawing	  shows	  the	  key	  steps	  of	  snRNP	  
biogenesis.	   The	  matured	   snRNA	   is	   shown	   as	   by	   green	   Sm	   proteins.	   The	  matured	   snRNP	   complex	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2.7.4 snRNP Biogenesis  SnRNAs	   are	   a	   small	   group	   of	   non-­‐polyadenylated	   ncRNAs	   that	   are	   highly	  abundant	   in	   the	   cell.	   They	   are	   classified	   either	   as	   Sm-­‐	   or	   Lsm-­‐class	   of	   RNAs	  depending	   on	   the	   structural	  motifs	   they	   contain	   and	   the	   type	   of	   proteins	   they	  associate	  with.	  U1,	  U2,	  U4	   and	  U5	  of	   the	  major	   spliceosome	  belong	   to	   the	   Sm-­‐class	  and	  are	  characterized	  by	  a	  7-­‐methylguanosine	  cap	  at	  their	  5’end	  (5’m7G),	  a	  3’stem	   loop	  and	  an	  Sm-­‐protein	  binding	  site.	  The	  U6	  snRNA,	  on	   the	  other	  hand,	  belongs	  to	  the	  Lsm-­‐class,	  which	  also	  forms	  a	  RNP	  but	  with	  Lsm-­‐proteins	  and	  has	  a	  different	  type	  of	  5’end	  and	  3’stem	  loop[163,164].	  The	   biogenesis	   of	   snRNPs	   prior	   to	   their	   assembly	   into	   the	   spliceosome	   is	   a	  complex	  process	   that	   includes	  both	  nuclear	  and	  cytoplasmic	  phases	   (Figure	  4).	  All	  spliceosomal	  snRNAs	  except	  U6	  are	  transcribed	  by	  a	  specialized	  form	  of	  RNA	  polymerase	   II[165],	   and	   then	  exported	   to	   the	   cytoplasm	  by	   an	   export	   complex	  consisting	   of	   the	   snRNA-­‐specific	   adaptor	   protein	   PHAX,	   the	   export	   receptor	  chromosome	   region	  maintenance-­‐1	   (CRM1),	   the	   cap-­‐binding	   complex	   and	   Ran	  GTPase[166,167].	  	  Once	  out	   in	   the	  cytoplasm,	   the	  export	  complex	  dissociates	  as	   the	  SMN	  complex	  binds	  to	  the	  snRNAs[166,168].	  The	  SMN	  complex,	  which	  will	  be	  described	  more	  in	   detail	   later,	   is	   a	   multimeric	   complex	   that	   recognises	   specific	   sequence	  elements	  in	  the	  snRNAs	  and	  brings	  together	  the	  snRNAs	  with	  a	  set	  of	  seven	  Sm-­‐proteins	  to	  form	  the	  Sm-­‐core	  RNP[169,170].	  The	  order	  of	  interaction	  seems	  to	  be	  important	   for	   the	   assembly	   of	   functional	   snRNP.	   The	   SMN	   complex	  must	   first	  bind	  to	  Sm-­‐proteins	  before	  binding	  to	  the	  snRNAs	  [171].	  Although	  Sm-­‐proteins	  are	   able	   to	   spontaneously	   assemble	   on	   snRNA	   in	   vitro[172,173],	   the	   SMN	  complex	   is	   required	   in	   vivo	   to	   facilitate	   the	   process	   and	   to	   ensure	   the	   specific	  binding	  of	  Sm-­‐proteins	  to	  the	  correct	  RNA	  targets[171,174].	  	  	  Upon	  assembly	  of	  the	  snRNP,	  SMN	  recruits	  TGS1	  for	  the	  hypermethylation	  of	  the	  5’cap	   to	   form	   a	   2,2,7-­‐trimethylguanosine	   (TMG)	   cap	   structure[175,176].	   In	  addition,	   the	   3’end	   is	   trimmed	   by	   a	   yet-­‐to-­‐be-­‐identified	   exonuclease[177,178],	  which	   further	   facilitates	   the	   nuclear	   import.	   The	   formation	   of	   the	   TMG-­‐cap	  triggers	   the	   assembly	   of	   the	   import	   complex.	   The	   nuclear	   import	   utilises	   the	  nuclear	   import	   receptor	   importinβ	   either	   by	   TMG	   cap-­‐dependent	   or	   Sm-­‐dependent	  pathway.	  The	  TMG	  cap-­‐dependent	  pathway	  operates	  via	   the	   import	  adaptor	  snurportin-­‐1,	  which	  binds	   the	  modified	  5’cap	  of	   the	  snRNA	  and	  brings	  the	  snRNP	  complex	   together	  with	   importinβ[179]	   to	  allow	   for	   the	  re-­‐import	  of	  the	  complex	  to	  the	  nucleus.	  In	  the	  Sm-­‐dependent	  pathway,	  SMN	  has	  been	  shown	  to	   link	   the	   snRNP	  complex	   to	   importinβ	  and	   the	   interaction	  between	  SMN	  and	  importinβ	   has	   been	   demonstrated	   to	   be	   enough	   for	   the	   nuclear	   import	   of	   the	  snRNP	   complex[180,181].	   However,	   the	   existence	   of	   an	   additional	   adaptor	  protein	   that	   mediates	   the	   interaction	   between	   the	   Sm/SMN	   protein	   and	  importinβ	  has	  been	  suggested	  [182].	  Upon	  re-­‐entry	  of	  the	  snRNP	  complexes	  into	  the	  nucleus	  via	  nuclear	  pore	  complexes[183],	  importinβ	  dissociates[184]	  and	  the	  complex	  localises	  to	  the	  Cajal	  bodies.	  	  	  Within	  the	  Cajal	  body,	  scaRNPs	  perform	  site-­‐specific	  pseudouridylation	  and	  2’-­‐O-­‐
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methylation	  of	   target	  snRNA	  residues[125],	  modifications	   that	  are	  essential	   for	  the	  function	  of	  the	  snRNPs[185].	  The	  matured	  snRNP	  complex	  is	  either	  directed	  to	   perichromatin	   fibrils	   to	   participate	   in	   splicing	   or	   stored	   in	   nuclear	   speckles	  (interchomatin	  granule	  clusters)	   for	   later	  use[186].	  There	  are	  also	  reports	   that	  suggest	   a	   transient	   stay	   of	   the	   mature	   snRNPs	   in	   the	   nucleolus	   prior	   to	   their	  localization	  in	  speckles[140].	  Cajal	  bodies	  have	  also	  been	  implicated	  as	  sites	  for	  the	  formation	  of	  the	  tri-­‐snRNPs,	  which	  are	  the	  central	  units	  of	  the	  spliceosome.	  The	   tri-­‐snRNPs	  consists	  of	  U4/U6	  and	  U5	  snRNPs	  and	  are	   first	   assembled	  as	  a	  U4/U6	   di-­‐snRNP	   and	   then	   into	   a	   U4/U6.U5	   tri-­‐snRNP	   prior	   to	   entering	   the	  spliceosome.	  After	  splicing,	  the	  spliceosome	  disintegrates	  and	  individual	  U4,	  U6	  and	   U5	   snRNPs	   reassemble	   into	   a	   new	   tri-­‐snRNP,	   before	   re-­‐entering	   the	   next	  splicing	  cycle[126,187,188].	  	  
	  Unlike	  U1,	  U2,	  U4	  and	  U5	  snRNPs,	  U6	  snRNP	  biogenesis	  is	  entirely	  nuclear.	  U6	  is	  transcribed	   by	  RNA	   polymerase	   III,	   and	   in	   a	   series	   of	   steps,	  which	   is	   not	   fully	  understood,	  a	  heptameric	  ring	  of	  Lsm-­‐proteins	  are	  added[189].	  Also,	  unlike	  the	  other	   snRNPs,	   U6	   snRNP	   undergoes	   maturation	   in	   the	   nucleolus	   by	  snoRNPs[190,191].	   The	   mature	   form	   of	   U6	   snRNP	   then	   localizes	   to	   the	   Cajal	  bodies	   for	   the	   formation	   of	   the	   U4/U6	   di-­‐	   and	   U4/U6.U5	   tri-­‐snRNPs	   prior	   to	  localizing	  to	  the	  nuclear	  speckles[126,187,188].	  	  
The	   SMN	   complex	   plays	   an	   essential	   role	   in	   snRNP	   assembly	   as	   well	   as	   in	   the	  
import	   of	   the	   complex	   into	   the	  nucleus.	  Due	   to	   its	   roles	   in	   snRNP	  biogenesis	   it	   is	  
also	  important	  for	  the	  Cajal	  body	  formation	  and	  function.	  
2.7.5 The Survival of Motor Neuron Complex  The	  SMN	  complex	   is	   a	  multiprotein	   complex	   that	   contains	  SMN,	  Gemin2-­‐8	  and	  Unrip.	  In	  addition	  to	  its	  function	  in	  the	  assembly	  of	  the	  spliceosomal	  snRNPs,	  it	  has	   also	   been	   suggested	   to	   have	   roles	   in	   the	   biogenesis	   of	   telomerase[192],	  microRNPs[193]	   and	   snoRNPs[194,195,196].	   The	   SMN	   complex	   has	   been	   the	  focus	  of	  intense	  research	  due	  to	  its	  link	  to	  the	  neurodegenerative	  disease	  Spinal	  Muscular	  Atrophy	  (SMA),	  which	  is	  associated	  with	  loss	  or	  mutations	  of	  the	  SMN1	  gene[197,198].	   The	   SMN	   complex	   is	   present	   both	   in	   the	   cytoplasm	   and	   in	   the	  nucleus,	   where	   it	   is	   highly	   enriched	   in	   nuclear	   structures	   called	   gems.	   Gems	  resemble	   Cajal	   bodies	   in	   number	   and	   size	   and	   colocalize	   with	   Cajal	   bodies	   in	  most	   adult	   tissue	   cell	   lines.	   However,	   in	   fetal	   tissues	   and	   certain	   types	   of	   cell	  lines,	   gems	   and	   Cajal	   bodies	   are	   separate	   distinct	   nuclear	   structures.	   Gems	  contain	  SMN	  and	  associated	  proteins	  but	  lack	  snRNPs	  and	  coilin.	  Their	  biological	  significance	  is	  not	  known[169].	  	  SMN	   is	   the	   central	   component	   of	   the	   SMN	   complex.	   It	   has	   an	   RNA	   binding	  domain	   at	   its	   N-­‐terminus[199],	   followed	   by	   a	   tudor	   domain	   that	   binds	   to	  arginine	  and	  glycine	  (RG)	  rich	  motifs,	  found	  in	  numerous	  proteins	  such	  as	  coilin	  and	  Sm-­‐proteins[151,200,201].	  These	  motifs	  are	  important	  for	  bringing	  the	  Sm-­‐proteins	  together	  with	  snRNAs.	  In	  its	  C-­‐terminal	  region,	  SMN	  has	  a	  proline	  rich	  region	  that	  acts	  as	  a	  protein	  binding	  domain[202]	  and	  a	  tyrosine	  and	  glycine	  rich	  region	   via	   which	   it	   oligomerizes.	   This	   self-­‐association	   is	   important	   for	   the	  stability	  of	  the	  protein[203,204].	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Although	  the	  precise	  function	  and	  stoichiometry	  of	  the	  individual	  components	  of	  the	  SMN	  complex	  is	  still	  not	  fully	  understood,	  it	  has	  been	  shown	  that	  Gemin2,	  3,	  5,	   7	   and	  8	  directly	   interact	  with	   SMN[169,205,206].	  Gemin4	   interacts	  with	   the	  complex	  via	  Gemin3,	  whereas	  Gemin6	  interact	  via	  Gemin7[207,208].	  The	  Unrip	  protein	  associates	  with	  the	  SMN	  complex	  through	  Gemin6	  and	  7[209].	  Gemin2	  is	  believed	   to	  play	  an	  essential	   role	   in	   the	  SMN	  complex	  by	   stabilizing	   it[210].	   In	  fact,	   just	   a	   minimal	   complex	   consisting	   of	   SMN	   and	   Gemin2	   is	   sufficient	   to	  facilitate	  Sm	  core	  formation[211,212],	  which	  suggests	  that	  there	  are	  redundant	  functions	   between	   the	   different	   components	   of	   the	   SMN	   complex	   in	   Sm-­‐core	  assembly.	  Gemin3	  is	  an	  RNA	  helicase	  that,	  together	  with	  Gemin4,	  is	  required	  for	  chaperoning	  of	   the	  snRNPs	  [207,213].	  Gemin5	  has	  been	  shown	  to	  directly	  bind	  snRNAs	  and	  is	  believed	  to	  be	  the	  specificity	  factor	  that	  allows	  the	  SMN	  complex	  to	   distinguish	   snRNAs	   from	   other	   cellular	   RNAs	   [214].	   Gemin6,	   Gemin7	   and	  Unrip	   form	   a	   complex	   required	   for	   efficient	   assembly	   of	   snRNPs	   and	   that	  associate	  with	  SMN	  via	  Gemin8[206].	  	  	  
2.7.6 Spinal Muscular Atrophy SMA	  is	  the	  leading	  genetic	  cause	  of	  infant	  mortality	  worldwide,	  affecting	  one	  in	  6000	   infants[215].	   It	   is	   a	   neuromuscular	   disease	   that	   causes	   the	   specific	  degeneration	   of	   motor	   neurons	   in	   the	   spinal	   cord.	   SMA	   is	   caused	   by	   reduced	  levels	  of	  the	  SMN	  protein.	  In	  humans,	  two	  genes,	  SMN1	  and	  SMN2,	  code	  for	  SMN	  and	  in	  95%	  of	  SMA	  cases	  the	  SMN1	  gene	  is	  absent	  [198,216].	  The	  clinical	  severity	  of	   the	  disease	   is	   linked	   to	   the	  copy	  number	  of	  SMN2.	  The	  SMN2	   gene	   is	  nearly	  identical	   to	  SMN1,	  but	  a	  C-­‐T	  change	   in	  exon	  7	   leads	  to	  the	   frequent	  skipping	  of	  exon	  7[217,218].	  Thus,	  90%	  of	  the	  SMN2	  transcripts	  encode	  a	  truncated	  unstable	  version	   of	   the	   SMN	  protein	   termed	   SMNΔexon7.	  However,	   the	   remaining	   10%	  that	  encode	  a	  functional	  full-­‐length	  protein	  is	  enough	  to	  compensate	  for	  the	  loss	  of	   the	  SMN1	  gene	  and	  allow	  the	  survival	  of	  some	  patients	  that	  have	  deletion	  of	  
SMN1.	  Thus,	  increased	  copy	  number	  of	  SMN2	  compensates	  for	  the	  loss	  of	  SMN1	  and	   leads	   to	  milder	   clinical	   symptoms.	   Patients	   with	   the	  most	   severe	   form	   of	  SMA	  (type	  I)	  have	  one	  or	  two	  copies	  of	  SMN2,	  patients	  with	  the	  less	  severe	  type	  II	  form	  of	  SMA	  have	  three	  or	  four	  copies,	  and	  the	  patients	  with	  the	  least	  severe	  form	  (type	  III)	  have	  5	  or	  6	  copies	  of	  SMN2[219,220].	  	  	  The	  reason	  for	  the	  specific	  degeneration	  of	  motor	  neurons	  in	  SMA	  patients	  is	  still	  not	  well	  understood.	  Two	  hypotheses	  have	  been	  proposed	  to	  explain	  SMA.	  The	  first	  model	  is	  based	  on	  the	  role	  of	  the	  SMN	  complex	  in	  snRNP	  biogenesis	  and	  the	  second	  model	  is	  based	  on	  its	  function	  in	  neuronal	  mRNA	  transport[197,198].	  	  	  In	  line	  with	  the	  first	  hypothesis,	  cells	  expressing	  reduced	  levels	  of	  SMN	  or	  SMN	  mutants	   are	   defective	   in	   snRNP	   assembly[221,222].	   Moreover,	   expression	  profiling	   of	   tissues	   from	   SMA	  mouse	  model	   show	   tissue–specific	   alterations	   in	  pre-­‐mRNA	   splicing	   and	   changes	   in	   repertoires	   of	   snRNPs	   [223].	   This	   suggests	  that	   loss	   of	   SMN	   may	   give	   tissue-­‐specific	   changes	   that	   might	   be	   specifically	  deleterious	   for	  motor	   neurons.	   However,	   the	   target	   genes	   that	   are	   specifically	  affected	   are	   still	   unknown.	  Moreover,	   SMN	   and	   snRNPs	   fail	   to	   localise	   to	   Cajal	  bodies	  in	  SMN	  mutant	  harbouring	  cells[182,224,225],	  a	  phenotype	  that	  is	  linked	  to	  SMA	  pathogenesis[225].	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SMN	  has	  also	  been	  proposed	  to	  function	  in	  the	  intracellular	  trafficking	  of	  mRNAs	  in	   motor	   neurons[226,227,228].	   It	   has	   been	   shown	   to	   be	   important	   for	   the	  localization	  of	  β-­‐actin	  mRNA	  to	  the	  growth	  cones	  of	  motor	  neurons[228],	  which	  are	   the	   tips	  of	   the	  axons	  and	   the	  dendrites	  of	   the	  nerve	  cell.	  These	  actin-­‐based	  extensions	  are	   important	   for	   the	  neuronal	  outgrowth,	  and	  rely	  on	   the	  constant	  synthesis	  of	  β-­‐actin.	  In	  SMA	  transgenic	  mice,	  the	  lengths	  of	  dendrites	  are	  reduced	  while	  the	  numbers	  of	  motor	  neurons	  remain	  the	  same[228].	  This,	  together	  with	  the	  fact	  that	  knockdown	  studies	  in	  zebrafish	  show	  deficit	  in	  motor	  neuron	  axonal	  outgrowth[229],	   suggest	   that	  dysfunction	  of	  neuronal	  mRNA	   transport	  may	  be	  the	  cause	  of	  SMA.	  	  	  
In	   addition	   to	   snRNP	   biogenesis	   and	   recycling,	   Cajal	   bodies	   have	   also	   been	  
implicated	  in	  snoRNP	  maturation.	  	  
	  
2.7.7 snoRNAs SnoRNAs	   represent	   one	   of	   the	  most	   diverse	   groups	   of	   ncRNAs	   and	  more	   than	  200	   unique	   snoRNAs	   have	   been	   identified	   up-­‐to-­‐date	   [230,231].	   Their	   main	  function	  is	  to	  guide	  site-­‐specific	  modification	  of	  other	  ncRNAs,	  mainly	  ribosomal	  (r)RNAs	  ,	  transfer	  (t)RNAs	  and	  snRNAs.	  However,	  they	  have	  also	  been	  implicated	  in	  pre-­‐rRNA	  endonucleolytic	  processing	  as	  well	  as	  in	  targeting	  other	  RNAs	  than	  rRNA	   such	   as	   brain-­‐specific	   mRNA	   in	   mammals	   [164,232].	   They	   are	   divided	  either	   into	   C/D	   and	   H/ACA	   snoRNAs	   based	   on	   their	   sequence	   elements	   and	  secondary	   structures.	   While	   C/D	   snoRNAs	   are	   in	   general	   responsible	   for	  methylation,	  H/ACA	  snoRNAs	  guide	  the	  conversion	  of	  uridine	  to	  pseudouridine	  in	   a	   process	   called	   pseudouridylation.	   Depending	   on	   the	   type	   of	   snoRNA,	   they	  associate	  with	  a	  set	  of	  four	  core	  proteins,	  forming	  a	  snoRNP.	  Each	  snoRNA	  has	  a	  stretch	  of	  10-­‐20	  nucleotides	  of	  complementary	  sequence	  to	  the	  target	  pre-­‐RNA	  molecule,	  providing	  specificity	  to	  snoRNP[164,232].	  
Cajal	  bodies	  have	  also	  their	  own	  set	  of	  ncRNAs	  called	  scaRNAs,	  found	  exclusively	  in	  
Cajal	  bodies.	  
2.7.8 scaRNAs  scaRNAs	   are	   related	   to	   snoRNAs	   but	   localize	   specifically	   to	   Cajal	   bodies	   and	  guide	  the	  modification/maturation	  of	  the	  snRNAs.	  ScaRNPs	  are	  in	  general	  more	  complex	   than	   snoRNP	   because	   they	   often	   contain	   two	   snoRNP	   domains.	   They	  can	   have	   either	   a	   C/D	   and	   a	   H/ACA	   domain,	   two	   box	   C/D	   or	   two	   box	   H/ACA	  domains.	   In	  addition,	  scaRNAs	  contain	  a	  conserved	  four-­‐base	  sequence	  called	  a	  Cajal	   body	   (CAB)	   box	   that	   is	   essential	   for	   Cajal	   body	   localization.	   Specific	   CAB	  box-­‐binding	  proteins	  bind	  this	  sequence	  and	  direct	  the	  scaRNAs	  to	  and/or	  retain	  scaRNAs	  in	  Cajal	  bodies.	  Mutations	  within	  the	  CAB	  box	  of	  a	  scaRNA	  mislocalizes	  it	  to	  the	  nucleolus[233,234].	  	  	  
2.7.9 The Telomerase Complex A	  famous	  member	  of	  the	  scaRNA	  family	  is	  TERC,	  the	  telomerase	  RNA	  component.	  TERC,	  together	  with	  the	  telomerase	  reverse	  transcriptase	  (TERT),	  dyskerin	  and	  the	   newly	   discovered	   WRAP53	   (alias	   TCAB1	   and	   Wdr79)	   protein	   form	   the	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telomerase	  holoenzyme	  that	  is	  required	  for	  maintaining	  the	  telomeres[235,236].	  Telomeres	  are	  regions	  of	  repetitive	  DNA	  that	  protect	  the	  ends	  of	  chromosomes	  from	  deterioration.	  As	  cells	  divide	  the	  telomeres	  grow	  shorter	  until	  they	  reach	  a	  critical	   level	   that	   will	   induce	   senescence	   and	   eventually	   cell	   death.	   By	  maintaining	   telomeres,	   telomerase	   supports	   proliferative	   potential	   of	  stem/progenitor	   cells	   as	   well	   as	   cancer	   cells.	   In	   fact,	   the	   maintenance	   of	   the	  telomerase,	   either	   by	   overexpression	   of	   telomerase	   or	   by	   the	   alternative	  lengthening	   of	   telomeres	   (ALT)	   pathway,	   is	   considered	   to	   be	   one	   of	   the	  hallmarks	   of	   tumourigenesis[237,238,239].	   Cajal	   bodies	   are	   important	   for	  telomere	  maintenance[129,235,240]	  and	  have	  been	  suggested	  to	  be	  involved	  in	  directing	  the	  telomerase	  complex	  to	  telomeres	  for	  extension[128,130,241].	  	  
The	  reason	  why	  our	  group	  got	  interested	  in	  the	  WRAP53	  gene,	  at	  the	  first,	  was	  its	  
close	   proximity	   to	   the	   p53	   gene.	   Farnebo	   hypothesized	   that	   there	   may	   be	   an	  
overlap	  between	   these	   two	  genes	  and	   that	   they	  might	  exert	   regulatory	  effects	  on	  
each	  other.	  Indeed,	  after	  careful	  investigation	  she	  found	  that	  WRAP53	  does	  overlap	  
p53	   and	   this	   discovery	   was	   the	   start	   of	   long	   journey	   that	   has	   taken	   us	   from	  
regulatory	  antisense	  transcripts	  to	  nuclear	  architecture	  and	  cancer.	  
	  
2.8 WRAP53 – IN ITS INFANCY  The	   WRAP53	   gene	   has	   three	   starting	   exons:	   1α,	   1β	   and	   1γ	   with	   seemingly	  different	   promoters	   (Figure	   5A).	   Transcripts	   initiated	   from	   these	   exons	   are	  referred	   to	   as	   WRAP53α,	   WRAP53β	   and	   WRAP53γ.	   WRAP53	   is	   a	   heavily	  alternatively	   spliced	   gene	   that	   gives	   rise	   to	   at	   least	   17	   different	   transcripts,	  several	  of	  which	  code	  for	  the	  WRAP53	  protein	  (also	  called	  TCAB1	  and	  Wdr79).	  Exon	  1α	  of	  WRAP53	   overlaps	  p53	   exon	  1	   in	   opposite	  direction	   and	   transcripts	  starting	   from	   this	   exon	   regulate	   p53	   levels	   (further	   described	   in	   Paper	   I).	  WRAP53β	   transcripts	   are	   the	   most	   abundant	   variant	   followed	   by	   WRAP53α	  transcripts,	   while	   the	   least	   prevalent	   transcripts	   originate	   from	   exon	   1γ.	  Considering	  the	  low	  abundance	  of	  WRAP53α	  and	  WRAP53γ	  transcripts,	  and	  that	  knockdown	  of	  WRAP53α	  and	  WRAP53γ	  does	  not	  affect	  WRAP53	  protein	  levels,	  it	   is	   highly	   likely	   that	  WRAP53	   proteins	   originate	   from	  WRAP53β	   transcripts.	  Nonetheless,	  WRAP53α	  and	  γ	  transcripts	  also	  seem	  to	  have	  the	  capacity	  to	  give	  rise	  to	  the	  full-­‐length	  protein[11].	  	  The	  WRAP53	  protein	  contains	  a	  proline-­‐rich	  region	  in	  the	  N-­‐terminus,	  followed	  by	   a	  WD40	   repeat	   domain	   and	   a	   glycine-­‐rich	   region	   in	   the	   C-­‐terminus	   (Figure	  5B).	   WD40	   motifs	   are	   involved	   in	   protein-­‐protein	   as	   well	   as	   in	   protein-­‐RNA	  interactions[242].	   They	   are	   believed	   to	   function	   as	   platforms	   to	   bring	   several	  proteins	  together	  and	  to	  allow	  the	  formation	  of	  macromolecules.	  It	  is	  a	  common	  structural	  domain	  that	  exists	  in	  a	  variety	  of	  proteins	  involved	  in	  everything	  from	  apoptosis	  and	  cell	  cycle	  control	  to	  RNA	  processing	  and	  protein	  degradation.	  In	   the	   last	   few	  years	   there	  has	  been	  a	  major	  boom	   in	   the	  WRAP53	   field.	   From	  being	  completely	  unknown,	  WRAP53	  has	  now	  been	   identified	  as	  a	   regulator	  of	  p53	   (Paper	   I)[11]	  and	  as	  a	  major	  player	   in	  Cajal	  body	   formation	  and	   functions	  (Paper	  II)[234,235,243,244].	  Around	  the	  same	  time	  as	  our	  paper	  describing	  the	  function	   of	   the	   antisense	   transcript	   was	   published,	   two	   papers	   came	   out	  
	   33	  
revealing	  a	  role	  of	  the	  WRAP53	  protein	  in	  directing	  scaRNAs,	  including	  TERT,	  to	  Cajal	  bodies[234,235].	  	  
	  















	   34	  
3. AIMS OF THIS THESIS 
The	  overall	  purpose	  of	   this	   thesis	  was	   to	   characterize	   the	   function	  of	   the	  
WRAP53	  gene	  and	  its	  link	  to	  cancer.	  	  
	  
Specific	  aims	  of	  the	  papers:	  
I. To	   elucidate	   the	   role	   of	   the	   WRAP53	   antisense	   transcript	   in	   the	  
regulation	  of	  p53.	  
	  
II. To	   investigate	   the	   function	   of	   the	   WRAP53	   protein	   in	   Cajal	   body	  
formation	  and	  function.	  
	  
III. To	  assess	  the	  potential	  of	  the	  WRAP53	  protein	  as	  a	  target	  for	  cancer	  
therapy.	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4. RESULTS AND DISCUSSION 
4.1 PAPER I This	   study	   was	   initiated	   because	   of	   the	   genomic	   localization	   of	   WRAP53	   on	  chromosome	  17.	  Considering	  the	  close	  proximity	  of	  the	  WRAP53	  gene	  to	  the	  p53	  gene,	  we	  hypothesised	  that	  these	  two	  genes	  might	  overlap.	  Careful	  investigation	  revealed	  that	  WRAP53	  has	  three	  starting	  exons,	  1α,	  1β	  and	  1γ,	  and	  that	  exon	  1α	  overlaps	   exon	   1	   of	   p53	   in	   an	   opposite	   direction.	   This	   finding	   suggested	   the	  existence	   of	   a	   cis-­‐acting	   regulatory	   circuit	   between	   the	   two	   overlapping	  transcripts.	  In	  support	  of	  this	  idea,	  expression	  profiling	  performed	  in	  cancer	  cell	  lines	  showed	  a	  positive	  correlation	  between	  the	  WRAP53α	  and	  p53	  transcripts.	  	  Initial	   knockdown	   experiments	   showed	   that	   silencing	   of	   WRAP53	  downregulated	   p53	   RNA	   and	   protein	   levels.	   Conversely,	   overexpression	   of	  WRAP53α	   increased	   p53	   levels.	   However,	   this	   regulation	   occurred	   in	   a	   non-­‐reciprocal	   manner	   since	   alterations	   of	   p53	   levels	   had	   no	   effect	   on	   WRAP53	  expression.	  Several	  lines	  of	  evidence	  clearly	  pinpointed	  the	  antisense	  RNA	  as	  the	  regulator	   of	   p53	   expression	   and	   not	   the	   non-­‐overlapping	   transcripts	   nor	   the	  protein.	  First,	  overexpression	  of	  only	  the	  constructs	  that	  contain	  the	  overlapping	  exon	  1α	  region	  induced	  p53	  levels.	  In	  fact,	  overexpression	  of	  just	  the	  overlapping	  region	  that	  does	  not	  encode	  any	  protein	  was	  enough	  to	  increase	  p53	  expression.	  Second,	   although	   the	  majority	   of	   the	   transcripts	   giving	   rise	   to	   the	   protein	   are	  initiated	  from	  exon	  1β,	  only	  siRNAs	  targeting	  exon1α	  transcripts	  downregulated	  p53	  expression.	  Third,	  p53	  levels	  could	  be	  rescued	  upon	  WRAP53	  knockdown	  by	  expression	  of	  WRAP53α	  cDNA	  constructs	  containing	  the	  overlapping	  region	  but	  not	   expressing	  WRAP53	  protein	  due	   to	   a	   premature	   stop	   codon.	  These	   results	  demonstrated	   convincingly	   that	   p53	   regulation	   is	   indeed	   mediated	   by	   the	  WRAP53α	  transcript	  via	  the	  overlapping	  region.	  	  Next	   we	   went	   on	   to	   characterize	   the	   molecular	   mechanism	   underlying	  WRAP53α-­‐mediated	   regulation	   of	   p53	   expression.	   Our	   data	   pointed	   to	   a	  predominant	   post-­‐transcriptional	   regulation.	   Since	   silencing	   of	   WRAP53	   only	  affected	   p53	   mature	   mRNA	   and	   not	   p53	   pre-­‐mRNA,	   and	   the	   fact	   that	   the	  regulation	  seems	  to	  occur	  both	  in	  the	  nucleus	  and	  in	  the	  cytoplasm,	  more	  or	  less	  excluded	   regulation	  at	   a	   transcriptional	   level.	   In	   support	  of	   these	  data,	   in	   vitro	  experiments	  where	  the	  p53	  promoter	  was	  put	   in	   front	  of	   luciferase	  showed	  no	  changes	   in	   luciferase	   activity	   upon	   altered	   levels	   of	   WRAP53α.	   Importantly,	  experiments	   using	   reporter	   constructs	   where	   exon	   1	   of	   p53	   was	   fused	   to	  luciferase	   cDNA,	   showed	   a	   dramatic	   decrease	   in	   luciferase	   activity	   upon	  WRAP53	   depletion.	   These	   data	   support	   a	   post-­‐transcriptional	   regulation	  mediated	  through	  the	  5’UTR	  of	  p53.	  	  	  In	   line	   with	   these	   data,	   transient	   transfection	   of	   2'-­‐O-­‐methyl	   oligonucleotides	  targeting	  either	  exon1α	  of	  WRAP53	  or	  exon1	  of	  p53	  resulted	  in	  decreased	  levels	  of	  p53.	  2'-­‐O-­‐methyl	  oligonucleotides	  are	  commonly	  used	  to	  the	  block	  binding	  of	  microRNA	   to	   their	   targets	   without	   the	   concomitant	   degradation	   of	   the	  microRNA.	  The	  fact	  that	  treatment	  with	  these	  oligos	  reduced	  p53	  levels	  suggests	  that	   WRAP53-­‐mediated	   regulation	   of	   p53	   occurs	   via	   WRAP53α/p53	   RNA	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interaction.	   Since	   transcription	   of	  WRAP53α	   gives	   rise	   to	   a	   perfectly	  matching	  complementary	   RNA	   to	   p53	  mRNA,	   it	   would	   be	   feasible	   that	  WRAP53α	   forms	  RNA	  duplexes	  with	  p53	  mRNA.	  However,	   in	   spite	   of	   our	   extensive	   attempts	   to	  find	  RNA	  duplexes	  in	  living	  cells,	  we	  were	  unable	  to	  detect	  them	  in	  vivo.	  	  	  While	   our	   inability	   to	   detect	   WRAP53α/p53	   duplexes	   may	   be	   due	   to	  experimental	   limitations,	   it	   could	  also	   reflect	   the	   transient	   and	   labile	  nature	  of	  the	   interaction.	   A	   transient	   binding	  would	   be	   enough	   to	   change	   the	   secondary	  structure	  of	  the	  p53	  mRNA,	  leading	  to	  a	  more	  stable	  conformation.	  This	  way,	  one	  WRAP53α	   transcript	   would	   be	   able	   to	   target	   several	   p53	   transcripts,	   which	  could	  also	  explain	  how	  WRAP53α	  is	  capable	  of	  protecting	  p53	  mRNA	  in	  excess.	  Also,	   the	   transient	  nature	  of	   the	   interaction	  may	  be	  essential	   in	  order	   to	  avoid	  activation	   of	   the	   cellular	   interferon-­‐mediated	   pathway	   that	   is	   triggered	   by	   the	  presence	  of	  viral	  RNA	  duplexes,	  resulting	  in	  shutdown	  of	  protein	  synthesis	  and	  culminating	  in	  apoptosis.	  Another	  possibility	  is	  that	  the	  interaction	  does	  not	  rely	  on	  base-­‐pairing	   interactions	   and	   is	   instead	  via	   the	   formation	  of	   secondary	  and	  tertiary	  structures.	  WRAP53α	  might	  also	  mimic	  regulatory	  elements	  within	  the	  p53	   exon1	   and	   block	   the	   binding	   of	   destabilizing	   factors	   to	   p53	   mRNA.	  Furthermore,	  the	  recent	  finding	  that	  the	  3’UTR	  of	  p53	  mRNA	  folds	  back	  on	  itself	  and	   interacts	  with	   the	  5’UTR	   raises	   the	  possibilities	   that	  WRAP53α	  might	   also	  affect	  regulatory	  sequences	  in	  the	  3’UTR.	  	  Although	   the	  molecular	  mechanism	   underlying	  WRAP53α-­‐mediated	   regulation	  of	   p53	   remains	   to	   be	   elucidated,	   the	   biological	   importance	   of	   this	   regulatory	  pathway	   is	   clear;	  WRAP53α	   is	  essential	   for	  p53	  DNA	  damage	  response.	  This	   is	  supported	  by	  the	  fact	  that	  depletion	  of	  WRAP53α	  prevents	  the	  induction	  of	  p53	  and	   several	   of	   its	   target	   genes,	   including	   p21	   and	   PUMA,	   upon	   DNA	   damage.	  Furthermore,	   ectopic	   expression	   of	   WRAP53α	   potentiates	   p53-­‐mediated	  apoptosis.	  Interestingly,	  we	  also	  observed	  an	  increase	  of	  both	  p53	  and	  WRAP53α	  transcripts	   upon	   DNA	   damage.	   This	   suggests	   that	   WRAP53α	   is	   not	   only	  important	   for	  maintaining	   steady-­‐state	   levels	   of	   p53	   but	   is	   also	   induced	   upon	  stress	  to	  confer	  greater	  stability	  and	  sustain	  increased	  levels	  of	  p53.	  Altogether,	  these	   results	   reveal	   an	   important	   role	   of	   WRAP53α	   in	   p53	   DNA	   damage	  response.	  The	  identification	  of	  WRAP53	  adds	  another	  layer	  of	  complexity	  to	  the	  regulation	  of	   p53.	   Although	   additional	   regulatory	   mechanisms	   to	   an	   already	   heavily	  controlled	  gene	  such	  as	  p53	  may	  seem	  redundant,	   it	   reflects	   the	   importance	  of	  maintaining	  the	  appropriate	  levels	  of	  p53	  at	  all	  times.	  Since	  WRAP53α	  is	  induced	  upon	  DNA	  damage,	  we	  can	  assume	  that	  it	  has	  a	  role	  in	  maintaining	  p53	  levels	  in	  response	   to	   DNA	   damage.	   Although	   p53	   is	   initially	   stabilized	   at	   a	   post-­‐translational	   level,	   an	   increase	   in	  WRAP53α	  ensures	   sustained	  de	  novo	   protein	  synthesis	  for	  enhanced	  and	  prolonged	  p53	  response.	  Considering	  the	  oscillating	  expression	   pattern	   of	   p53	   upon	   DNA	   damage[57],	   the	   induction	   of	  WRAP53α	  could	  potentially	  allow	  for	  an	  increased	  p53	  induction	  after	  the	  initial	  activation	  to	  shift	  from	  cell	  cycle	  arrest	  to	  apoptosis.	  	  WRAP53α	   is,	   in	  addition,	   important	   for	  retaining	  basal	  p53	   levels,	   suggesting	  a	  role	   in	   p53	   functions	   that	   are	   not	   stress-­‐induced.	   The	   important	   role	   of	  WRAP53α	  in	  p53	  action	  also	  opens	  the	  possibility	  that	  dysfunction	  of	  WRAP53α	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itself	  may	   contribute	   to	   cancer.	   Future	   studies	  will	   reveal	   the	   exact	  molecular	  pathway	  of	  WRAP53α-­‐mediated	  p53	   regulation	   and	  will	   also	   shed	   light	   on	   the	  importance	  of	  WRAP53α	  in	  different	  aspects	  of	  p53	  function.	  
4.2 PAPER II This	  paper	  was	  initiated	  by	  the	  observation	  that	  the	  WRAP53	  protein	  localizes	  to	  Cajal	   bodies	   and	   that	   WRAP53	   depletion	   leads	   to	   disruption	   of	   these	   nuclear	  organelles.	  Around	   the	  same	   time	  as	  our	   initial	  observations,	   two	  papers	  came	  out	   identifying	   WRAP53	   as	   a	   Cajal	   body	   specific	   protein,	   important	   for	   the	  localization	  of	  scaRNAs	  to	  these	  structures[234,235].	  Functional	  studies	  altering	  WRAP53	  levels	  revealed	  the	  importance	  of	  WRAP53	  in	   Cajal	   body	   formation	   and	   integrity.	   Knockdown	   of	   WRAP53	   using	   two	  different	  siRNA	  oligos	  led	  to	  the	  disappearance	  of	  specifically	  Cajal	  bodies	  with	  a	  concomitant	  mislocalization	  of	  Cajal	  body	  components,	  including	  coilin,	  SMN,	  Sm,	  Gemin2	   and	   Gemin3.	  We	   also	   obtained	   similar	   results	   in	   cells	   overexpressing	  FLAG/GFP	   tagged-­‐WRAP53	   at	   high	   levels.	   While	   cells	   with	   low	   ectopic	  expression	   of	  WRAP53	   displayed	   a	   similar	   distribution	   pattern	   as	   endogenous	  WRAP53,	   exogenous	   expression	   of	  WRAP53	   at	   high	   levels	   led	   to	   disruption	   of	  Cajal	   body	   structure	   and	   the	   subsequent	   mislocalization	   of	   its	   components.	  Neither	  silencing	  nor	  overexpression	  of	  WRAP53	  altered	  the	  expression	  levels	  of	  Cajal	   body	   components,	   suggesting	   a	   direct	   role	   of	   WRAP53	   in	   Cajal	   body	  maintenance.	   This	   idea	  was	   in	   line	  with	  previous	   studies	   identifying	   a	   role	   for	  WRAP53	  in	  directing	  scaRNPs	  to	  Cajal	  bodies[234,235].	  	  In	   contrast	   to	   previous	   studies,	   immunofluorescence	   (IF)	   analyses	   in	   our	   lab	  showed	  a	  different	  intracellular	  distribution	  pattern	  of	  WRAP53.	  We	  detected	  a	  clear	   cytoplasmic	   staining	   in	   addition	   to	   the	   described	   Cajal	   body	   localization.	  Comparing	   the	   cellular	   distribution	   pattern	   of	   WRAP53	   to	   other	   known	   Cajal	  body	  components,	  we	  saw	  a	  strong	  resemblance	   to	   the	   localization	  of	   the	  SMN	  complex.	   Thus	   we	   hypothesised	   that	   WRAP53	   might	   be	   interacting	   with	   this	  complex,	   perhaps	   directing	   it	   to	   Cajal	   bodies.	   Indeed,	   IF,	   immunoprecipitation	  (IP)	   and	   in	   situ	   proximity	   ligation	   assay	   (PLA)	   experiments	   demonstrated	   that	  WRAP53	  both	   co-­‐localizes	   and	   interacts	  with	   components	  of	   the	  SMN	  complex	  both	  in	  the	  nucleus	  and	  in	  the	  cytoplasm.	  In	  addition,	  WRAP53	  IPs	   in	  coilin-­‐	  or	  SMN-­‐depleted	  cells	  revealed	  that	  WRAP53	  interacts	  with	  SMN	  independently	  of	  coilin,	  and	  with	  coilin	  independently	  of	  SMN.	  Strikingly,	  IPs	  using	  coilin	  or	  SMN	  antibodies	   in	  WRAP53	  depleted	  cells	  revealed	  that	  WRAP53	  is	  required	  for	  the	  interaction	   between	   these	   two	   proteins.	   Since	   SMN	   and	   coilin	   have	   previously	  been	  shown	  to	  interact	  directly[151],	  these	  data	  suggested	  that	  WRAP53	  brings	  these	  proteins	  together	  to	  allow	  them	  to	  bind	  each	  other.	  Thus,	  WRAP53	  appears	  to	  have	  a	  role	  in	  directing	  the	  SMN	  complex	  to	  Cajal	  bodies.	  Considering	  that	  WRAP53	  interacts	  with	  the	  SMN	  complex	  in	  the	  cytoplasm	  and	  in	  the	  nucleus,	  we	  hypothesized	  that	  WRAP53	  may	  have	  an	  additional	  role	  in	  the	  nuclear	   import	   of	   the	   complex.	   As	   previously	   mentioned,	   the	   SMN	   complex	  together	   with	   the	   snRNP	   utilises	   the	   importinβ	   pathway	   to	   enter	   the	   nucleus.	  This	  is	  achieved	  either	  by	  the	  TMG	  cap-­‐dependent	  or	  the	  Sm-­‐dependent	  pathway	  [179,180].	  Interestingly,	  the	  existence	  of	  an	  additional	  adaptor	  protein	  has	  been	  
	   38	  
suggested,	  which	  mediates	   the	   interaction	   between	   importinβ	   and	   SMN	   in	   the	  Sm-­‐dependent	   pathway[182].	   Indeed,	   our	   results	   showed	   that	   WRAP53	  facilitates	   the	  nuclear	   import	  of	   the	  SMN	  complex.	  Depletion	  of	  WRAP53	   led	  to	  increased	   levels	   of	   SMN	   in	   the	   cytoplasm	   with	   a	   subsequent	   decrease	   in	   the	  nucleus.	  Moreover,	  the	  interaction	  between	  SMN	  and	  importinβ	  was	  disrupted	  in	  cells	  depleted	  for	  WRAP53.	  Thus,	  WRAP53	  seems	  to	  bind	  to	  the	  SMN	  complex	  in	  the	   cytoplasm,	   facilitate	   its	   nuclear	   import	   via	   importinβ	   and	   direct	   it	   to	   Cajal	  bodies.	  	  	  	  WRAP53	   may	   also	   be	   involved	   in	   the	   pathogenesis	   of	   the	   neurodegenerative	  disease	   SMA.	  We	   found	   that	   the	   interactions	  between	   SMN	  and	  WRAP53	  were	  disrupted	  in	  fibroblasts	  from	  SMA	  patients	  and	  that	  this	  correlated	  with	  reduced	  number	  of	  SMN	  foci	   in	  the	  nuclei	  of	  these	  cells.	  As	  reduced	  nuclear	  foci	  of	  SMN	  correlates	  with	   the	   severity	   of	   the	   disease,	   an	   inability	   of	  mutant	   SMN	   to	   bind	  WRAP53	  could	  contribute	  to	  SMN	  dysfunction	  in	  SMA.	  	  Our	  results	  also	  suggest	  that	  WRAP53	  has	  functions	  in	  the	  Cajal	  body	  beyond	  its	  role	   in	   snRNP	   biogenesis.	   Cajal	   bodies	   have	   been	   suggested	   to	   have	  compartments	   constituting	   the	   different	   activities[140].	   The	   fact	   that	  WRAP53	  but	   not	   SMN	   knockdown	   removes	   both	   canonical	   and	   residual	   Cajal	   bodies	  indicates	   that	   WRAP53	   is	   important	   for	   the	   additional	   ongoing	   processes	   in	  these	  structures.	  	  	  From	  this	  study,	  we	  conclude	  that	  WRAP53	  is	  essential	  for	  Cajal	  body	  formation	  and	  maintenance.	  WRAP53	   facilitates	   the	   nuclear	   import	   of	   the	   SMN	   complex	  and	  further	  mediates	  the	   interaction	  between	  the	  SMN	  complex	  and	  coilin.	  Our	  findings,	   together	  with	  what	  has	  previously	  been	  published,	   establish	   a	   crucial	  role	  of	  WRAP53	  in	  Cajal	  body	  formation	  and	  function.	  	  
4.3 PAPER III  During	  our	  functional	  studies	  of	  the	  WRAP53	  protein,	  we	  observed	  that	  WRAP53	  depletion	   resulted	   in	  massive	   cell	  death.	  Time-­‐lapse	  experiments	   revealed	   that	  starting	  from	  approximately	  48h	  post	  siWRAP53	  transfection,	  the	  cells	  begin	  to	  die	   and	   that	   by	   96h	  most	   cells	   are	   dead.	   In	   depth	   characterization	   of	   the	   cell	  death	   revealed	   that	   cells	  undergo	   classical	  mitochondrial-­‐dependent	  apoptosis.	  This	   conclusion	   was	   supported	   by	   the	   fact	   that	   we	   observed	   morphological	  changes	  in	  WRAP53-­‐depleted	  cells	  associated	  with	  apoptosis,	  such	  as	  membrane	  blebbing	   and	   cell	   shrinkage.	   In	   addition,	   we	   detected	   caspase	   activation	   and	  PARP	   cleavage,	   two	  molecular	   processes	   that	   are	   strongly	   linked	   to	   apoptosis.	  Moreover,	   we	   observed	   cyt	   c	   release	   and	   a	   drop	   in	   mitochondrial	   membrane	  potential,	   indicating	  a	  disruption	  of	   the	  mitochondria	  upon	  WRAP53	  depletion.	  The	   effect	   on	   the	   mitochondria	   seems	   to	   be	   linked	   to	   Bax	   and	   Bak	   activation	  since	   we	   observed	   activation	   of	   Bax	   and	   Bak	   already	   at	   48h.	   However,	   the	  strongest	  evidence	  supporting	  a	  mitochondrial-­‐dependent	  apoptosis	  was	  the	  fact	  that	  we	  could	  rescue	  the	  observed	  cell	  death	  by	  ectopic	  expression	  of	  Bcl-­‐2.	  	  	  Most	  of	  the	  initial	  studies	  to	  characterize	  the	  apoptotic	  pathway	  were	  performed	  in	  U2OS	  and	  HeLa	  cells.	  Next	  we	  extended	  our	  phenotypic	  studies	   to	  other	  cell	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types,	   including	  additional	  human	  cancer	  cell	   lines	  as	  well	  as	  primary	  cells.	  We	  observed	  similar	  effects	  upon	  WRAP53	  depletion	  in	  H1299	  and	  HEK293	  cancer	  cells;	  however,	  knocking	  down	  WRAP53	  in	  three	  different	  primary	  cells,	  namely	  HDF,	   AG68014	   and	  MCF10a,	   did	   not	   result	   in	   any	   significant	   cell	   death.	   Thus,	  cancer	  cells	  seems	  to	  be	  more	  sensitive	  to	  WRAP53	  depletion	  than	  primary	  cells,	  identifying	  WRAP53	  as	  a	  target	  for	  cancer	  therapy.	  The	   fact	   that	   cancer	   cells	   appear	   to	   have	   acquired	   a	   dependency	   on	  WRAP53	  expression	   encouraged	   us	   to	   investigate	   whether	   WRAP53	   has	   oncogenic	  properties.	   In	   line	  with	   this	   idea,	  we	   found	   that	  WRAP53	   levels	   are	   in	   general	  elevated	   in	   cancer	   cells	   compared	   to	   primary	   cells	   and,	   more	   importantly,	  anchorage-­‐independent	   transformation	   assays	   using	   murine	   NIH3T3	   cells	  displayed	   increased	   numbers	   of	   colonies	   in	   WRAP53	   overexpressing	   cells	  compared	   to	   control	   cells.	   These	   data	   support	   a	   role	   of	   WRAP53	   in	  tumourigenesis	  by	  promoting	  cell	  survival.	  	  Next	   we	   looked	   at	   the	   impact	   of	   WRAP53	   expression	   in	   primary	   tumours.	  Interestingly,	  WRAP53	   levels	  were	   found	   to	  be	   correlated	   to	  patient	  prognosis	  and	  intrinsic	  radiosensitivity,	  a	  measurement	  of	  the	  sensitivity	  of	  the	  cancer	  cells	  to	   radiotherapy,	   in	   head	   and	   neck	   squamous	   cell	   carcinoma	   cell	   lines	   derived	  form	   primary	   tumours.	   We	   found	   that	   enhanced	   WRAP53	   expression	   was	  correlated	   to	  poor	  outcome	  and	   low	   intrinsic	  radiosenstivity,	  which	  supports	  a	  role	  of	  WRAP53	  in	  the	  survival	  of	  cancer	  cells	  in	  vivo	  and	  indicates	  that	  WRAP53	  may	  be	  a	  novel	  marker	  for	  the	  prognosis	  of	  head	  and	  neck	  cancer.	  The	  question	  of	  how	  the	  WRAP53	  protein	  promotes	  cell	  survival	  and	  transforms	  cells	   remains	   to	   be	   elucidated.	  However,	   these	   actions	   of	   the	  WRAP53	  protein	  seem	  to	  be	  independent	  of	  WRAP53α-­‐mediated	  regulation	  of	  p53.	  The	  reason	  is	  that	  the	  protein	  is	  mainly	  transcribed	  from	  the	  WRAP53β	  transcript,	  which	  is	  not	  involved	  in	  the	  p53	  regulation,	  and	  also	  because	  knockdown	  of	  WRAP53	  induces	  cell	  death	   in	  p53	  wt	  and	  null	  cells.	   In	   fact,	  no	  currently	  known	  functions	  of	   the	  WRAP53	  protein	  can	  account	  for	  the	  cell	  survival	  promoting	  ability	  of	  WRAP53	  in	  a	  satisfactory	  way.	  The	  role	  of	  WRAP53	  in	  telomere	  extension	  could	  partially	  explain	   the	   oncogenic	   properties	   of	   WRAP53	   as	   well	   as	   the	   cancer-­‐cell	  dependency.	   However,	   ectopic	   expression	   of	   WRAP53	   transforms	   cells	   with	  already	  high	  telomerase	  activity	  and	  depletion	  of	  WRAP53	  kills	  telomerase	  null	  cells	  that	  rely	  on	  the	  ALT	  pathway,	  suggesting	  telomerase-­‐independent	  functions	  of	  WRAP53.	  	  Furthermore,	   no	   solid	   data	   links	   Cajal	   bodies	   to	   tumour	   development	   and	  progression	   and	   Cajal	   bodies	   are	   not	   essential	   for	   cell	   survival.	   Coilin	   has	  recently	  been	  assigned	   functions	   in	  maintaining	  genomic	  stability,	   independent	  of	  its	  function	  in	  Cajal	  bodies.	  However,	  knockdown	  of	  coilin	  does	  not	  kill	  cancer	  cells	  (data	  not	  shown).	  In	  contrast,	  reduced	  levels	  of	  SMN	  have	  been	  reported	  to	  induce	  mitochondrial	   associated	   cell	   death.	   Nonetheless,	   since	   cells	   survive	   in	  absence	  of	  Cajal	  bodies,	  the	  function	  of	  WRAP53	  in	  directing	  the	  SMN	  complex	  to	  Cajal	   bodies	   should	   not	   be	   the	   underlying	   mechanism.	   Also,	   SMN	   has	   not	  previously	   been	   implicated	   in	   cancer	   and	   no	   enhanced	   levels	   of	   SMN	   were	  observed	   in	   cancer	   cells	   compared	   to	   primary	   cells.	   Altogether,	   these	   results	  suggest	  additional	  functions	  of	  WRAP53	  in	  cancer	  cell	  survival.	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From	  this	  study,	  we	  conclude	  that	  WRAP53	  expression	  is	  elevated	  in	  cancer	  cells	  compared	   to	   primary	   cells	   and	   that	   WRAP53	   has	   oncogenic	   properties.	  Furthermore,	   the	   fact	   that	   cancer	   cells	   are	   more	   sensitive	   to	   depletion	   of	  WRAP53	  than	  primary	  cells	  opens	  up	  possibilities	   for	   therapeutic	   intervention.	  Overall,	   our	   findings	   establish	   a	   clear	   link	   between	   the	   WRAP53	   protein	   and	  cancer	   and	   identify	   WRAP53	   as	   a	   target	   for	   cancer	   therapeutics	   and	   as	   a	  prognostic	  marker.	  	  	  	  
	  
Figure	   6:	   Schematic	   illustration	   of	   the	   WRAP53	   gene	   locus	   and	   the	   potential	   implications	   of	  
expressing	  the	  different	  WRAP53	  transcripts.	  	  	  	  
 4.4 THE TWO FACES OF WRAP53   
WRAP53	   is	  a	  gene	  of	  multiple	   functions;	   it	   gives	   rise	   to	  an	  antisense	   transcript	  that	   regulates	   the	   actions	   of	   the	   tumour	   suppressor	   p53	   and	   it	   encodes	   for	   a	  protein	   with	   oncogenic	   properties	   (Figure	   6).	   These	   somewhat	   contradictory	  functions	  of	  WRAP53	  are	  possible	  because	  of	  its	  genomic	  arrangement.	  WRAP53	  has	   three	   starting	   exons	   and,	   depending	   on	   the	   origin	   of	   the	   transcript,	   it	   can	  have	  different	  activities.	  Transcripts	  originating	  from	  exon	  1α	  stabilize	  p53	  and	  transcripts	  mainly	   starting	   from	  exon	  1β	  code	   for	   the	  protein.	   Since	  WRAP53α	  and	  WRAP53β	   seem	   to	   have	   separate	   promoters,	   they	   allow	   for	   independent	  regulation	   of	   each	   transcript.	   Moreover,	   the	   induction	   of	   WRAP53α	   seems	   to	  repress	   the	   expression	   of	   WRAP53β,	   suggesting	   inter-­‐regulation	   between	   the	  transcripts[11].	  Thus,	   the	  upregulation	  of	   the	  WRAP53β	   transcripts	  could	  have	  dual	   growth-­‐promoting	   effects:	   by	   inducing	   the	   WRAP53	   protein	   and	  simultaneously	  getting	  rid	  of	  p53	  through	  blockage	  of	  WRAP53α	  expression.	  On	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the	  contrary,	  the	  expression	  of	  WRAP53α	  could	  act	  on	  a	  double	  level	  to	  suppress	  growth	   by	   promoting	   p53	   expression	   and	   preventing	   WRAP53	   protein	  expression.	  This	  could	  be	  a	  way	  of	  nature	  to	  balance	  the	  growth	  promoting	  and	  growth	   suppressive	   actions	   of	   important	   cellular	   regulators	   and	   raises	   the	  possibility	   that	   other	   sense/antisense	   genes	   have	   acquired	   a	   similar	   genomic	  arrangement	  to	  allow	  for	  a	  similar	  type	  of	  regulation.	  	  RNA	  plays	  an	  important	  role	  in	  WRAP53	  functions;	  WRAP53α	  transcripts	  act	  as	  regulatory	  RNAs	  to	  stabilize	  p53	  and	  the	  WRAP53	  protein	  binds	  to	  scaRNAs.	  In	  fact,	   all	   the	   currently	   characterized	   functions	   of	   the	   WRAP53	   protein	   revolve	  around	  RNA-­‐protein	  complexes.	  WRAP53	  protein	  was	  shown	  to	  be	  important	  for	  the	   localization	  of	  scaRNPs	  and	  the	  telomerase	  complex	  to	  Cajal	  bodies	  and	  we	  show	  that	  WRAP53	  directs	  the	  SMN	  complex	  together	  with	  snRNPs	  to	  the	  same	  nuclear	   structure	   (Figure	   7)[234,235,243].	   Also,	   it	   was	   shown	   that	   WRAP53	  binds	  directly	  to	  scaRNAs	  and	  the	  inability	  of	  the	  scaRNAs	  to	  bind	  WRAP53	  leads	  to	   their	   mislocalization	   to	   nucleoli[234].	   Furthermore,	   interaction	   between	  WRAP53	  and	  the	  catalytic	  unit	  of	  the	  telomerase	  complex,	  TERC,	  was	  disrupted	  by	  ribonuclease	  A	  (RNase	  A)	  treatment[235],	  indicating	  that	  their	  association	  is	  mediated	   via	   RNA.	   Similar	   experiments	   performed	   in	   our	   lab	   showed	   that	   the	  WRAP53	   interaction	   with	   SMN,	   importinβ	   and	   coilin	   is	   dependent	   on	   RNA	  (unpublished	  data).	  Thus,	  RNA	  seems	  to	  play	  an	  important	  role	  in	  the	  association	  of	  the	  WRAP53	  protein	  with	  other	  proteins.	  	  Although,	  previous	   studies	  described	  a	   specific	  binding	  of	  WRAP53	   to	   the	  CAB	  domains	   of	   scaRNAs,	   our	   data	   showing	   that	   the	   interaction	   between	  WRAP53	  and	   the	   SMN	   complex	   is	  mediated	   via	   RNA,	   suggests	   that	  WRAP53	   binds	   to	   a	  broader	  repertoire	  of	  RNAs.	  This	  opens	  up	  the	  possibility	  that	  WRAP53	  may	  be	  involved	   in	   the	   processing/transport	   of	   other	   types	   of	   RNAs.	   Considering	   the	  large	   number	   of	   orphan	   snoRNAs	   (snoRNAs	   with	   no	   known	   sequence	  complementarities),	  it	  is	  plausible	  that	  WRAP53	  is	  part	  of	  these	  complexes.	  Also	  since	  the	  majority	  of	  WRAP53	  resides	  in	  the	  cytoplasm,	  it	  may	  have	  functions	  in	  the	  biogenesis	  of	  other	   types	  of	   cytoplasmic	  RNAs,	   including	  mRNAs.	  The	  SMN	  complex	  has	  been	  shown	  to	  play	  a	  role	   in	  axonal	  RNA	  transport	  [226,227,228],	  and	  since	  WRAP53	  binds	  to	  SMN	  in	  the	  cytoplasm,	  it	  is	  likely	  that	  it	  has	  a	  role	  in	  other	  SMN	  functions	  beside	  snRNP	  biogenesis.	  	  Many	  questions	  remain	  to	  be	  answered	  regarding	  the	  function	  and	  the	  biological	  significance	   of	   the	  WRAP53	   gene.	   Nevertheless,	   the	   therapeutical	   potential	   is	  encouraging.	  Alteration	  of	  WRAP53α	  levels,	  such	  as	  upregulation	  of	  WRAP53α	  to	  enhance	  p53	  expression	  or	  downregulation	  of	  WRAP53α	  to	   inhibit	  mutant	  p53	  action,	   could	   turn	   out	   to	   be	   promising	   strategies	   for	   cancer	   treatment.	  Furthermore,	  considering	  that	  cancer	  cells	  are	  more	  sensitive	  to	  knockdown	  of	  the	   WRAP53	   protein	   highlights	   the	   protein	   as	   a	   putative	   target	   for	   cancer	  therapeutics.	  Future	  studies	  will	  surely	  provide	  us	  with	  answers.	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Figure	  7:	  The	  various	  roles	  of	  the	  WRAP53	  protein.	  WRAP53	  act	  as	  a	  transport	  system	  for	  the	  Cajal	  
bodies,	  bringing	  together	  the	  different	  components.	  WRAP53	  may	  have	  additional	  functions	  in	  the	  
cytoplasm	   together	   with	   the	   SMN	   complex.	   Moreover,	   it	   might	   be	   involved	   in	   the	  
processing/transport	  of	  other	  types	  of	  RNAs	  in	  the	  nucleus	  or	  in	  the	  cytoplasm.	  The	  type	  of	  RNAs	  in	  
the	  different	  complexes	  are	  illustrated	  next	  to	  each	  complex.	  TC	  stands	  for	  Telomerase	  complex	  
 
4.5 CONCLUSIONS IN SUMMARY 
Paper	  I	  
WRAP53	  is	  a	  natural	  antisense	  transcript	  of	  p53	  that	  regulates	  the	  action	  of	  
p53	  upon	  DNA	  damage	  by	  stabilizing	  p53	  mRNA.	  	  
	  
Paper	  II	  
WRAP53	  is	  essential	  for	  Cajal	  body	  formation	  and	  maintenance.	  It	  binds	  to	  
the	  SMN	  complex	  in	  the	  cytoplasm	  and	  directs	  it	  to	  the	  Cajal	  bodies.	  	  
	  
Paper	  III	  
WRAP53	   is	   overexpressed	   in	   cancer	   and	   has	   oncogenic	   properties.	  
Knockdown	  of	  WRAP53	  leads	  to	  massive	  cell	  death	  of	  cancer	  cells	  but	  not	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  like	   basically	   having	   a	   camcord	   along	   with	   you	   recording	   everything	   that	   has	  been	  said	  and	  done.	   It	   is	  also	  because	  you	  were	  the	  first	  one	  to	  understand	  my	  type	  of	  humour	  after	  3	  years	  here	  at	  CCK!	  You	  are	  the	  perfect	  partner	  in	  crime	  in	  joking	  with	  people,	  the	  wedding	  joke	  being	  already	  a	  classic.	  Someone	  once	  wrote	  “It’s	  not	  easy	  to	  have	  a	  redhead	  for	  a	  girlfriend…”.	  Well,	  try	  having	  a	  redhead	  as	  a	  colleague,	  especially	  when	  she	  actually	  spends	  all	  her	  time	  in	  the	  lab!	  Anna	  darling,	  you	  and	  me	  have	  been	  through	  much,	  experiencing	  each	  and	   every	   step	  of	   the	  PhD-­‐studies	   together.	   I	   am	   just	   happy	  you	  were	   about	  2	  months	   ahead	   of	  me	   in	   everything	   so	   that	   when	   I	   needed	   something	   you	   had	  already	   done	   it	  	   You	   are	   the	   one	   that	   I	   could	   always	   count	   on	   no	   matter	  whether	  it	  involved	  helping	  out	  at	  work,	  “playing”	  soccer	  or	  going	  out	  for	  a	  beer.	  Thank	  you	  for	  all	  the	  great	  times,	  bad	  times	  and	  especially	  the	  conference	  times!	  New	  Haven	  watch	  out,	   there	   is	   a	   superstar	  heading	  your	  way!	  Also,	   thanks	   for	  sharing	  Markus	  with	  us,	  he	  is	  a	  real	  stand-­‐up	  guy!	   	  
Elisabeth	   H,	   you	   have	   been	   a	   great	   addition	   to	   the	   Farnebo	   group!	   Finally	  someone	  who	  laughs	  at	  my	  jokes!	  Without	  you	  I	  would	  still	  have	  been	  that	  quiet	  guy	  in	  the	  corner	  	  With	  classic	  jokes	  like	  “hajpojken”	  and	  “vardagsvargen”	  we	  should	  start	  our	  own	  radioshow.	  All	  the	  present	  and	  past	  members	  of	  the	  Wiman	  group:	  Ruby,	  things	  were	  never	  the	  same	  after	  you	  left.	  No	  more	  gossiping…	  ehmm..	  much	  less	  gossiping	   	  and	  I	  still	  miss	  those	  countless	  unforgettable	  goodbye-­‐parties.	  Jin,	  today	  you	  look	  like	  an	   orange	   glazed	   with	   dark	   Peruvian	   chocolate	   	   I	   look	   forward	   to	   our	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continued	  adventures	  at	  Stanford!	  Nader	  for	  always	  having	  a	  smile	  on	  your	  face	  and	  looking	  at	  life	  as	  a	  glass	  half-­‐full.	  Thanks	  for	  all	  the	  advice	  and	  you’ve	  got	  to	  teach	  me	  to	  drive	  .	  Cinzia,	  the	  crazy	  hard	  rock	  darky	  Italian	  girl	  who	  suddenly	  falls	   into	   tears.	   Honestly,	   I	   have	   never	   seen	   anyone	   cry	   as	   much	   as	   you	   do.	  
Masoud,	  with	  your	  “life	  sucks”	  attitude	  and	  dark	  humour,	  you	  are	  definitely	  one	  of	   a	   kind!	   Vladimir	   thanks	   for	   always	   taking	   your	   time	   answering	   questions	  although	  your	  answers	  are	  never	  as	  straight	  as	  I	  am	  hoping	  for.	  But	  hey,	  that	  is	  research.	  Susanne,	  I	  will	  give	  you	  a	  ride	  in	  my	  CAR	  as	  soon	  as	  I	  will	  be	  back	  from	  the	  US.	  Now,	   that	   is	  a	  promise	  	  The	  Chinese	  mafia,	   including	  Qiang,	  Lidi	  and	  
Mei,	  thanks	  for	  the	  hotpots	  and	  fun.	  Gregor,	  Tao,	  Maggan,	  Lena,	  Linn,	  Magda,	  
Piotr,	   Jeremy,	  Nina,	  Francesca	  and	   Emarn,	  you	  have	  all	   enriched	   the	  Wiman	  group	  in	  so	  many	  ways	   	  Thanks	   to	   the	   Nistér	   group,	   especially	   Inga	   and	   Tomadher.	   It	   is	   always	   a	  pleasure	   to	   bump	   into	   you	   two.	   Your	   nasty	   sense	   of	   humour	   and	   crazy	   dance	  style	  is	  a	  real	  treat.	  Still,	  you	  guys	  had	  no	  chance	  against	  my	  jumpy	  robot	  dance	  
.	  New	  and	  old	  members	  of	  the	  Larsson	  group,	  in	  particular;	  Olle	  for	  always	  taking	  your	   time	  discussing	   the	   latest	   in	   football	  or	  any	  other	  sport	  event	   imaginable.	  
Eric	  T,	  the	  year	  you	  were	  here	  was	  great!	  Coffee	  breaks,	  summer	  houses,	  and	  a	  midsummer	  with	  non-­‐functional	  grills	  	  Those	  were	  the	  days.	  Hanif,	  thanks	  for	  all	   the	   stories	   and	   that	   educational	   trip	   though	   your	   neighbourhood	  	   Barça	  forever!	  Dudi	  and	  Sylvia	  for	  always	  supplying	  us	  with	  whatever	  we	  are	  missing	  in	  the	  lab.	  Margeritha	  for	  showing	  up	  in	  one	  crazy	  jacket	  after	  another,	  I	  know	  you	  do	  it	  to	  make	  me	  happy	  	  Eiman	  no	  worries,	  I	  did	  pass	  on	  your	  email	  and	  home	  address	  to	  the	  Egyptian	  lady	  	  Ahmed,	  Yingbo	  and	  Thomas	  for	  fun	  talks	  and	  all	  the	  help.	  	  Past	   and	  present	  people	   on	  4th	   floor:	  Pär	   best	   of	   luck	   in	   your	   future!	  Liss	   and	  
Ingrid,	   you	   two	   light	  up	   floor	  4	  with	  your	  wonderful	   smiles	  and	  great	  positive	  attitudes.	  There	  should	  be	  two	  of	  you	  on	  each	  floor.	  The	  singing	  subunits	  of	  the	  
Sangfelt	   group;	   Nimesh	   your	   singing	   is…	   interesting…	   credit	   for	   not	   caring	  though	  .	  Shahab,	  I	  have	  never	  seen	  anyone	  devour	  a	  princesscake	  like	  you	  did	  that	  day,	  respect!	  Olle	  Sangfelt	  for	  showing	  me	  that	  it	  is	  possible	  to	  have	  a	  great	  body	  and	  a	  brilliant	  scientific	  mind!	  I	  am	  doing	  my	  best	  .	  Aljona,	  still	  waiting	  for	  that	  invite	  to	  join	  your	  group	  in	  Australia.	  	  Lots	  of	  thanks	  to	  friends	  and	  colleagues	  on	  the	  3rd	  floor:	  Past	   and	   present	  members	   of	   the	  Grandér	   group:	  Danne,	   you	  were	   a	  worthy	  contender	  at	   the	  “Cancer	  Therapy”	  play,	  although,	  at	   least	   for	  charm	  I	  believe	   I	  deserved	  to	  win	  once	  .	  Micke	  L,	   I	  do	  not	  think	   it	  was	  a	  coincidence	  that	  they	  choose	  you	  as	  Mr	  13,	  you	  are	  just	  that	  good.	  Science	  will	  not	  be	  the	  same	  without	  you.	  Martin	   C,	   I	   really	   enjoyed	   our	   collaboration	   on	   the	   first	   paper.	   It	   oozes	  smartness	  from	  you.	  Masako,	  thanks	  for	  great	  times	  in	  Japan!	  Best	  karaoke	  and	  puffer-­‐fish	  I	  ever	  had	  	  Per,	  thanks	  for	  being	  the	  best	  host	  ever	  in	  San	  Diego	  and	  for	   great	   times	   involving	   Margaritas,	   Margeritha	   and	   Jeagers.	   Katja	   for	   your	  generous	  input.	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Holmgren	  group	  for	  always	  helping	  out	  with	  the	  microscope!	  Mahdi,	  who	  would	  have	   known	   that	   we	   would	   turn	   out	   to	   be	   such	   good	   friends	   after	   that	   first	  encounter	   in	   the	  men’s	  restroom,	  when	  you	  were	  knocking	  on	  the	  door.	  Thank	  you	   for	   bringing	   some	  well-­‐needed	   “hood”	   to	  CCK.	   I	  will	   be	  warming	  up	   those	  weights	  for	  you	  in	  Cali.	  Zheng,	  thanks	  for	  sharing	  some	  great	  gossips	  and	  for	  the	  help	  with	  migration	  assays.	  Natalie,	  Jacob	  E,	  Mira	  and	  Sarah.	  Members	   of	   the	  Östman	   group:	  Arne	   you	   are	   probably	   the	   coolest	   PI	   around.	  Tequila	  shots	  on	  me	  this	  time.	  Elin,	  you	  and	  Sofia	  are	  the	  proof	  that	  blondes	  have	  most	   fun!	   You	   two	   are	   like	   a	   crazy	   tornado	   at	   any	   given	   party,	   nobody	   knows	  what	   hits	   them	   until	   it	   is	   too	   late.	   Thanks	   to	  Martin	   A,	  Markus,	   Christina,	  
Jeroen	  and	  Daniel	  for	  nice	  discussions	  and	  fun	  times.	  Past	  and	  present	  members	  of	  the	  Bertrand	  group:	  Poppy,	  thanks	  for	  all	  the	  help	  with	  the	  time-­‐lapse	  machine,	  unfortunately	  not	  even	  300	  Greeks	  could	  bring	  any	  sense	  to	  those	  results	  	  Vivienne	  and	  Ulrika.	  
Panaretakis	   group	   for	   all	   the	   help	   with	   the	   FACS,	   in	   particular	   Aris	   and	  
Pedram.	  People	   at	   CCK	   for	   great	   times:	   Dali,	   I	   have	   never	   missed	   a	   guy	   as	   much	   as	   I	  missed	  you	  when	  you	  had	  broken	  your	  arm,	  Walid,	  you	  are	  up	  next!	  Barry,	  you	  will	  always	  be	  the	  “Beast”	  to	  me	  	  Alvaro,	  save	  a	  spot	  for	  me	  in	  Chile,	  Erik	  W,	  
Pádraig,	   Bertha,	  Anna	   DG,	   Ninib,	   Emma,	   you	  must	   have	   some	   pretty	   sweet	  dreams	  for	  always	  wanting	  to	  fall	  asleep	  	  Petra,	  Amir	  and	  all	  the	  members	  of	  the	  CKK	  Champions	  team	  for	  all	  the	  trophies,	  keep	  up	  the	  good	  work!	  	  	  	  	  	  People	   that	   have	  made	  my	   life	   easier	   at	   CCK,	   especially	   Sören,	  Eva	   Lena	   and	  
Juan	   for	   solving	   all	   sorts	   of	   practical	   issues.	   Elisabeth,	   Elle	   and	   Emily,	   for	  making	  shopping	  enjoyable.	  Others	   at	   KI	   -­‐	  Therese,	   there	  was	   competition	   at	   first	   sight!	   I	   have	   never	  met	  anyone	   as	   competitive	   as	   you	   and	   I	   love	   it!	   There	   is	   no	   other	   person	   I	   rather	  loose	   to	   than	   you,	   you	   are	   a	   true	   superstar!	   Let’s	   conquer	   the	   world	   of	  neuroscience	   together!	   Jakob	  L,	   talking	   to	  you	   is	  always	  an	   inspiration	  Emma,	  thanks	  for	  all	  the	  help	  with	  the	  masspec.	  You	  are	  a	  great	  loss	  for	  science.	  Eddie,	  not	  only	  a	  great	  footballista	  but	  also	  great	  with	  the	  crystals!	  Clemens	  and	  Fedor,	  there	  is	  no	  one	  else	  I	  rather	  share	  a	  bottle	  of	  blue	  cheese	  rice	  wine	  with!	  Cheers	  to	  good	  times!	  	  Ying,	  Martin	  E	  and	  Ersen.	  Near	  and	  far	  collaborators	  that	  have	  made	  work	  easier	  and	  more	  enjoyable:	  	  
Martin	  Corcoran	   (CCK,	  KI)	   and	  Christina	  Méndez-­‐Vidal	   for	   all	   the	   help	  with	  the	  first	  paper.	  Stephen	  Smith	  and	  Staffan	  Strömblad	  (Novum,	  KI),	  and	  Irene	  
Weibrecht	   and	   Ola	   Söderberg	   (Uppsala	   University),	   for	   all	   the	   help	  with	   the	  second	   paper.	   It	   was	   great	   to	   visit	   Uppsala	   once	   in	   a	   while	   to	   re-­‐live	   the	  kanelbulle	  at	  Café	  Linné.	  They	  do	  not	  make	  them	  like	   that	   in	  Stockholm.	  Karin	  
Roberg	   and	  Lovisa	  Farnebo	   (Linköping	  University)	   for	  all	   the	  help	  with	   third	  paper.	  Anne-­‐Lise	  Børresen-­‐Dale’s	  group	  in	  Norway,	  especially	  Anita	  Langerød	  and	  Laxmi	  Silwal-­‐Pandit	  for	  the	  collaboration	  with	  the	  breast	  cancer	  material.	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My	  friends	  from	  outside	  the	  lab:	  The	   Uppsala	   Party	   Crew	   with	   their	   respective	   ladies	   (when	   applicable):	   Chia,	  you	  are	  a	  fantastic	  person,	  do	  not	  ever	  change!	  Your	  time	  here	  at	  CCK	  was	  simply	  the	   best,	   although	   I	   still	   cannot	   get	   the	   Borat	   imitations	   out	   of	   my	   mind	  ,	  
Chiara,	   you	   are	   the	   perfect	   fit	   for	   Chia,	   endlessly	   loving	   and	   always	   ready	   to	  make	   an	   Italian	   speciality.	   Sergej,	   I	   can	   still	   remember	   you	   in	   that	   woman’s	  dress,	   you	   looked	   hot!!	  	  Yuko,	   can	   I	   have	   that	   job	   you	   left	   at	   NIKE,	   please?	  Sergej	  is	  lucky	  to	  have	  you!	  Björn,	  I	  will	  never	  forget	  that	  KGB-­‐party.	  Let’s	  have	  a	  re-­‐run	  of	  that	  for	  my	  defence	  .	  	  The	   Inglorious	   Ballers	   with	   the	   long-­‐lasting	   members;	   Eddie,	   Yilmaz,	   Dali,	  
Mahdi,	   Stephen,	   Joel	   and	  Daniel.	  We	   have	   enjoyed	  many	   victories	   and	   some	  really	   embarrassing	   defeats	   but	   we	   are	   always	   ready	   to	   take	   on	   the	   next	  opponents.	  Playing	  football	  has	  been	  the	  only	  way	  to	  stay	  sane	  during	  all	   these	  years.	  Most	  importantly	  to	  my	  family	  who	  have	  been	  standing	  by	  my	  side	  all	  this	  time:	  Mi	  familia	  de	  Colombia;	  Mamasita	  Flora	  y	  Papasito	  Carlos	  –	  es	  un	  honor	  hacer	  parte	  de	  la	  Familia!	  Gracias	  por	  los	  momentos	  en	  Colombia	  y	  el	  resto	  del	  mundo.	  Lil’sis	  Andrea,	   I	   see	   it	  as	  my	  duty	   to	  annoy	  the	  hell	  out	  of	  you,	  but	   that’s	  what	  lil’sis	  are	  there	  for	  	  Can’t	  wait	  to	  visit	  you	  in	  Vancouver!	  Big’sis	  Lina	  and	  Danil,	  thanks	  for	  providing	  us	  with	  a	  beautiful	  nephew,	  Carlos.	  We’ll	  see	  if	  I	  can	  return	  the	  favour	  soon,	  but	  only	  if	  Danil	  changes	  the	  diapers	  .	  	  
Mamma	  och	  Farman,	  tack	  för	  allt	  det	  lilla	  och	  det	  stora!	  Med	  er	  kärek	  och	  stöd	  har	  allting	  varit	  möjligt!	  	  Och	  självklart	  mormor,	  som	  har	  tillägnat	  sitt	  liv	  för	  att	  vi	  ska	  ha	  det	  så	  bra	  som	  möjligt.	  Tack	  för	  din	  ändlösa	  kärlek!	  	  My	  dear	  Bror	  Safa,	   you	  are	   the	  best	  damn	  brother	  and	   friend	  one	   can	  ask	   for!	  Thanks	   for	   taking	   care	   of	  me	   for	   the	   past	   29	   years,	   or	  who	   did	  what	   now?	  	  
Parastoo,	   you	   are	   a	   great	   addition	   to	   our	   little	   VIP	   group.	   Just	   thinking	   about	  your	  food	  makes	  my	  belly	  go	  Yum!	  Little	  fatty	  furry	  Elvis,	  you	  have	  brought	  so	  much	  joy	  (and	  hairballs)	  to	  my	  life!	  To	  my	  beautiful	  Diana,	   you	   are	   still	   as	   stunning	   as	   you	  were	   seven	   something	  years	  ago	  when	  I	  first	  saw	  you	  walking	  into	  the	  classroom.	  You	  know	  I	  started	  to	  do	  well	  in	  class	  just	  to	  impress	  you	  and	  that	  has	  not	  changed	  since.	  Without	  you	  none	  of	   this	  would	  have	  made	  any	   sense	   and	  with	  you	  next	   to	  me	   I	   feel	   like	   a	  superstar	   every	   day!	   This	   year	   has	   so	   much	   in	   store	   for	   us;	   both	   becoming	  doctors,	  moving	   to	   the	   States	   and	   us	   getting	  married!	   I	   look	   forward	   to	   every	  minute	   and	   second	   of	   it!	   Thank	   you	   for	   fulfilling	   me	   in	   every	   possible	   way!	  Monkeys	  like	  you	  don’t	  grow	  trees	  	  	  	  	  
 	  
	   47	  
6 REFERENCES 1.	  Hanahan	  D,	  Weinberg	  RA	  (2000)	  The	  hallmarks	  of	  cancer.	  Cell	  100:	  57-­‐70.	  2.	  Pennisi	  E	  (2007)	  Genomics.	  DNA	  study	  forces	  rethink	  of	  what	  it	  means	  to	  be	  a	  gene.	  Science	  316:	  1556-­‐1557.	  3.	   Hume	   DA	   (2008)	   Our	   evolving	   knowledge	   of	   the	   transcriptional	   landscape.	  Mamm	  Genome	  19:	  663-­‐666.	  4.	   Wilusz	   JE,	   Sunwoo	   H,	   Spector	   DL	   (2009)	   Long	   noncoding	   RNAs:	   functional	  surprises	  from	  the	  RNA	  world.	  Genes	  Dev	  23:	  1494-­‐1504.	  5.	  Birney	  E,	  Stamatoyannopoulos	  JA,	  Dutta	  A,	  Guigo	  R,	  Gingeras	  TR,	  et	  al.	  (2007)	  Identification	   and	   analysis	   of	   functional	   elements	   in	   1%	   of	   the	   human	  genome	  by	  the	  ENCODE	  pilot	  project.	  Nature	  447:	  799-­‐816.	  6.	   Chen	   J,	   Sun	  M,	   Kent	  WJ,	   Huang	   X,	   Xie	   H,	   et	   al.	   (2004)	   Over	   20%	   of	   human	  transcripts	  might	  form	  sense-­‐antisense	  pairs.	  Nucleic	  Acids	  Res	  32:	  4812-­‐4820.	  7.	  Yelin	  R,	  Dahary	  D,	  Sorek	  R,	  Levanon	  EY,	  Goldstein	  O,	  et	  al.	  (2003)	  Widespread	  occurrence	   of	   antisense	   transcription	   in	   the	   human	   genome.	   Nat	  Biotechnol	  21:	  379-­‐386.	  8.	   Katayama	   S,	   Tomaru	   Y,	   Kasukawa	   T,	   Waki	   K,	   Nakanishi	   M,	   et	   al.	   (2005)	  Antisense	   transcription	   in	   the	   mammalian	   transcriptome.	   Science	   309:	  1564-­‐1566.	  9.	   Cheng	   J,	   Kapranov	   P,	   Drenkow	   J,	   Dike	   S,	   Brubaker	   S,	   et	   al.	   (2005)	  Transcriptional	   maps	   of	   10	   human	   chromosomes	   at	   5-­‐nucleotide	  resolution.	  Science	  308:	  1149-­‐1154.	  10.	   Dahary	   D,	   Elroy-­‐Stein	   O,	   Sorek	   R	   (2005)	   Naturally	   occurring	   antisense:	  transcriptional	  leakage	  or	  real	  overlap?	  Genome	  Res	  15:	  364-­‐368.	  11.	  Mahmoudi	   S,	   Henriksson	   S,	   Corcoran	  M,	  Mendez-­‐Vidal	   C,	  Wiman	  KG,	   et	   al.	  (2009)	   Wrap53,	   a	   natural	   p53	   antisense	   transcript	   required	   for	   p53	  induction	  upon	  DNA	  damage.	  Mol	  Cell	  33:	  462-­‐471.	  12.	   Faghihi	   MA,	   Kocerha	   J,	   Modarresi	   F,	   Engstrom	   PG,	   Chalk	   AM,	   et	   al.	   RNAi	  screen	   indicates	   widespread	   biological	   function	   for	   human	   natural	  antisense	  transcripts.	  PLoS	  One	  5.	  13.	  Wahlestedt	   C	   (2006)	   Natural	   antisense	   and	   noncoding	   RNA	   transcripts	   as	  potential	  drug	  targets.	  Drug	  Discov	  Today	  11:	  503-­‐508.	  14.	   Faghihi	   MA,	   Modarresi	   F,	   Khalil	   AM,	   Wood	   DE,	   Sahagan	   BG,	   et	   al.	   (2008)	  Expression	   of	   a	   noncoding	   RNA	   is	   elevated	   in	   Alzheimer's	   disease	   and	  drives	  rapid	  feed-­‐forward	  regulation	  of	  beta-­‐secretase.	  Nat	  Med	  14:	  723-­‐730.	  15.	  Matsui	  K,	  Nishizawa	  M,	  Ozaki	  T,	  Kimura	  T,	  Hashimoto	  I,	  et	  al.	  (2008)	  Natural	  antisense	  transcript	  stabilizes	   inducible	  nitric	  oxide	  synthase	  messenger	  RNA	  in	  rat	  hepatocytes.	  Hepatology	  47:	  686-­‐697.	  16.	   Faghihi	   MA,	   Wahlestedt	   C	   (2009)	   Regulatory	   roles	   of	   natural	   antisense	  transcripts.	  Nat	  Rev	  Mol	  Cell	  Biol	  10:	  637-­‐643.	  17.	   Lapidot	   M,	   Pilpel	   Y	   (2006)	   Genome-­‐wide	   natural	   antisense	   transcription:	  coupling	  its	  regulation	  to	  its	  different	  regulatory	  mechanisms.	  EMBO	  Rep	  7:	  1216-­‐1222.	  18.	  Peterson	  JA,	  Myers	  AM	  (1993)	  Functional	  analysis	  of	  mRNA	  3'	  end	  formation	  signals	   in	   the	   convergent	   and	   overlapping	   transcription	   units	   of	   the	   S.	  cerevisiae	  genes	  RHO1	  and	  MRP2.	  Nucleic	  Acids	  Res	  21:	  5500-­‐5508.	  
	   48	  
19.	   Puig	   S,	   Perez-­‐Ortin	   JE,	   Matallana	   E	   (1999)	   Transcriptional	   and	   structural	  study	   of	   a	   region	   of	   two	   convergent	   overlapping	   yeast	   genes.	   Curr	  Microbiol	  39:	  369-­‐0373.	  20.	   Prescott	   EM,	   Proudfoot	   NJ	   (2002)	   Transcriptional	   collision	   between	  convergent	   genes	   in	   budding	   yeast.	   Proc	  Natl	   Acad	   Sci	   U	   S	   A	   99:	   8796-­‐8801.	  21.	  Crampton	  N,	  Bonass	  WA,	  Kirkham	  J,	  Rivetti	  C,	  Thomson	  NH	  (2006)	  Collision	  events	  between	  RNA	  polymerases	  in	  convergent	  transcription	  studied	  by	  atomic	  force	  microscopy.	  Nucleic	  Acids	  Res	  34:	  5416-­‐5425.	  22.	  Osato	  N,	  Suzuki	  Y,	  Ikeo	  K,	  Gojobori	  T	  (2007)	  Transcriptional	  interferences	  in	  cis	  natural	  antisense	  transcripts	  of	  humans	  and	  mice.	  Genetics	  176:	  1299-­‐1306.	  23.	   Beltran	   M,	   Puig	   I,	   Pena	   C,	   Garcia	   JM,	   Alvarez	   AB,	   et	   al.	   (2008)	   A	   natural	  antisense	   transcript	  regulates	  Zeb2/Sip1	  gene	  expression	  during	  Snail1-­‐induced	  epithelial-­‐mesenchymal	  transition.	  Genes	  Dev	  22:	  756-­‐769.	  24.	   Berx	   G,	   van	   Roy	   F	   (2009)	   Involvement	   of	   members	   of	   the	   cadherin	  superfamily	  in	  cancer.	  Cold	  Spring	  Harb	  Perspect	  Biol	  1:	  a003129.	  25.	   Tufarelli	   C,	   Stanley	   JA,	   Garrick	   D,	   Sharpe	   JA,	   Ayyub	   H,	   et	   al.	   (2003)	  Transcription	  of	  antisense	  RNA	  leading	  to	  gene	  silencing	  and	  methylation	  as	  a	  novel	  cause	  of	  human	  genetic	  disease.	  Nat	  Genet	  34:	  157-­‐165.	  26.	  Yu	  W,	  Gius	  D,	  Onyango	  P,	  Muldoon-­‐Jacobs	  K,	  Karp	  J,	  et	  al.	  (2008)	  Epigenetic	  silencing	   of	   tumour	   suppressor	   gene	   p15	   by	   its	   antisense	   RNA.	   Nature	  451:	  202-­‐206.	  27.	   Imamura	  T,	  Yamamoto	  S,	  Ohgane	   J,	  Hattori	  N,	  Tanaka	  S,	   et	   al.	   (2004)	  Non-­‐coding	   RNA	   directed	  DNA	   demethylation	   of	   Sphk1	   CpG	   island.	   Biochem	  Biophys	  Res	  Commun	  322:	  593-­‐600.	  28.	  Morris	  KV,	  Santoso	  S,	  Turner	  AM,	  Pastori	  C,	  Hawkins	  PG	  (2008)	  Bidirectional	  transcription	  directs	  both	  transcriptional	  gene	  activation	  and	  suppression	  in	  human	  cells.	  PLoS	  Genet	  4:	  e1000258.	  29.	   Morris	   KV,	   Vogt	   PK	   Long	   antisense	   non-­‐coding	   RNAs	   and	   their	   role	   in	  transcription	  and	  oncogenesis.	  Cell	  Cycle	  9.	  30.	  Gott	  JM,	  Emeson	  RB	  (2000)	  Functions	  and	  mechanisms	  of	  RNA	  editing.	  Annu	  Rev	  Genet	  34:	  499-­‐531.	  31.	   DeCerbo	   J,	   Carmichael	   GG	   (2005)	   Retention	   and	   repression:	   fates	   of	  hyperedited	  RNAs	  in	  the	  nucleus.	  Curr	  Opin	  Cell	  Biol	  17:	  302-­‐308.	  32.	  Neeman	  Y,	  Dahary	  D,	  Levanon	  EY,	  Sorek	  R,	  Eisenberg	  E	  (2005)	  Is	  there	  any	  sense	  in	  antisense	  editing?	  Trends	  Genet	  21:	  544-­‐547.	  33.	  Borsani	  O,	  Zhu	   J,	  Verslues	  PE,	  Sunkar	  R,	  Zhu	   JK	  (2005)	  Endogenous	  siRNAs	  derived	   from	   a	   pair	   of	   natural	   cis-­‐antisense	   transcripts	   regulate	   salt	  tolerance	  in	  Arabidopsis.	  Cell	  123:	  1279-­‐1291.	  34.	  Ghildiyal	  M,	  Seitz	  H,	  Horwich	  MD,	  Li	  C,	  Du	  T,	  et	  al.	  (2008)	  Endogenous	  siRNAs	  derived	  from	  transposons	  and	  mRNAs	  in	  Drosophila	  somatic	  cells.	  Science	  320:	  1077-­‐1081.	  35.	  Watanabe	   T,	   Totoki	   Y,	   Toyoda	   A,	   Kaneda	  M,	   Kuramochi-­‐Miyagawa	   S,	   et	   al.	  (2008)	   Endogenous	   siRNAs	   from	   naturally	   formed	   dsRNAs	   regulate	  transcripts	  in	  mouse	  oocytes.	  Nature	  453:	  539-­‐543.	  36.	  Kawaji	  H,	  Nakamura	  M,	  Takahashi	  Y,	   Sandelin	  A,	  Katayama	  S,	   et	   al.	   (2008)	  Hidden	  layers	  of	  human	  small	  RNAs.	  BMC	  Genomics	  9:	  157.	  
	   49	  
37.	   Uchida	   T,	   Rossignol	   F,	   Matthay	   MA,	   Mounier	   R,	   Couette	   S,	   et	   al.	   (2004)	  Prolonged	  hypoxia	  differentially	  regulates	  hypoxia-­‐inducible	  factor	  (HIF)-­‐1alpha	  and	  HIF-­‐2alpha	  expression	   in	   lung	  epithelial	   cells:	   implication	  of	  natural	  antisense	  HIF-­‐1alpha.	  J	  Biol	  Chem	  279:	  14871-­‐14878.	  38.	  Soussi	  T,	  Wiman	  KG	  (2007)	  Shaping	  genetic	  alterations	  in	  human	  cancer:	  the	  p53	  mutation	  paradigm.	  Cancer	  Cell	  12:	  303-­‐312.	  39.	   Janicke	   RU,	   Sohn	   D,	   Schulze-­‐Osthoff	   K	   (2008)	   The	   dark	   side	   of	   a	   tumor	  suppressor:	  anti-­‐apoptotic	  p53.	  Cell	  Death	  Differ	  15:	  959-­‐976.	  40.	  Vousden	  KH,	  Prives	  C	  (2009)	  Blinded	  by	  the	  Light:	  The	  Growing	  Complexity	  of	  p53.	  Cell	  137:	  413-­‐431.	  41.	  Helton	  ES,	  Chen	  X	  (2007)	  p53	  modulation	  of	  the	  DNA	  damage	  response.	  J	  Cell	  Biochem	  100:	  883-­‐896.	  42.	  Cicalese	  A,	  Bonizzi	  G,	  Pasi	  CE,	  Faretta	  M,	  Ronzoni	  S,	  et	  al.	  (2009)	  The	  tumor	  suppressor	  p53	  regulates	  polarity	  of	  self-­‐renewing	  divisions	  in	  mammary	  stem	  cells.	  Cell	  138:	  1083-­‐1095.	  43.	   Zhao	   T,	   Xu	   Y	   p53	   and	   stem	   cells:	   new	   developments	   and	   new	   concerns.	  Trends	  Cell	  Biol	  20:	  170-­‐175.	  44.	  Tyner	  SD,	  Venkatachalam	  S,	  Choi	  J,	  Jones	  S,	  Ghebranious	  N,	  et	  al.	  (2002)	  p53	  mutant	  mice	  that	  display	  early	  ageing-­‐associated	  phenotypes.	  Nature	  415:	  45-­‐53.	  45.	   Garcia-­‐Cao	   I,	   Garcia-­‐Cao	   M,	   Martin-­‐Caballero	   J,	   Criado	   LM,	   Klatt	   P,	   et	   al.	  (2002)	   "Super	   p53"	   mice	   exhibit	   enhanced	   DNA	   damage	   response,	   are	  tumor	  resistant	  and	  age	  normally.	  EMBO	  J	  21:	  6225-­‐6235.	  46.	  Matheu	  A,	  Maraver	  A,	  Serrano	  M	  (2008)	  The	  Arf/p53	  pathway	  in	  cancer	  and	  aging.	  Cancer	  Res	  68:	  6031-­‐6034.	  47.	   Resnick-­‐Silverman	   L,	   Manfredi	   JJ	   (2006)	   Gene-­‐specific	   mechanisms	   of	   p53	  transcriptional	   control	   and	  prospects	   for	   cancer	   therapy.	   J	  Cell	  Biochem	  99:	  679-­‐689.	  48.	   Menendez	   D,	   Inga	   A,	   Resnick	   MA	   (2009)	   The	   expanding	   universe	   of	   p53	  targets.	  Nat	  Rev	  Cancer	  9:	  724-­‐737.	  49.	  Wang	  B,	  Xiao	  Z,	  Ko	  HL,	  Ren	  EC	  The	  p53	  response	  element	  and	  transcriptional	  repression.	  Cell	  Cycle	  9:	  870-­‐879.	  50.	  Speidel	  D	  Transcription-­‐independent	  p53	  apoptosis:	  an	  alternative	  route	   to	  death.	  Trends	  Cell	  Biol	  20:	  14-­‐24.	  51.	   Suzuki	   HI,	   Yamagata	   K,	   Sugimoto	   K,	   Iwamoto	   T,	   Kato	   S,	   et	   al.	   (2009)	  Modulation	  of	  microRNA	  processing	  by	  p53.	  Nature	  460:	  529-­‐533.	  52.	  Vousden	  KH,	  Ryan	  KM	  (2009)	  p53	  and	  metabolism.	  Nat	  Rev	  Cancer	  9:	  691-­‐700.	  53.	  Junttila	  MR,	  Evan	  GI	  (2009)	  p53-­‐-­‐a	  Jack	  of	  all	  trades	  but	  master	  of	  none.	  Nat	  Rev	  Cancer	  9:	  821-­‐829.	  54.	  Riley	  T,	  Sontag	  E,	  Chen	  P,	  Levine	  A	  (2008)	  Transcriptional	  control	  of	  human	  p53-­‐regulated	  genes.	  Nat	  Rev	  Mol	  Cell	  Biol	  9:	  402-­‐412.	  55.	   Levine	   AJ,	   Oren	   M	   (2009)	   The	   first	   30	   years	   of	   p53:	   growing	   ever	   more	  complex.	  Nat	  Rev	  Cancer	  9:	  749-­‐758.	  56.	  Ciccia	  A,	  Elledge	  SJ	  The	  DNA	  damage	   response:	  making	   it	   safe	   to	  play	  with	  knives.	  Mol	  Cell	  40:	  179-­‐204.	  57.	   Batchelor	   E,	   Loewer	   A,	   Lahav	   G	   (2009)	   The	   ups	   and	   downs	   of	   p53:	  understanding	   protein	   dynamics	   in	   single	   cells.	   Nat	   Rev	   Cancer	   9:	   371-­‐377.	  
	   50	  
58.	  Cazzalini	  O,	  Scovassi	  AI,	  Savio	  M,	  Stivala	  LA,	  Prosperi	  E	  Multiple	  roles	  of	  the	  cell	  cycle	  inhibitor	  p21(CDKN1A)	  in	  the	  DNA	  damage	  response.	  Mutat	  Res	  704:	  12-­‐20.	  59.	  Vousden	  KH,	  Lu	  X	  (2002)	  Live	  or	  let	  die:	  the	  cell's	  response	  to	  p53.	  Nat	  Rev	  Cancer	  2:	  594-­‐604.	  60.	  Xu	  Y	  (2003)	  Regulation	  of	  p53	  responses	  by	  post-­‐translational	  modifications.	  Cell	  Death	  Differ	  10:	  400-­‐403.	  61.	  Braithwaite	  AW,	  Del	  Sal	  G,	  Lu	  X	  (2006)	  Some	  p53-­‐binding	  proteins	  that	  can	  function	  as	  arbiters	  of	  life	  and	  death.	  Cell	  Death	  Differ	  13:	  984-­‐993.	  62.	  Marine	   JC,	   Lozano	   G	  Mdm2-­‐mediated	   ubiquitylation:	   p53	   and	   beyond.	   Cell	  Death	  Differ	  17:	  93-­‐102.	  63.	  Kruse	  JP,	  Gu	  W	  (2009)	  Modes	  of	  p53	  regulation.	  Cell	  137:	  609-­‐622.	  64.	  Lynch	  CJ,	  Milner	  J	  (2006)	  Loss	  of	  one	  p53	  allele	  results	  in	  four-­‐fold	  reduction	  of	  p53	  mRNA	  and	  protein:	  a	  basis	   for	  p53	  haplo-­‐insufficiency.	  Oncogene	  25:	  3463-­‐3470.	  65.	   Liu	   H,	   Lu	   ZG,	   Miki	   Y,	   Yoshida	   K	   (2007)	   Protein	   kinase	   C	   delta	   induces	  transcription	   of	   the	   TP53	   tumor	   suppressor	   gene	   by	   controlling	   death-­‐promoting	   factor	  Btf	   in	   the	  apoptotic	  response	  to	  DNA	  damage.	  Mol	  Cell	  Biol	  27:	  8480-­‐8491.	  66.	   Raman	   V,	  Martensen	   SA,	   Reisman	  D,	   Evron	   E,	   Odenwald	  WF,	   et	   al.	   (2000)	  Compromised	  HOXA5	  function	  can	  limit	  p53	  expression	  in	  human	  breast	  tumours.	  Nature	  405:	  974-­‐978.	  67.	   Phan	  RT,	  Dalla-­‐Favera	  R	   (2004)	  The	  BCL6	  proto-­‐oncogene	   suppresses	  p53	  expression	  in	  germinal-­‐centre	  B	  cells.	  Nature	  432:	  635-­‐639.	  68.	  Wilusz	   CJ,	  Wormington	  M,	   Peltz	   SW	   (2001)	  The	   cap-­‐to-­‐tail	   guide	   to	  mRNA	  turnover.	  Nat	  Rev	  Mol	  Cell	  Biol	  2:	  237-­‐246.	  69.	  Gingerich	  TJ,	  Feige	  JJ,	  LaMarre	  J	  (2004)	  AU-­‐rich	  elements	  and	  the	  control	  of	  gene	  expression	  through	  regulated	  mRNA	  stability.	  Anim	  Health	  Res	  Rev	  5:	  49-­‐63.	  70.	  Keene	  JD	  (2007)	  RNA	  regulons:	  coordination	  of	  post-­‐transcriptional	  events.	  Nat	  Rev	  Genet	  8:	  533-­‐543.	  71.	  Hollams	  EM,	  Giles	  KM,	  Thomson	  AM,	  Leedman	  PJ	  (2002)	  MRNA	  stability	  and	  the	   control	   of	   gene	   expression:	   implications	   for	   human	   disease.	  Neurochem	  Res	  27:	  957-­‐980.	  72.	   Vogel	   C,	   Abreu	   Rde	   S,	   Ko	   D,	   Le	   SY,	   Shapiro	   BA,	   et	   al.	   (2010)	   Sequence	  signatures	   and	   mRNA	   concentration	   can	   explain	   two-­‐thirds	   of	   protein	  abundance	  variation	  in	  a	  human	  cell	  line.	  Mol	  Syst	  Biol	  6:	  400.	  73.	  Yang	  E,	  van	  Nimwegen	  E,	  Zavolan	  M,	  Rajewsky	  N,	  Schroeder	  M,	  et	  al.	  (2003)	  Decay	  rates	  of	  human	  mRNAs:	  correlation	  with	  functional	  characteristics	  and	  sequence	  attributes.	  Genome	  Res	  13:	  1863-­‐1872.	  74.	  Audic	  Y,	  Hartley	  RS	  (2004)	  Post-­‐transcriptional	  regulation	  in	  cancer.	  Biol	  Cell	  96:	  479-­‐498.	  75.	  Barreau	  C,	   Paillard	  L,	  Osborne	  HB	   (2005)	  AU-­‐rich	   elements	   and	  associated	  factors:	  are	  there	  unifying	  principles?	  Nucleic	  Acids	  Res	  33:	  7138-­‐7150.	  76.	  Meyer	  S,	  Temme	  C,	  Wahle	  E	  (2004)	  Messenger	  RNA	  turnover	  in	  eukaryotes:	  pathways	  and	  enzymes.	  Crit	  Rev	  Biochem	  Mol	  Biol	  39:	  197-­‐216.	  77.	  Vilborg	  A,	  Wilhelm	  MT,	  Wiman	  KG	  Regulation	  of	  tumor	  suppressor	  p53	  at	  the	  RNA	  level.	  J	  Mol	  Med	  88:	  645-­‐652.	  
	   51	  
78.	  Kim	  H,	  You	  S,	  Foster	  LK,	  Farris	  J,	  Foster	  DN	  (2001)	  The	  rapid	  destabilization	  of	  p53	  mRNA	  in	  immortal	  chicken	  embryo	  fibroblast	  cells.	  Oncogene	  20:	  5118-­‐5123.	  79.	   Takagi	   M,	   Absalon	   MJ,	   McLure	   KG,	   Kastan	   MB	   (2005)	   Regulation	   of	   p53	  translation	   and	   induction	   after	   DNA	   damage	   by	   ribosomal	   protein	   L26	  and	  nucleolin.	  Cell	  123:	  49-­‐63.	  80.	   Grover	   R,	   Candeias	   MM,	   Fahraeus	   R,	   Das	   S	   (2009)	   p53	   and	   little	   brother	  p53/47:	   linking	   IRES	   activities	   with	   protein	   functions.	   Oncogene	   28:	  2766-­‐2772.	  81.	   Ofir-­‐Rosenfeld	   Y,	   Boggs	   K,	   Michael	   D,	   Kastan	   MB,	   Oren	   M	   (2008)	   Mdm2	  regulates	   p53	   mRNA	   translation	   through	   inhibitory	   interactions	   with	  ribosomal	  protein	  L26.	  Mol	  Cell	  32:	  180-­‐189.	  82.	  Candeias	  MM,	  Malbert-­‐Colas	  L,	  Powell	  DJ,	  Daskalogianni	  C,	  Maslon	  MM,	  et	  al.	  (2008)	   P53	   mRNA	   controls	   p53	   activity	   by	   managing	   Mdm2	   functions.	  Nat	  Cell	  Biol	  10:	  1098-­‐1105.	  83.	  Mazan-­‐Mamczarz	  K,	  Galban	  S,	  Lopez	  de	  Silanes	  I,	  Martindale	  JL,	  Atasoy	  U,	  et	  al.	  (2003)	  RNA-­‐binding	  protein	  HuR	  enhances	  p53	  translation	  in	  response	  to	  ultraviolet	  light	  irradiation.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  100:	  8354-­‐8359.	  84.	   Schumacher	   B,	   Hanazawa	  M,	   Lee	   MH,	   Nayak	   S,	   Volkmann	   K,	   et	   al.	   (2005)	  Translational	   repression	   of	   C.	   elegans	   p53	   by	   GLD-­‐1	   regulates	   DNA	  damage-­‐induced	  apoptosis.	  Cell	  120:	  357-­‐368.	  85.	  Zou	  T,	  Mazan-­‐Mamczarz	  K,	  Rao	  JN,	  Liu	  L,	  Marasa	  BS,	  et	  al.	  (2006)	  Polyamine	  depletion	   increases	   cytoplasmic	   levels	   of	   RNA-­‐binding	   protein	   HuR	  leading	   to	   stabilization	   of	   nucleophosmin	   and	   p53	  mRNAs.	   J	   Biol	   Chem	  281:	  19387-­‐19394.	  86.	  Vilborg	  A,	  Glahder	  JA,	  Wilhelm	  MT,	  Bersani	  C,	  Corcoran	  M,	  et	  al.	  (2009)	  The	  p53	   target	   Wig-­‐1	   regulates	   p53	   mRNA	   stability	   through	   an	   AU-­‐rich	  element.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  106:	  15756-­‐15761.	  87.	  Fu	  L,	  Ma	  W,	  Benchimol	  S	  (1999)	  A	  translation	  repressor	  element	  resides	   in	  the	   3'	   untranslated	   region	   of	   human	   p53	   mRNA.	   Oncogene	   18:	   6419-­‐6424.	  88.	  Le	  MT,	  Teh	  C,	  Shyh-­‐Chang	  N,	  Xie	  H,	  Zhou	  B,	  et	  al.	  (2009)	  MicroRNA-­‐125b	  is	  a	  novel	  negative	  regulator	  of	  p53.	  Genes	  Dev	  23:	  862-­‐876.	  89.	  Zhang	  Y,	  Gao	  JS,	  Tang	  X,	  Tucker	  LD,	  Quesenberry	  P,	  et	  al.	   (2009)	  MicroRNA	  125a	  and	  its	  regulation	  of	  the	  p53	  tumor	  suppressor	  gene.	  FEBS	  Lett	  583:	  3725-­‐3730.	  90.	   Hu	  W,	   Chan	   CS,	  Wu	  R,	   Zhang	   C,	   Sun	   Y,	   et	   al.	   Negative	   regulation	   of	   tumor	  suppressor	  p53	  by	  microRNA	  miR-­‐504.	  Mol	  Cell	  38:	  689-­‐699.	  91.	  Li	  J,	  Donath	  S,	  Li	  Y,	  Qin	  D,	  Prabhakar	  BS,	  et	  al.	  miR-­‐30	  regulates	  mitochondrial	  fission	   through	   targeting	   p53	   and	   the	   dynamin-­‐related	   protein-­‐1	  pathway.	  PLoS	  Genet	  6:	  e1000795.	  92.	   Tian	   S,	   Huang	   S,	   Wu	   S,	   Guo	   W,	   Li	   J,	   et	   al.	   MicroRNA-­‐1285	   inhibits	   the	  expression	   of	   p53	   by	   directly	   targeting	   its	   3'	   untranslated	   region.	  Biochem	  Biophys	  Res	  Commun	  396:	  435-­‐439.	  93.	  Jin	  Z,	  El-­‐Deiry	  WS	  (2005)	  Overview	  of	  cell	  death	  signaling	  pathways.	  Cancer	  Biol	  Ther	  4:	  139-­‐163.	  94.	   Conradt	  B	   (2009)	  Genetic	   control	   of	   programmed	   cell	   death	  during	   animal	  development.	  Annu	  Rev	  Genet	  43:	  493-­‐523.	  
	   52	  
95.	  Fadeel	  B,	  Orrenius	  S	  (2005)	  Apoptosis:	  a	  basic	  biological	  phenomenon	  with	  wide-­‐ranging	  implications	  in	  human	  disease.	  J	  Intern	  Med	  258:	  479-­‐517.	  96.	   Vermeulen	   K,	   Van	   Bockstaele	   DR,	   Berneman	   ZN	   (2005)	   Apoptosis:	  mechanisms	  and	  relevance	  in	  cancer.	  Ann	  Hematol	  84:	  627-­‐639.	  97.	   Zimmermann	   KC,	   Green	   DR	   (2001)	   How	   cells	   die:	   apoptosis	   pathways.	   J	  Allergy	  Clin	  Immunol	  108:	  S99-­‐103.	  98.	  Fink	  SL,	  Cookson	  BT	  (2005)	  Apoptosis,	  pyroptosis,	  and	  necrosis:	  mechanistic	  description	   of	   dead	   and	   dying	   eukaryotic	   cells.	   Infect	   Immun	   73:	   1907-­‐1916.	  99.	   Clarke	   PG,	   Clarke	   S	   (1996)	   Nineteenth	   century	   research	   on	   naturally	  occurring	   cell	   death	   and	   related	   phenomena.	   Anat	   Embryol	   (Berl)	   193:	  81-­‐99.	  100.	  Lockshin	  RA,	  Zakeri	  Z	  (2001)	  Programmed	  cell	  death	  and	  apoptosis:	  origins	  of	  the	  theory.	  Nat	  Rev	  Mol	  Cell	  Biol	  2:	  545-­‐550.	  101.	   Gupta	   S	   (2001)	   Molecular	   steps	   of	   death	   receptor	   and	   mitochondrial	  pathways	  of	  apoptosis.	  Life	  Sci	  69:	  2957-­‐2964.	  102.	  Zhivotovsky	  B	  (2003)	  Caspases:	  the	  enzymes	  of	  death.	  Essays	  Biochem	  39:	  25-­‐40.	  103.	  Chowdhury	   I,	  Tharakan	  B,	  Bhat	  GK	   (2006)	  Current	   concepts	   in	  apoptosis:	  the	   physiological	   suicide	   program	   revisited.	   Cell	   Mol	   Biol	   Lett	   11:	   506-­‐525.	  104.	  Kroemer	  G,	  Reed	  JC	  (2000)	  Mitochondrial	  control	  of	  cell	  death.	  Nat	  Med	  6:	  513-­‐519.	  105.	  Desagher	  S,	  Martinou	  JC	  (2000)	  Mitochondria	  as	  the	  central	  control	  point	  of	  apoptosis.	  Trends	  Cell	  Biol	  10:	  369-­‐377.	  106.	   Riedl	   SJ,	   Salvesen	   GS	   (2007)	   The	   apoptosome:	   signalling	   platform	   of	   cell	  death.	  Nat	  Rev	  Mol	  Cell	  Biol	  8:	  405-­‐413.	  107.	   van	   Gurp	   M,	   Festjens	   N,	   van	   Loo	   G,	   Saelens	   X,	   Vandenabeele	   P	   (2003)	  Mitochondrial	   intermembrane	   proteins	   in	   cell	   death.	   Biochem	   Biophys	  Res	  Commun	  304:	  487-­‐497.	  108.	   Youle	  RJ,	   Strasser	  A	   (2008)	  The	  BCL-­‐2	   protein	   family:	   opposing	   activities	  that	  mediate	  cell	  death.	  Nat	  Rev	  Mol	  Cell	  Biol	  9:	  47-­‐59.	  109.	  Giam	  M,	  Huang	  DC,	  Bouillet	  P	  (2008)	  BH3-­‐only	  proteins	  and	  their	  roles	   in	  programmed	  cell	  death.	  Oncogene	  27	  Suppl	  1:	  S128-­‐136.	  110.	  Chipuk	   JE,	  Green	  DR	  (2008)	  How	  do	  BCL-­‐2	  proteins	   induce	  mitochondrial	  outer	  membrane	  permeabilization?	  Trends	  Cell	  Biol	  18:	  157-­‐164.	  111.	  Tsujimoto	  Y	  (2003)	  Cell	  death	  regulation	  by	  the	  Bcl-­‐2	  protein	  family	  in	  the	  mitochondria.	  J	  Cell	  Physiol	  195:	  158-­‐167.	  112.	  Yu	   J,	  Zhang	  L,	  Hwang	  PM,	  Kinzler	  KW,	  Vogelstein	  B	  (2001)	  PUMA	  induces	  the	  rapid	  apoptosis	  of	  colorectal	  cancer	  cells.	  Mol	  Cell	  7:	  673-­‐682.	  113.	  Wallach	  D,	  Kang	  TB,	  Kovalenko	  A	  (2008)	  The	  extrinsic	  cell	  death	  pathway	  and	  the	  elan	  mortel.	  Cell	  Death	  Differ	  15:	  1533-­‐1541.	  114.	   Creagh	   EM,	   Conroy	   H,	   Martin	   SJ	   (2003)	   Caspase-­‐activation	   pathways	   in	  apoptosis	  and	  immunity.	  Immunol	  Rev	  193:	  10-­‐21.	  115.	  Hofseth	  LJ,	  Hussain	  SP,	  Harris	  CC	  (2004)	  p53:	  25	  years	  after	   its	  discovery.	  Trends	  Pharmacol	  Sci	  25:	  177-­‐181.	  116.	   Tsang	  WP,	   Chau	   SP,	  Kong	   SK,	   Fung	  KP,	  Kwok	  TT	   (2003)	  Reactive	   oxygen	  species	  mediate	  doxorubicin	  induced	  p53-­‐independent	  apoptosis.	  Life	  Sci	  73:	  2047-­‐2058.	  
	   53	  
117.	  Sheridan	  C,	  Brumatti	  G,	  Elgendy	  M,	  Brunet	  M,	  Martin	  SJ	  An	  ERK-­‐dependent	  pathway	   to	   Noxa	   expression	   regulates	   apoptosis	   by	   platinum-­‐based	  chemotherapeutic	  drugs.	  Oncogene.	  118.	  Yu	  J,	  Zhang	  L	  (2008)	  PUMA,	  a	  potent	  killer	  with	  or	  without	  p53.	  Oncogene	  27	  Suppl	  1:	  S71-­‐83.	  119.	  Lafarga	  M,	  Casafont	   I,	  Bengoechea	  R,	  Tapia	  O,	  Berciano	  MT	   (2009)	  Cajal's	  contribution	  to	  the	  knowledge	  of	  the	  neuronal	  cell	  nucleus.	  Chromosoma	  118:	  437-­‐443.	  120.	  Liu	  JL,	  Murphy	  C,	  Buszczak	  M,	  Clatterbuck	  S,	  Goodman	  R,	  et	  al.	  (2006)	  The	  Drosophila	  melanogaster	  Cajal	  body.	  J	  Cell	  Biol	  172:	  875-­‐884.	  121.	  Matera	  AG,	  Shpargel	  KB	  (2006)	  Pumping	  RNA:	  nuclear	  bodybuilding	  along	  the	  RNP	  pipeline.	  Curr	  Opin	  Cell	  Biol	  18:	  317-­‐324.	  122.	   Platani	  M,	   Goldberg	   I,	   Swedlow	   JR,	   Lamond	  AI	   (2000)	   In	   vivo	   analysis	   of	  Cajal	   body	  movement,	   separation,	   and	   joining	   in	   live	   human	   cells.	   J	   Cell	  Biol	  151:	  1561-­‐1574.	  123.	  Spector	  DL	  (2006)	  SnapShot:	  Cellular	  bodies.	  Cell	  127:	  1071.	  124.	  Darzacq	  X,	   Jady	  BE,	  Verheggen	  C,	  Kiss	  AM,	  Bertrand	  E,	   et	   al.	   (2002)	  Cajal	  body-­‐specific	   small	   nuclear	  RNAs:	   a	   novel	   class	   of	   2'-­‐O-­‐methylation	   and	  pseudouridylation	  guide	  RNAs.	  EMBO	  J	  21:	  2746-­‐2756.	  125.	   Jady	   BE,	   Darzacq	   X,	   Tucker	   KE,	   Matera	   AG,	   Bertrand	   E,	   et	   al.	   (2003)	  Modification	  of	  Sm	  small	  nuclear	  RNAs	  occurs	  in	  the	  nucleoplasmic	  Cajal	  body	  following	  import	  from	  the	  cytoplasm.	  EMBO	  J	  22:	  1878-­‐1888.	  126.	  Schaffert	  N,	  Hossbach	  M,	  Heintzmann	  R,	  Achsel	  T,	  Luhrmann	  R	  (2004)	  RNAi	  knockdown	   of	   hPrp31	   leads	   to	   an	   accumulation	   of	   U4/U6	   di-­‐snRNPs	   in	  Cajal	  bodies.	  EMBO	  J	  23:	  3000-­‐3009.	  127.	   Stanek	   D,	   Neugebauer	   KM	   (2004)	   Detection	   of	   snRNP	   assembly	  intermediates	  in	  Cajal	  bodies	  by	  fluorescence	  resonance	  energy	  transfer.	  J	  Cell	  Biol	  166:	  1015-­‐1025.	  128.	   Jady	   BE,	   Richard	   P,	   Bertrand	   E,	   Kiss	   T	   (2006)	   Cell	   cycle-­‐dependent	  recruitment	  of	  telomerase	  RNA	  and	  Cajal	  bodies	  to	  human	  telomeres.	  Mol	  Biol	  Cell	  17:	  944-­‐954.	  129.	  Jady	  BE,	  Bertrand	  E,	  Kiss	  T	  (2004)	  Human	  telomerase	  RNA	  and	  box	  H/ACA	  scaRNAs	  share	  a	  common	  Cajal	  body-­‐specific	  localization	  signal.	  J	  Cell	  Biol	  164:	  647-­‐652.	  130.	  Tomlinson	  RL,	  Ziegler	  TD,	  Supakorndej	  T,	  Terns	  RM,	  Terns	  MP	  (2006)	  Cell	  cycle-­‐regulated	   trafficking	   of	   human	   telomerase	   to	   telomeres.	   Mol	   Biol	  Cell	  17:	  955-­‐965.	  131.	   Tomlinson	   RL,	   Abreu	   EB,	   Ziegler	   T,	   Ly	   H,	   Counter	   CM,	   et	   al.	   (2008)	  Telomerase	   reverse	   transcriptase	   is	   required	   for	   the	   localization	   of	  telomerase	  RNA	  to	  cajal	  bodies	  and	  telomeres	  in	  human	  cancer	  cells.	  Mol	  Biol	  Cell	  19:	  3793-­‐3800.	  132.	  Cioce	  M,	  Lamond	  AI	  (2005)	  Cajal	  bodies:	  a	  long	  history	  of	  discovery.	  Annu	  Rev	  Cell	  Dev	  Biol	  21:	  105-­‐131.	  133.	   Bongiorno-­‐Borbone	   L,	   De	   Cola	   A,	   Vernole	   P,	   Finos	   L,	   Barcaroli	   D,	   et	   al.	  (2008)	   FLASH	   and	   NPAT	   positive	   but	   not	   Coilin	   positive	   Cajal	   Bodies	  correlate	  with	  cell	  ploidy.	  Cell	  Cycle	  7:	  2357-­‐2367.	  134.	  Sun	  J,	  Xu	  H,	  Subramony	  SH,	  Hebert	  MD	  (2005)	  Interactions	  between	  coilin	  and	  PIASy	  partially	  link	  Cajal	  bodies	  to	  PML	  bodies.	  J	  Cell	  Sci	  118:	  4995-­‐5003.	  
	   54	  
135.	  Li	  CF,	  Pontes	  O,	  El-­‐Shami	  M,	  Henderson	  IR,	  Bernatavichute	  YV,	  et	  al.	  (2006)	  An	  ARGONAUTE4-­‐containing	  nuclear	   processing	   center	   colocalized	  with	  Cajal	  bodies	  in	  Arabidopsis	  thaliana.	  Cell	  126:	  93-­‐106.	  136.	   Pontes	  O,	   Li	   CF,	  Nunes	  PC,	  Haag	   J,	   Ream	  T,	   et	   al.	   (2006)	  The	  Arabidopsis	  chromatin-­‐modifying	   nuclear	   siRNA	   pathway	   involves	   a	   nucleolar	   RNA	  processing	  center.	  Cell	  126:	  79-­‐92.	  137.	  Collier	  S,	  Pendle	  A,	  Boudonck	  K,	  van	  Rij	  T,	  Dolan	  L,	  et	  al.	   (2006)	  A	  distant	  coilin	   homologue	   is	   required	   for	   the	   formation	   of	   cajal	   bodies	   in	  Arabidopsis.	  Mol	  Biol	  Cell	  17:	  2942-­‐2951.	  138.	   Liu	   JL,	  Wu	  Z,	  Nizami	   Z,	  Deryusheva	   S,	  Rajendra	  TK,	   et	   al.	   (2009)	  Coilin	   is	  essential	  for	  Cajal	  body	  organization	  in	  Drosophila	  melanogaster.	  Mol	  Biol	  Cell	  20:	  1661-­‐1670.	  139.	   Whittom	   AA,	   Xu	   H,	   Hebert	   MD	   (2008)	   Coilin	   levels	   and	   modifications	  influence	  artificial	  reporter	  splicing.	  Cell	  Mol	  Life	  Sci	  65:	  1256-­‐1271.	  140.	  Lemm	  I,	  Girard	  C,	  Kuhn	  AN,	  Watkins	  NJ,	  Schneider	  M,	  et	  al.	  (2006)	  Ongoing	  U	  snRNP	  biogenesis	  is	  required	  for	  the	  integrity	  of	  Cajal	  bodies.	  Mol	  Biol	  Cell	  17:	  3221-­‐3231.	  141.	   Walker	   MP,	   Tian	   L,	   Matera	   AG	   (2009)	   Reduced	   viability,	   fertility	   and	  fecundity	  in	  mice	  lacking	  the	  cajal	  body	  marker	  protein,	  coilin.	  PLoS	  One	  4:	  e6171.	  142.	   Strzelecka	  M,	  Trowitzsch	  S,	  Weber	  G,	  Luhrmann	  R,	  Oates	  AC,	   et	   al.	  Coilin-­‐dependent	  snRNP	  assembly	  is	  essential	  for	  zebrafish	  embryogenesis.	  Nat	  Struct	  Mol	  Biol	  17:	  403-­‐409.	  143.	  Deryusheva	  S,	  Gall	   JG	  (2009)	  Small	  Cajal	  body-­‐specific	  RNAs	  of	  Drosophila	  function	  in	  the	  absence	  of	  Cajal	  bodies.	  Mol	  Biol	  Cell	  20:	  5250-­‐5259.	  144.	  Klingauf	  M,	  Stanek	  D,	  Neugebauer	  KM	  (2006)	  Enhancement	  of	  U4/U6	  small	  nuclear	   ribonucleoprotein	   particle	   association	   in	   Cajal	   bodies	   predicted	  by	  mathematical	  modeling.	  Mol	  Biol	  Cell	  17:	  4972-­‐4981.	  145.	  Yoon	  JH,	  Parker	  R	  (2010)	  Coil-­‐in-­‐to	  snRNP	  assembly	  and	  Cajal	  bodies.	  Nat	  Struct	  Mol	  Biol	  17:	  391-­‐393.	  146.	  Nizami	  Z,	  Deryusheva	  S,	  Gall	  JG	  The	  Cajal	  body	  and	  histone	  locus	  body.	  Cold	  Spring	  Harb	  Perspect	  Biol	  2:	  a000653.	  147.	   Spector	   DL,	   Lark	   G,	   Huang	   S	   (1992)	   Differences	   in	   snRNP	   localization	  between	  transformed	  and	  nontransformed	  cells.	  Mol	  Biol	  Cell	  3:	  555-­‐569.	  148.	  Zhu	  Y,	  Tomlinson	  RL,	  Lukowiak	  AA,	  Terns	  RM,	  Terns	  MP	  (2004)	  Telomerase	  RNA	  accumulates	  in	  Cajal	  bodies	  in	  human	  cancer	  cells.	  Mol	  Biol	  Cell	  15:	  81-­‐90.	  149.	  Buschges	  R,	  Ichimura	  K,	  Weber	  RG,	  Reifenberger	  G,	  Collins	  VP	  (2002)	  Allelic	  gain	  and	  amplification	  on	   the	   long	  arm	  of	   chromosome	  17	   in	   anaplastic	  meningiomas.	  Brain	  Pathol	  12:	  145-­‐153.	  150.	   Velma	   V,	   Carrero	   ZI,	   Cosman	   AM,	   Hebert	   MD	   Coilin	   interacts	   with	   Ku	  proteins	   and	   inhibits	   in	   vitro	   non-­‐homologous	   DNA	   end	   joining.	   FEBS	  Lett.	  151.	  Hebert	  MD,	  Szymczyk	  PW,	  Shpargel	  KB,	  Matera	  AG	  (2001)	  Coilin	  forms	  the	  bridge	   between	   Cajal	   bodies	   and	   SMN,	   the	   spinal	   muscular	   atrophy	  protein.	  Genes	  Dev	  15:	  2720-­‐2729.	  152.	  Lallemand-­‐Breitenbach	  V,	  de	  The	  H	  PML	  nuclear	  bodies.	  Cold	  Spring	  Harb	  Perspect	  Biol	  2:	  a000661.	  
	   55	  
153.	  Hebert	  MD,	  Matera	  AG	  (2000)	  Self-­‐association	  of	   coilin	   reveals	  a	   common	  theme	  in	  nuclear	  body	  localization.	  Mol	  Biol	  Cell	  11:	  4159-­‐4171.	  154.	   Xu	  H,	   Pillai	   RS,	   Azzouz	  TN,	   Shpargel	   KB,	   Kambach	   C,	   et	   al.	   (2005)	   The	   C-­‐terminal	   domain	   of	   coilin	   interacts	   with	   Sm	   proteins	   and	   U	   snRNPs.	  Chromosoma	  114:	  155-­‐166.	  155.	  Tucker	  KE,	  Berciano	  MT,	   Jacobs	  EY,	  LePage	  DF,	  Shpargel	  KB,	  et	  al.	   (2001)	  Residual	   Cajal	   bodies	   in	   coilin	   knockout	  mice	   fail	   to	   recruit	   Sm	   snRNPs	  and	  SMN,	  the	  spinal	  muscular	  atrophy	  gene	  product.	  J	  Cell	  Biol	  154:	  293-­‐307.	  156.	  Lam	  YW,	  Lyon	  CE,	  Lamond	  AI	   (2002)	  Large-­‐scale	   isolation	  of	  Cajal	  bodies	  from	  HeLa	  cells.	  Mol	  Biol	  Cell	  13:	  2461-­‐2473.	  157.	   Morency	   E,	   Sabra	   M,	   Catez	   F,	   Texier	   P,	   Lomonte	   P	   (2007)	   A	   novel	   cell	  response	  triggered	  by	  interphase	  centromere	  structural	  instability.	  J	  Cell	  Biol	  177:	  757-­‐768.	  158.	  Wachtel	  C,	  Manley	  JL	  (2009)	  Splicing	  of	  mRNA	  precursors:	  the	  role	  of	  RNAs	  and	  proteins	  in	  catalysis.	  Mol	  Biosyst	  5:	  311-­‐316.	  159.	   Nilsen	   TW	   (2003)	   The	   spliceosome:	   the	   most	   complex	   macromolecular	  machine	  in	  the	  cell?	  Bioessays	  25:	  1147-­‐1149.	  160.	   Will	   CL,	   Luhrmann	   R	   (2001)	   Spliceosomal	   UsnRNP	   biogenesis,	   structure	  and	  function.	  Curr	  Opin	  Cell	  Biol	  13:	  290-­‐301.	  161.	   Rino	   J,	   Carmo-­‐Fonseca	   M	   (2009)	   The	   spliceosome:	   a	   self-­‐organized	  macromolecular	  machine	  in	  the	  nucleus?	  Trends	  Cell	  Biol	  19:	  375-­‐384.	  162.	  Will	  CL,	  Luhrmann	  R	  (2005)	  Splicing	  of	  a	  rare	  class	  of	  introns	  by	  the	  U12-­‐dependent	  spliceosome.	  Biol	  Chem	  386:	  713-­‐724.	  163.	   Patel	   SB,	   Bellini	   M	   (2008)	   The	   assembly	   of	   a	   spliceosomal	   small	   nuclear	  ribonucleoprotein	  particle.	  Nucleic	  Acids	  Res	  36:	  6482-­‐6493.	  164.	  Matera	  AG,	  Terns	  RM,	  Terns	  MP	  (2007)	  Non-­‐coding	  RNAs:	  lessons	  from	  the	  small	  nuclear	  and	  small	  nucleolar	  RNAs.	  Nat	  Rev	  Mol	  Cell	  Biol	  8:	  209-­‐220.	  165.	   Hernandez	   N	   (2001)	   Small	   nuclear	   RNA	   genes:	   a	   model	   system	   to	   study	  fundamental	   mechanisms	   of	   transcription.	   J	   Biol	   Chem	   276:	   26733-­‐26736.	  166.	  Ohno	  M,	  Segref	  A,	  Bachi	  A,	  Wilm	  M,	  Mattaj	  IW	  (2000)	  PHAX,	  a	  mediator	  of	  U	  snRNA	   nuclear	   export	   whose	   activity	   is	   regulated	   by	   phosphorylation.	  Cell	  101:	  187-­‐198.	  167.	  Segref	  A,	  Mattaj	  IW,	  Ohno	  M	  (2001)	  The	  evolutionarily	  conserved	  region	  of	  the	  U	  snRNA	  export	  mediator	  PHAX	  is	  a	  novel	  RNA-­‐binding	  domain	  that	  is	  essential	  for	  U	  snRNA	  export.	  RNA	  7:	  351-­‐360.	  168.	   Kitao	   S,	   Segref	   A,	   Kast	   J,	   Wilm	   M,	   Mattaj	   IW,	   et	   al.	   (2008)	   A	  compartmentalized	   phosphorylation/dephosphorylation	   system	   that	  regulates	  U	  snRNA	  export	  from	  the	  nucleus.	  Mol	  Cell	  Biol	  28:	  487-­‐497.	  169.	  Gubitz	  AK,	  Feng	  W,	  Dreyfuss	  G	  (2004)	  The	  SMN	  complex.	  Exp	  Cell	  Res	  296:	  51-­‐56.	  170.	  Battle	  DJ,	  Kasim	  M,	  Yong	  J,	  Lotti	  F,	  Lau	  CK,	  et	  al.	  (2006)	  The	  SMN	  complex:	  an	   assembly	  machine	   for	   RNPs.	   Cold	   Spring	   Harb	   Symp	   Quant	   Biol	   71:	  313-­‐320.	  171.	  Pellizzoni	  L,	  Yong	  J,	  Dreyfuss	  G	  (2002)	  Essential	  role	  for	  the	  SMN	  complex	  in	  the	  specificity	  of	  snRNP	  assembly.	  Science	  298:	  1775-­‐1779.	  172.	   Raker	   VA,	   Hartmuth	   K,	   Kastner	   B,	   Luhrmann	   R	   (1999)	   Spliceosomal	   U	  snRNP	   core	   assembly:	   Sm	   proteins	   assemble	   onto	   an	   Sm	   site	   RNA	  
	   56	  
nonanucleotide	   in	   a	   specific	   and	   thermodynamically	   stable	  manner.	  Mol	  Cell	  Biol	  19:	  6554-­‐6565.	  173.	   Raker	   VA,	   Plessel	   G,	   Luhrmann	   R	   (1996)	   The	   snRNP	   core	   assembly	  pathway:	  identification	  of	  stable	  core	  protein	  heteromeric	  complexes	  and	  an	  snRNP	  subcore	  particle	  in	  vitro.	  EMBO	  J	  15:	  2256-­‐2269.	  174.	  Meister	  G,	  Buhler	  D,	  Pillai	  R,	  Lottspeich	  F,	  Fischer	  U	  (2001)	  A	  multiprotein	  complex	   mediates	   the	   ATP-­‐dependent	   assembly	   of	   spliceosomal	   U	  snRNPs.	  Nat	  Cell	  Biol	  3:	  945-­‐949.	  175.	  Mouaikel	  J,	  Narayanan	  U,	  Verheggen	  C,	  Matera	  AG,	  Bertrand	  E,	  et	  al.	  (2003)	  Interaction	  between	   the	  small-­‐nuclear-­‐RNA	  cap	  hypermethylase	  and	   the	  spinal	  muscular	  atrophy	  protein,	  survival	  of	  motor	  neuron.	  EMBO	  Rep	  4:	  616-­‐622.	  176.	   Mouaikel	   J,	   Verheggen	   C,	   Bertrand	   E,	   Tazi	   J,	   Bordonne	   R	   (2002)	  Hypermethylation	  of	  the	  cap	  structure	  of	  both	  yeast	  snRNAs	  and	  snoRNAs	  requires	  a	  conserved	  methyltransferase	  that	  is	  localized	  to	  the	  nucleolus.	  Mol	  Cell	  9:	  891-­‐901.	  177.	   Allmang	   C,	   Kufel	   J,	   Chanfreau	   G,	   Mitchell	   P,	   Petfalski	   E,	   et	   al.	   (1999)	  Functions	  of	  the	  exosome	  in	  rRNA,	  snoRNA	  and	  snRNA	  synthesis.	  EMBO	  J	  18:	  5399-­‐5410.	  178.	   Huang	   Q,	   Pederson	   T	   (1999)	   A	   human	   U2	   RNA	  mutant	   stalled	   in	   3'	   end	  processing	   is	   impaired	   in	   nuclear	   import.	   Nucleic	   Acids	   Res	   27:	   1025-­‐1031.	  179.	  Huber	   J,	   Cronshagen	  U,	  Kadokura	  M,	  Marshallsay	  C,	  Wada	  T,	   et	   al.	   (1998)	  Snurportin1,	   an	  m3G-­‐cap-­‐specific	   nuclear	   import	   receptor	   with	   a	   novel	  domain	  structure.	  EMBO	  J	  17:	  4114-­‐4126.	  180.	  Narayanan	  U,	  Ospina	  JK,	  Frey	  MR,	  Hebert	  MD,	  Matera	  AG	  (2002)	  SMN,	  the	  spinal	  muscular	  atrophy	  protein,	  forms	  a	  pre-­‐import	  snRNP	  complex	  with	  snurportin1	  and	  importin	  beta.	  Hum	  Mol	  Genet	  11:	  1785-­‐1795.	  181.	   Ospina	   JK,	   Gonsalvez	   GB,	   Bednenko	   J,	   Darzynkiewicz	   E,	   Gerace	   L,	   et	   al.	  (2005)	   Cross-­‐talk	   between	   snurportin1	   subdomains.	   Mol	   Biol	   Cell	   16:	  4660-­‐4671.	  182.	   Narayanan	   U,	   Achsel	   T,	   Luhrmann	   R,	  Matera	   AG	   (2004)	   Coupled	   in	   vitro	  import	  of	  U	   snRNPs	  and	  SMN,	   the	   spinal	  muscular	   atrophy	  protein.	  Mol	  Cell	  16:	  223-­‐234.	  183.	   Rollenhagen	   C,	   Muhlhausser	   P,	   Kutay	   U,	   Pante	   N	   (2003)	   Importin	   beta-­‐depending	  nuclear	   import	  pathways:	   role	  of	   the	   adapter	  proteins	   in	   the	  docking	  and	  releasing	  steps.	  Mol	  Biol	  Cell	  14:	  2104-­‐2115.	  184.	  Wohlwend	  D,	  Strasser	  A,	  Dickmanns	  A,	  Ficner	  R	  (2007)	  Structural	  basis	  for	  RanGTP	   independent	  entry	  of	  spliceosomal	  U	  snRNPs	   into	   the	  nucleus.	   J	  Mol	  Biol	  374:	  1129-­‐1138.	  185.	  Donmez	  G,	  Hartmuth	  K,	  Luhrmann	  R	  (2004)	  Modified	  nucleotides	  at	  the	  5'	  end	   of	   human	   U2	   snRNA	   are	   required	   for	   spliceosomal	   E-­‐complex	  formation.	  RNA	  10:	  1925-­‐1933.	  186.	   Lamond	   AI,	   Spector	   DL	   (2003)	   Nuclear	   speckles:	   a	   model	   for	   nuclear	  organelles.	  Nat	  Rev	  Mol	  Cell	  Biol	  4:	  605-­‐612.	  187.	  Stanek	  D,	  Rader	  SD,	  Klingauf	  M,	  Neugebauer	  KM	  (2003)	  Targeting	  of	  U4/U6	  small	  nuclear	  RNP	  assembly	  factor	  SART3/p110	  to	  Cajal	  bodies.	  J	  Cell	  Biol	  160:	  505-­‐516.	  
	   57	  
188.	  Nesic	  D,	  Tanackovic	  G,	  Kramer	  A	  (2004)	  A	  role	  for	  Cajal	  bodies	  in	  the	  final	  steps	  of	  U2	  snRNP	  biogenesis.	  J	  Cell	  Sci	  117:	  4423-­‐4433.	  189.	  Achsel	  T,	  Brahms	  H,	  Kastner	  B,	  Bachi	  A,	  Wilm	  M,	  et	  al.	  (1999)	  A	  doughnut-­‐shaped	   heteromer	   of	   human	   Sm-­‐like	   proteins	   binds	   to	   the	   3'-­‐end	   of	  U6	  snRNA,	  thereby	  facilitating	  U4/U6	  duplex	  formation	  in	  vitro.	  EMBO	  J	  18:	  5789-­‐5802.	  190.	   Tycowski	   KT,	   You	   ZH,	   Graham	   PJ,	   Steitz	   JA	   (1998)	   Modification	   of	   U6	  spliceosomal	  RNA	  is	  guided	  by	  other	  small	  RNAs.	  Mol	  Cell	  2:	  629-­‐638.	  191.	  Ganot	  P,	   Jady	  BE,	  Bortolin	  ML,	  Darzacq	  X,	  Kiss	  T	   (1999)	  Nucleolar	   factors	  direct	   the	   2'-­‐O-­‐ribose	   methylation	   and	   pseudouridylation	   of	   U6	  spliceosomal	  RNA.	  Mol	  Cell	  Biol	  19:	  6906-­‐6917.	  192.	  Bachand	  F,	  Boisvert	  FM,	  Cote	  J,	  Richard	  S,	  Autexier	  C	  (2002)	  The	  product	  of	  the	   survival	   of	   motor	   neuron	   (SMN)	   gene	   is	   a	   human	   telomerase-­‐associated	  protein.	  Mol	  Biol	  Cell	  13:	  3192-­‐3202.	  193.	   Mourelatos	   Z,	   Dostie	   J,	   Paushkin	   S,	   Sharma	   A,	   Charroux	   B,	   et	   al.	   (2002)	  miRNPs:	   a	   novel	   class	   of	   ribonucleoproteins	   containing	   numerous	  microRNAs.	  Genes	  Dev	  16:	  720-­‐728.	  194.	   Jones	   KW,	   Gorzynski	   K,	   Hales	   CM,	   Fischer	   U,	   Badbanchi	   F,	   et	   al.	   (2001)	  Direct	   interaction	   of	   the	   spinal	   muscular	   atrophy	   disease	   protein	   SMN	  with	   the	   small	   nucleolar	   RNA-­‐associated	   protein	   fibrillarin.	   J	   Biol	   Chem	  276:	  38645-­‐38651.	  195.	  Pellizzoni	  L,	  Baccon	  J,	  Charroux	  B,	  Dreyfuss	  G	  (2001)	  The	  survival	  of	  motor	  neurons	  (SMN)	  protein	  interacts	  with	  the	  snoRNP	  proteins	  fibrillarin	  and	  GAR1.	  Curr	  Biol	  11:	  1079-­‐1088.	  196.	  Watkins	  NJ,	  Lemm	  I,	   Ingelfinger	  D,	  Schneider	  C,	  Hossbach	  M,	  et	  al.	   (2004)	  Assembly	  and	  maturation	  of	  the	  U3	  snoRNP	  in	  the	  nucleoplasm	  in	  a	  large	  dynamic	  multiprotein	  complex.	  Mol	  Cell	  16:	  789-­‐798.	  197.	   Kolb	   SJ,	   Battle	   DJ,	   Dreyfuss	   G	   (2007)	   Molecular	   functions	   of	   the	   SMN	  complex.	  J	  Child	  Neurol	  22:	  990-­‐994.	  198.	  Burghes	  AH,	  Beattie	  CE	  (2009)	  Spinal	  muscular	  atrophy:	  why	  do	  low	  levels	  of	   survival	   motor	   neuron	   protein	   make	   motor	   neurons	   sick?	   Nat	   Rev	  Neurosci	  10:	  597-­‐609.	  199.	   Bertrandy	   S,	   Burlet	   P,	   Clermont	   O,	   Huber	   C,	   Fondrat	   C,	   et	   al.	   (1999)	   The	  RNA-­‐binding	   properties	   of	   SMN:	   deletion	   analysis	   of	   the	   zebrafish	  orthologue	   defines	   domains	   conserved	   in	   evolution.	   Hum	  Mol	   Genet	   8:	  775-­‐782.	  200.	  Selenko	  P,	  Sprangers	  R,	  Stier	  G,	  Buhler	  D,	  Fischer	  U,	  et	  al.	  (2001)	  SMN	  tudor	  domain	  structure	  and	  its	  interaction	  with	  the	  Sm	  proteins.	  Nat	  Struct	  Biol	  8:	  27-­‐31.	  201.	   Buhler	   D,	   Raker	   V,	   Luhrmann	   R,	   Fischer	   U	   (1999)	   Essential	   role	   for	   the	  tudor	  domain	  of	  SMN	  in	  spliceosomal	  U	  snRNP	  assembly:	  implications	  for	  spinal	  muscular	  atrophy.	  Hum	  Mol	  Genet	  8:	  2351-­‐2357.	  202.	  Giesemann	  T,	  Rathke-­‐Hartlieb	  S,	  Rothkegel	  M,	  Bartsch	  JW,	  Buchmeier	  S,	  et	  al.	   (1999)	   A	   role	   for	   polyproline	  motifs	   in	   the	   spinal	  muscular	   atrophy	  protein	  SMN.	  Profilins	  bind	  to	  and	  colocalize	  with	  smn	  in	  nuclear	  gems.	  J	  Biol	  Chem	  274:	  37908-­‐37914.	  203.	  Lorson	  CL,	  Strasswimmer	  J,	  Yao	  JM,	  Baleja	  JD,	  Hahnen	  E,	  et	  al.	  (1998)	  SMN	  oligomerization	  defect	   correlates	  with	   spinal	  muscular	  atrophy	  severity.	  Nat	  Genet	  19:	  63-­‐66.	  
	   58	  
204.	   Burnett	   BG,	   Munoz	   E,	   Tandon	   A,	   Kwon	   DY,	   Sumner	   CJ,	   et	   al.	   (2009)	  Regulation	  of	  SMN	  protein	  stability.	  Mol	  Cell	  Biol	  29:	  1107-­‐1115.	  205.	  Carissimi	  C,	  Saieva	  L,	  Baccon	  J,	  Chiarella	  P,	  Maiolica	  A,	  et	  al.	  (2006)	  Gemin8	  is	  a	  novel	  component	  of	  the	  survival	  motor	  neuron	  complex	  and	  functions	  in	   small	   nuclear	   ribonucleoprotein	   assembly.	   J	   Biol	   Chem	   281:	   8126-­‐8134.	  206.	  Carissimi	  C,	   Saieva	  L,	  Gabanella	  F,	  Pellizzoni	  L	   (2006)	  Gemin8	   is	   required	  for	  the	  architecture	  and	  function	  of	  the	  survival	  motor	  neuron	  complex.	  J	  Biol	  Chem	  281:	  37009-­‐37016.	  207.	  Charroux	  B,	  Pellizzoni	  L,	  Perkinson	  RA,	  Yong	  J,	  Shevchenko	  A,	  et	  al.	  (2000)	  Gemin4.	   A	   novel	   component	   of	   the	   SMN	   complex	   that	   is	   found	   in	   both	  gems	  and	  nucleoli.	  J	  Cell	  Biol	  148:	  1177-­‐1186.	  208.	   Baccon	   J,	   Pellizzoni	   L,	   Rappsilber	   J,	   Mann	   M,	   Dreyfuss	   G	   (2002)	  Identification	  and	  characterization	  of	  Gemin7,	  a	  novel	   component	  of	   the	  survival	  of	  motor	  neuron	  complex.	  J	  Biol	  Chem	  277:	  31957-­‐31962.	  209.	  Carissimi	  C,	  Baccon	  J,	  Straccia	  M,	  Chiarella	  P,	  Maiolica	  A,	  et	  al.	  (2005)	  Unrip	  is	   a	   component	   of	   SMN	   complexes	   active	   in	   snRNP	  assembly.	   FEBS	  Lett	  579:	  2348-­‐2354.	  210.	   Ogawa	   C,	   Usui	   K,	   Aoki	   M,	   Ito	   F,	   Itoh	   M,	   et	   al.	   (2007)	   Gemin2	   plays	   an	  important	  role	  in	  stabilizing	  the	  survival	  of	  motor	  neuron	  complex.	  J	  Biol	  Chem	  282:	  11122-­‐11134.	  211.	  Kroiss	  M,	  Schultz	  J,	  Wiesner	  J,	  Chari	  A,	  Sickmann	  A,	  et	  al.	  (2008)	  Evolution	  of	  an	  RNP	  assembly	  system:	  a	  minimal	  SMN	  complex	  facilitates	  formation	  of	  UsnRNPs	   in	   Drosophila	   melanogaster.	   Proc	   Natl	   Acad	   Sci	   U	   S	   A	   105:	  10045-­‐10050.	  212.	  Chari	  A,	  Golas	  MM,	  Klingenhager	  M,	  Neuenkirchen	  N,	  Sander	  B,	  et	  al.	  (2008)	  An	  assembly	   chaperone	   collaborates	  with	   the	   SMN	  complex	   to	   generate	  spliceosomal	  SnRNPs.	  Cell	  135:	  497-­‐509.	  213.	  Charroux	  B,	  Pellizzoni	  L,	  Perkinson	  RA,	  Shevchenko	  A,	  Mann	  M,	  et	  al.	  (1999)	  Gemin3:	   A	   novel	   DEAD	   box	   protein	   that	   interacts	  with	   SMN,	   the	   spinal	  muscular	  atrophy	  gene	  product,	   and	   is	   a	   component	  of	   gems.	   J	  Cell	  Biol	  147:	  1181-­‐1194.	  214.	  Battle	  DJ,	  Lau	  CK,	  Wan	  L,	  Deng	  H,	  Lotti	  F,	  et	  al.	  (2006)	  The	  Gemin5	  protein	  of	  the	  SMN	  complex	  identifies	  snRNAs.	  Mol	  Cell	  23:	  273-­‐279.	  215.	  Ogino	   S,	  Wilson	  RB	   (2002)	  Genetic	   testing	   and	   risk	   assessment	   for	   spinal	  muscular	  atrophy	  (SMA).	  Hum	  Genet	  111:	  477-­‐500.	  216.	  Wirth	  B	  (2000)	  An	  update	  of	  the	  mutation	  spectrum	  of	  the	  survival	  motor	  neuron	   gene	   (SMN1)	   in	   autosomal	   recessive	   spinal	   muscular	   atrophy	  (SMA).	  Hum	  Mutat	  15:	  228-­‐237.	  217.	  Gavrilov	  DK,	   Shi	   X,	  Das	  K,	   Gilliam	  TC,	  Wang	  CH	   (1998)	  Differential	   SMN2	  expression	  associated	  with	  SMA	  severity.	  Nat	  Genet	  20:	  230-­‐231.	  218.	   Soler-­‐Botija	   C,	   Cusco	   I,	   Caselles	   L,	   Lopez	   E,	   Baiget	   M,	   et	   al.	   (2005)	  Implication	   of	   fetal	   SMN2	   expression	   in	   type	   I	   SMA	   pathogenesis:	  protection	  or	  pathological	  gain	  of	  function?	  J	  Neuropathol	  Exp	  Neurol	  64:	  215-­‐223.	  219.	   Prior	   TW,	   Swoboda	   KJ,	   Scott	   HD,	   Hejmanowski	   AQ	   (2004)	   Homozygous	  SMN1	   deletions	   in	   unaffected	   family	   members	   and	   modification	   of	   the	  phenotype	  by	  SMN2.	  Am	  J	  Med	  Genet	  A	  130A:	  307-­‐310.	  
	   59	  
220.	  Wirth	   B,	   Brichta	   L,	   Schrank	   B,	   Lochmuller	  H,	   Blick	   S,	   et	   al.	   (2006)	  Mildly	  affected	  patients	  with	  spinal	  muscular	  atrophy	  are	  partially	  protected	  by	  an	  increased	  SMN2	  copy	  number.	  Hum	  Genet	  119:	  422-­‐428.	  221.	   Shpargel	   KB,	  Matera	   AG	   (2005)	   Gemin	   proteins	   are	   required	   for	   efficient	  assembly	   of	   Sm-­‐class	   ribonucleoproteins.	   Proc	  Natl	  Acad	   Sci	  U	   S	  A	  102:	  17372-­‐17377.	  222.	  Wan	  L,	   Battle	  DJ,	   Yong	   J,	   Gubitz	  AK,	  Kolb	   SJ,	   et	   al.	   (2005)	  The	   survival	   of	  motor	   neurons	   protein	   determines	   the	   capacity	   for	   snRNP	   assembly:	  biochemical	  deficiency	  in	  spinal	  muscular	  atrophy.	  Mol	  Cell	  Biol	  25:	  5543-­‐5551.	  223.	  Zhang	  Z,	   Lotti	   F,	  Dittmar	  K,	  Younis	   I,	  Wan	  L,	   et	   al.	   (2008)	  SMN	  deficiency	  causes	   tissue-­‐specific	   perturbations	   in	   the	   repertoire	   of	   snRNAs	   and	  widespread	  defects	  in	  splicing.	  Cell	  133:	  585-­‐600.	  224.	  Winkler	  C,	  Eggert	  C,	  Gradl	  D,	  Meister	  G,	  Giegerich	  M,	  et	  al.	  (2005)	  Reduced	  U	  snRNP	  assembly	  causes	  motor	  axon	  degeneration	  in	  an	  animal	  model	  for	  spinal	  muscular	  atrophy.	  Genes	  Dev	  19:	  2320-­‐2330.	  225.	   Renvoise	   B,	   Khoobarry	   K,	   Gendron	   MC,	   Cibert	   C,	   Viollet	   L,	   et	   al.	   (2006)	  Distinct	   domains	   of	   the	   spinal	   muscular	   atrophy	   protein	   SMN	   are	  required	   for	   targeting	   to	  Cajal	  bodies	   in	  mammalian	  cells.	   J	  Cell	  Sci	  119:	  680-­‐692.	  226.	   Zhang	   HL,	   Pan	   F,	   Hong	   D,	   Shenoy	   SM,	   Singer	   RH,	   et	   al.	   (2003)	   Active	  transport	  of	  the	  survival	  motor	  neuron	  protein	  and	  the	  role	  of	  exon-­‐7	  in	  cytoplasmic	  localization.	  J	  Neurosci	  23:	  6627-­‐6637.	  227.	   Bassell	   GJ,	   Singer	   RH	   (2001)	   Neuronal	   RNA	   localization	   and	   the	  cytoskeleton.	  Results	  Probl	  Cell	  Differ	  34:	  41-­‐56.	  228.	  Rossoll	  W,	  Jablonka	  S,	  Andreassi	  C,	  Kroning	  AK,	  Karle	  K,	  et	  al.	  (2003)	  Smn,	  the	   spinal	  muscular	   atrophy-­‐determining	   gene	  product,	  modulates	   axon	  growth	   and	   localization	   of	   beta-­‐actin	   mRNA	   in	   growth	   cones	   of	  motoneurons.	  J	  Cell	  Biol	  163:	  801-­‐812.	  229.	  McWhorter	  ML,	  Monani	  UR,	  Burghes	  AH,	  Beattie	  CE	  (2003)	  Knockdown	  of	  the	   survival	  motor	   neuron	   (Smn)	   protein	   in	   zebrafish	   causes	   defects	   in	  motor	  axon	  outgrowth	  and	  pathfinding.	  J	  Cell	  Biol	  162:	  919-­‐931.	  230.	  Brown	  JW,	  Echeverria	  M,	  Qu	  LH,	  Lowe	  TM,	  Bachellerie	  JP,	  et	  al.	  (2003)	  Plant	  snoRNA	  database.	  Nucleic	  Acids	  Res	  31:	  432-­‐435.	  231.	  Lestrade	  L,	  Weber	  MJ	  (2006)	  snoRNA-­‐LBME-­‐db,	  a	  comprehensive	  database	  of	  human	  H/ACA	  and	  C/D	  box	  snoRNAs.	  Nucleic	  Acids	  Res	  34:	  D158-­‐162.	  232.	  Dieci	  G,	  Preti	  M,	  Montanini	  B	   (2009)	  Eukaryotic	   snoRNAs:	  a	  paradigm	   for	  gene	  expression	  flexibility.	  Genomics	  94:	  83-­‐88.	  233.	   Richard	   P,	   Darzacq	   X,	   Bertrand	   E,	   Jady	   BE,	   Verheggen	   C,	   et	   al.	   (2003)	   A	  common	  sequence	  motif	  determines	  the	  Cajal	  body-­‐specific	  localization	  of	  box	  H/ACA	  scaRNAs.	  EMBO	  J	  22:	  4283-­‐4293.	  234.	  Tycowski	  KT,	  Shu	  MD,	  Kukoyi	  A,	  Steitz	  JA	  (2009)	  A	  conserved	  WD40	  protein	  binds	   the	  Cajal	  body	   localization	  signal	  of	   scaRNP	  particles.	  Mol	  Cell	  34:	  47-­‐57.	  235.	   Venteicher	   AS,	   Abreu	   EB,	  Meng	   Z,	  McCann	   KE,	   Terns	   RM,	   et	   al.	   (2009)	   A	  human	   telomerase	   holoenzyme	   protein	   required	   for	   Cajal	   body	  localization	  and	  telomere	  synthesis.	  Science	  323:	  644-­‐648.	  
	   60	  
236.	   Cohen	   SB,	   Graham	   ME,	   Lovrecz	   GO,	   Bache	   N,	   Robinson	   PJ,	   et	   al.	   (2007)	  Protein	   composition	   of	   catalytically	   active	   human	   telomerase	   from	  immortal	  cells.	  Science	  315:	  1850-­‐1853.	  237.	   O'Sullivan	   RJ,	   Karlseder	   J	   Telomeres:	   protecting	   chromosomes	   against	  genome	  instability.	  Nat	  Rev	  Mol	  Cell	  Biol	  11:	  171-­‐181.	  238.	   Artandi	   SE,	   DePinho	   RA	   Telomeres	   and	   telomerase	   in	   cancer.	  Carcinogenesis	  31:	  9-­‐18.	  239.	   Cesare	   AJ,	   Reddel	   RR	   Alternative	   lengthening	   of	   telomeres:	   models,	  mechanisms	  and	  implications.	  Nat	  Rev	  Genet	  11:	  319-­‐330.	  240.	   Cristofari	   G,	   Adolf	   E,	   Reichenbach	   P,	   Sikora	   K,	   Terns	   RM,	   et	   al.	   (2007)	  Human	   telomerase	   RNA	   accumulation	   in	   Cajal	   bodies	   facilitates	  telomerase	   recruitment	   to	   telomeres	   and	   telomere	   elongation.	   Mol	   Cell	  27:	  882-­‐889.	  241.	   Venteicher	   AS,	   Artandi	   SE	   (2009)	   TCAB1:	   driving	   telomerase	   to	   Cajal	  bodies.	  Cell	  Cycle	  8:	  1329-­‐1331.	  242.	  Lau	  CK,	  Bachorik	  JL,	  Dreyfuss	  G	  (2009)	  Gemin5-­‐snRNA	  interaction	  reveals	  an	  RNA	  binding	  function	  for	  WD	  repeat	  domains.	  Nat	  Struct	  Mol	  Biol	  16:	  486-­‐491.	  243.	   Mahmoudi	   S,	   Henriksson	   S,	   Weibrecht	   I,	   Smith	   S,	   Soderberg	   O,	   et	   al.	  WRAP53	   Is	   Essential	   for	   Cajal	   Body	   Formation	   and	   for	   Targeting	   the	  Survival	   of	   Motor	   Neuron	   Complex	   to	   Cajal	   Bodies.	   PLoS	   Biol	   8:	  e1000521.	  244.	  Nizami	  ZF,	  Deryusheva	  S,	  Gall	   JG	  Cajal	  Bodies	  and	  Histone	  Locus	  Bodies	  in	  Drosophila	  and	  Xenopus.	  Cold	  Spring	  Harb	  Symp	  Quant	  Biol.	  245.	   Garcia-­‐Closas	   M,	   Kristensen	   V,	   Langerod	   A,	   Qi	   Y,	   Yeager	   M,	   et	   al.	   (2007)	  Common	   genetic	   variation	   in	   TP53	   and	   its	   flanking	   genes,	  WDR79	   and	  ATP1B2,	  and	  susceptibility	  to	  breast	  cancer.	  Int	  J	  Cancer	  121:	  2532-­‐2538.	  246.	  Schildkraut	  JM,	  Goode	  EL,	  Clyde	  MA,	  Iversen	  ES,	  Moorman	  PG,	  et	  al.	  (2009)	  Single	  nucleotide	  polymorphisms	  in	  the	  TP53	  region	  and	  susceptibility	  to	  invasive	  epithelial	  ovarian	  cancer.	  Cancer	  Res	  69:	  2349-­‐2357.	  247.	  Mahmoudi	  S	  HS,	  Farnebo	  L,	  Roberg	  K,	  	  Farnebo	  M	  (2010,	  In	  Press)	  WRAP53	  promotes	  cancer	  cell	  survival	  and	  is	  a	  potential	  target	  for	  cancer	  therapy	  Cell	  Death	  and	  Disease.	  	  	  	  
	  
